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ABSTRACT
An investigation was made into the effect of different dietary fats (com oil, olive 
oil and MaxEPA) on membrane phospholipids (phosphatidylinositol, 
phosphatidylcholine and phosphatidylethanolamine) in the rat mammary gland 
and red blood cells. It was demonstrated that phosphatidylinositol is the least 
responsive phospholipid to dietary fatty acid modification in both o f the tissues 
studied. Overall, erythrocytes responded to the different diets more than 
mammary gland membranes. Phosphatidylethanolamine incorporated more w3 
fatty acids from the marine oil diet than either phosphatidylcholine or 
phosphatidylinositol. The arachidonic acid (20:4>v6) content of 
phosphatidylcholine and phosphatidylethanolamine was highest in animals fed 
com oil, less in animals fed olive oil and the least in those fed marine oil. The 
relative proportions of phospholipids in the mammary gland and red blood cell 
membranes were not affected by feeding rats different diets.
It was also demonstrated that the fatty acid profile of phospholipids from rat, N- 
ethyl-#-nitrosourea (ENU) induced mammary tumours are not very different to 
those from normal rat mammary tissue. However, in the phosphatidylinositol 
fraction, in rats on all three diets the stearic acid content was higher in the 
tumours than in the normal mammary tissue. This was most evident in the olive 
oil group (12 mol%; p<0.05) and least in the marine oil group (<3 mol%; NS).
Rats administered ENU and fed a MaxEPA diet presented with fewer mammary 
tumours than those fed either a corn oil diet or an olive oil diet (p<0.05). Possible 
mechanisms for the protective effect of marine oil on mammary tumourigenesis 
are discussed.
The effect of a low fat diet on human female erythrocyte membrane phospholipids 
was studied. Only a few changes to membrane phospholipids were demonstrated.
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There was no significant effect on the fatty acid profile of phosphatidylcholine 
after two months of a low fat diet; and there was only a small change in the 
phosphatidylinositol fraction (increased arachidonic acid [2 0 :4>v6 ], p<0.05). 
Serum prolactin and oestradiol were also measured in this study. There was no 
effect o f diet on prolactin levels as measured by radioimmunoassay. However, 
there was a significant decrease in serum oestradiol (p<0.05) after two months on 
the low fat diet. This may have significance to the relationship between dietary 
fat and breast cancer.
The effect of marine oil supplementation on erythrocyte and platelet 
phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamine from 
human volunteers was also investigated. Erythrocyte phosphatidylcholine showed 
an increased incorporation of eicosapentaenoic acid (2 0 :5w3 ) and 
docosahexaenoic acid (22:6w3) after 4 weeks of supplementation. None of the 
other phospholipids showed a significantly increased incorporation of w3 fatty 
acids in either erythrocytes or platelets. There was a small change in the w9 
content of erythrocyte phosphatidylinositol with decreases in palmitoleic acid 
(16:lw9) after 3 weeks of supplementation and decreases in oleic acid (18:lw9) 
after 4 weeks of supplementation. Compliance in this study was considered good 
as measured by a significant decrease in plasma triglyceride content. This study 
demonstrated that there are very few changes in the fatty acid profile of 
erythrocyte and platelet phospholipids after short term dietary marine oil 
supplementation. Furthermore, the relative proportions of the phospholipids in 
both tissues studied were found to be resistant to dietary modification under these 
conditions.
The final study was a comparison of the phospholipid fatty acid profiles o f human 
mammary malignant tumours, benign tumours and normal breast tissue. 
Erythrocytes were also studied to see if these cells reflected any differences
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detected in the mammary tissue. In breast tissue phosphatidylcholine, differences 
in oleic acid (18:lw9), eicosatrienoic acid (20:3iv6) and arachidonic acid (2 0 :4w6 ) 
were seen between the three tissues. Normal tissue differed from both the 
malignant and benign tumour tissue but the two types of tumours did not differ 
significantly from each other. In phosphatidylinositol there were fewer 
differences, however, malignant tissue contained more stearic acid than both 
benign and normal mammary tissue. These differences were not detected in 
erythrocyte phospholipids which contained a different fatty acid profile from the 
mammary tissue.
E rra tu m  : I k r m g k o u t  this thesis pl-ease irac( t n 'a y t ^ L ^ c e r o f s  
in  place tn^lycm'cies.
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Of making many books there is no end, 
and much study wearies the body.
Ecclesiastes 12:12 (NIV)
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Initial studies were carried out using a 15%^DEGS (universal B 80-100) column, 
nitrogen flow rate 50 ml/minute and an oven temperature of 180°C. 
Unsatisfactory separation and detection of the long chain fatty acid methyl esters 
was obtained and thus an alternative column packing material was sought. 
Further analyses were performed using a 3%^PEGA (chromasorb G AW-DMCS) 
column with a nitrogen flow rate of 60 ml/minute and an oven temperature of 
190°C (Harbige, 1986). This gave better separation of the polyunsaturated fatty 
acid methyl esters, however, there was still unsatisfactory detection of the C22 
fatty acids due to the long elution time for these methyl esters of 90 minutes.
The availability of a Varian 3400 gas chromatogram with full integration and data 
handling facilities together with microprocessor controlled operation of gas flow 
rates and oven temperature greatly improved the reproducibility of the method. 
However, the detection of the C22 fatty acid methyl esters remained
-44-A
-  V
To
Mum and Dad
and
my husband John
-  VI -
ACKNOWLEDGEMENTS
I am indebted to my supervisor, Dr Chris Williams, for her continual 
encouragement, advice and friendship throughout the entire course of this work. I 
also wish to thank Professor D V Parke for his interest and support.
My thanks are extended to Mr I Burns, Dr P Dawson and Dr S Blair for their 
permission and help with collection of breast tumours from theatre at Charing 
Cross Hospital, and also for allowing me to spend many interesting hours 
watching them work. Also, I am grateful to Mr F Nicoll for the provision of 
normal breast tissue from the Harley Street Clinic, and to Dr S Shousha from the 
histopathology department of Charing Cross Hospital for providing the 
histological data on the breast tumours.
I am grateful to Dr R Howland for his advice on the statistical methods and 
training in the use of the SPSS-X programme.
Thanks to all the staff and students at Surrey University who bravely volunteered 
for my studies.
A  special thank you to Matthew Walters for not only excellent technical help, but 
for hours of commi t ment and also for a precious friendship. Thanks also to my 
friends Miggy, Sarah and Sean.
My sincere thanks are extended to my managers and friends at Norwich Eaton 
Limited for their understanding and support during the writing phase of this work, 
and also I gratefully acknowledge financial help with continuing student fees.
Finally, I wish to thank all my friends at The Coign Fellowship, Woking, and 
Runnymede Community Church, Chertsey for their loving and prayerful support 
throughout this part of my life, and especially my husband John, without whom I 
would never have completed this thesis.
- vil -
CONTENTS
PAGE
ABSTRACT
ACKNOWLEDGEMENTS
CONTENTS
LIST OF TABLES
LIST OF FIGURES
FATTY ACID NOMENCLATURE
ABBREVIATIONS
1
vi
vil
xi
xviii
xxii
xxiii
CHAPTER ONE: INTRODUCTION 
Epidemiology 
Case Control Studies 
Body Weight and Obesity 
Animal Studies 
Mechanisms
Steroid Hormones 
Prolactin 
Growth Factors 
Prostaglandins 
Membrane Fatty Acids 
Phosphatidylinositol 
General Aims
1
2
4
6
7
9
11
12
15
18
21
24
30
vin -
PAGE
CHAPTER TWO: MATERIALS AND METHODS 31
Introduction 32
Chemicals 34
General Precautions Taken in Lipid Analysis 34
Preparation of Platelets 34
Preparation of Lipid Extracts 35
Platelets 35
Erythrocytes 36
Mammary Epithelium 36
Lipid Separation 36
Acetone Removal of Neutral Lipids 36
Phospholipid Separation by Thin Layer Chromatography 37
Phospholipid Saponification and Méthylation 40
Method 40
Fatty Acid Analysis 42
Evaluation of the Silar IOC Packed Column for 
Separation of Phospholipid Fatty Acids 45
Determination of the Relative Proportions of Phospholipids in 
Cell Membranes 51
Phosphorus Assay 51
Method 52
Quantitative Analysis of Neutral Lipids in Plasma 54
Total Cholesterol 54
HDL-Cholesterol 55
Triglycerides 55
Quantitative Analysis of Plasma Hormones 56
Plasma Oestrogen 56
Plasma Prolactin 5 7
Anthropometric and Dietary Determinations 57
Body Fat 5 7
Nutrient Intake Measurements 5 7
-  IX -
PAGE
CHAPTER THREE: AN INVESTIGATION OF THE EFFECT OF DIET
ON THE PHOSPHOLIID HEAD GROUP COMPOSITION AND FATTY
ACID PROFILE OF PHOSPHATIDYLINOSITOL, PHOSPHATIDYLCHOLINE
AND PHOSPHATIDYLETHANOLAMINE IN NORMAL RAT MAMMARY
TISSUE AND ERYTHROCYTES 60
Introduction 61
Methods 66
Results 69
Discussion 82
CHAPTER FOUR: AN INVESTIGATION OF THE EFFECT OF DIET ON 
ENU INDUCED TUMOUR INCIDENCE, AND A COMPARISON OF 
PHOSPHOLIPID CONTENT AND PHOSPHATIDYLINOSITOL,
CHOLINE AND ETHANOLAMINE FATTY ACID PROFILES OF
ERYTHROCYTES AND MAMMARY TISSUE MEMBRANES FROM
ENU DOSED RATS AND NORMAL HEALTHY CONTROL RATS. 90
Introduction 91
Methods 95
Results 96
Discussion 114
CHAPTER FIVE: THE EFFECT OF A LOW FAT DIET ON 
ERYTHROCYTE MEMBRANE PHOSPHOLIPID COMPOSITION
IN HUMAN VOLUNTEERS. 123
Introduction 124
Design of Study and Dietary Compliance 125
Results 127
Discussion I 3 4
CHAPTER SIX: EFFECT OF MARINE OIL SUPPLEMENTATION
ON ERYTHROCYTE AND PLATELET INOSITOL, CHOLINE AND
ETHANOLAMINE PHOSPHOLIPIDS IN HUMAN VOLUNTEERS. 139
Introduction 140
Study Design and Subjects 143
Results 146
Discussion I 59
- X -
PAGE
CHAPTER SEVEN: ANALYSIS OF FATTY ACID PROFILE OF BREAST 
TISSUE AND ERYTHROCYTE PHOSPHATIDYLINOSITOL AND 
PHOSPHATIDYLCHOLINE FROM WOMEN WITH MALIGNANT AND 
BENIGN BREAST DISEASE AND IN NORMAL CONTROLS.
Introduction
Study Design
Results
Discussion
166
167
168 
170 
179
CHAPTER EIGHT: GENERAL DISCUSSION 
Discussion 
Conclusions 
Future Work
193
194 
206 
207
REFERENCES 209
APPENDICES:
I
II
III
IV
V
VI
CHAPTER THREE: TABLE OF RESULTS 
CHAPTER FOUR : TABLES OF RESULTS 
CHAPTER SIX: QUESTIONNAIRES 
CHAPTER SIX: TABLES OF RESULTS 
CHAPTER SEVEN: TABLES OF RESULTS 
CHAPTER SEVEN: TUMOUR HISTOLOGY
238
240
249
253
262
268
-  XI -
LIST OF TABLES
TABLE 1 : REPEATED INJECTION OF A MIXTURE OF STANDARD
FATTY ACID METHYL ESTERS
PAGE
46
TABLE 2: RESULTS FROM THREE REPEATED INJECTIONS OF
METHYLATED PHOSPHATIDYLCHOLINE STANDARD 46
TABLE 3: COMPARISON OF REPEATED INJECTIONS OF A
PHOSPHATIDYLCHOLINE STANDARD ON DAY 1 WITH 
REPEATED INJECTIONS OF THE SAME STANDARD ON 
DAY 2 47
TABLE 4: MEAN PHOSPHATIDYLCHOLINE FATTY ACID PROFILE
FROM SIX SAMPLES OF STANDARD METHYLATED 
INDIVIDUALLY 49
TABLE 5: MEAN PHOSPHATIDYLETHANOLAMINE FATTY ACID
PROFILE ANALYSED FROM SIX ALIQUOTS OF BLOOD 50
TABLE 6: RELATIVE PROPORTIONS OF THE MAJOR
PHOSPHOLIPIDS IN RED BLOOD CELLS DETERMINED 
BY PHOSPHATE ANALYSIS OF SIX ALIQUOTS OF 
BLOOD 54
TABLE 7: PERCENTAGE FATTY ACIDS IN THE CORN OIL, OLIVE
OIL AND MAX-EPA DIETS 67
TABLE 8: MEAN FOOD INTAKES (WEEKS 1 TO 15) IN ANIMALS
FROM THE THREE DIETARY GROUPS 69
TABLE 9: MEAN BODY WEIGHT AT TIME OF SACRIFICE FOR
RATS IN THE THREE DIETARY GROUPS
TABLE 10: MEAN AGE AT SACRIFICE
69
71
-  X ll -
TABLE 11 : COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLINOSITOL FROM MAMMARY TISSUE 
OF RATS FED DIETS CONTAINING EITHER CORN OIL, 
OLIVE OIL OR MAX-EPA
PAGE
73
TABLE 12: COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLCHOLINE FROM MAMMARY TISSUE 
OF RATS FED DIETS CONTAINING EITHER CORN OIL, 
OLIVE OIL OR MAX-EPA 74
TABLE 13: COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLETHANOLAMINE FROM MAMMARY 
TISSUE OF RATS FED DIETS CONTAINING EITHER 
CORN OIL, OLIVE OIL OR MAX-EPA 75
TABLE 14: COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLINOSITOL FROM ERYTHROCYTES 
OF RATS FED DIETS CONTAINING EITHER CORN OIL, 
OLIVE OIL OR MAX-EPA 76
TABLE 15: COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLCHOLDsTE FROM ERYTHROCYTES 
OF RATS FED DIETS CONTAINING EITHER CORN OIL, 
OLIVE OIL OR MAX-EPA 77
TABLE 16: COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLETHANOLAMINE FROM ERYTHROCYTES 
OF RATS FED DIETS CONTAINING EITHER CORN OIL, 
OLIVE OIL OR MAX-EPA 78
TABLE 17: COMPARISONS BETWEEN MAMMARY TISSUE AND
ERYTHROCYTE PHOSPHATIDYLINOSITOL, 
PHOSPHATIDYLCHOLINE AND PHOSPHATIDYL­
ETHANOLAMINE FATTY ACID PROFILES FROM RATS 
FED A CORN OIL DIET 79
- X lll -
TABLE 18: MEAN FOOD INTAKES (WEEKS 1 TO 15) IN CONTROL
AND ENU TREATED RATS FROM THE THREE DIETARY 
GROUPS
PAGE
97
TABLE 19: BODY WEIGHT OF CONTROL AND ENU TREATED RATS
AT SACRIFICE IN EACH DIETARY GROUP 97
TABLE 20: TUMOUR INCIDENCE IN THE RATS FROM THE THREE
DIETARY REGIMENS 99
TABLE 21 : DAILY DIETARY INTAKE OF MAJOR NUTRIENTS
BY WOMEN BEFORE AND AT 2 MONTHS AFTER 
COMMENCING A LOW-FAT DIET REGIMEN 128
TABLE 22: ANTHROPOMETRIC MEASUREMENTS ON WOMEN
BEFORE AND AT 2 MONTHS FOLLOWING THE 
COMMENCEMENT OF A LOW-FAT DIETARY 
REGIMEN 129
TABLE 23: THE FATTY ACID PROHLE (MOL%) OF RED BLOOD
CELL MEMBRANE PHOSPHATIDYLCHOLINE OF 
WOMEN BEFORE AND AT 2 MONTHS FOLLOWING 
THE COMMENCEMENT OF A LOW FAT DIETARY 
REGIMEN 130
TABLE 24: THE FATTY ACID PROFILE (MOL%) OF RED BLOOD CELL
MEMBRANE PHOSPHATIDYLINOSITOL OF WOMEN 
PRE-DIET AND AFTER 2 MONTHS FOLLOWING A 
LOW-FAT DIETARY REGIMEN 131
TABLE 25: RELATIVE PROPORTIONS (MOL%) OF ERYTHROCYTE
PHOSPHOLIPIDS IN WOMEN BEFORE AND AT 2 MONTHS 
AFTER COMMENCING A LOW-FAT DIETARY REGIMEN 132
-  XIV -
TABLE 26: LUTEAL-PHASE PLASMA OESTRADIOL, PROLACTIN AND
LIPID CONCENTRATIONS IN WOMEN BEFORE AND 
2 MONTHS FOLLOWING THE COMMENCEMENT OF 
A LOW-FAT DIETARY REGIMEN
PAGE
134
TABLE 27: FATTY ACID COMPOSITION OF SUPER EPA1200 CAPSULES 146
TABLE 28: DEMOGRAPHIC DATA 147
TABLE 29: BODY WEIGHT OF MALE AND FEMALE VOLUNTEERS
BEFORE AND AFTER FOUR WEEKS OF FISH OIL 
SUPPLEMENTATION 148
TABLE 30: PLASMA TRIGLYCERIDE AND TOTAL CHOLESTEROL
CONCENTRATIONS AT BASELINE AND AFTER FOUR 
WEEKS OF MARINE OIL SUPPLEMENTATION 148
TABLE 31 : AGE, WEIGHT AND NUMBER OF CHILDREN (PARITY)
AT THE TIME OF LUMPECTOMY 170
TABLE 32: COMPARISON OF THE RELATIVE PROPORTIONS OF
MAMMARY AND ERYTHROCYTE MEMBRANE 
PHOSPHOLIPIDS FROM RATS FED A CORN OIL, 
OLIVE OIL OR MAX-EPA DIET 239
TABLE 33: COMPARISON OF NORMAL MAMMARY TISSUE AND ENU-
INDUCED MAMMARY TUMOUR PHOSPHATIDYLINOSITOL 
FATTY ACID PROHLE FROM RATS FED CORN OIL, OLIVE 
OIL AND MAX-EPA DIETS 241
TABLE 34: COMPARISON OF NORMAL MAMMARY TISSUE AND ENU-
INDUCED MAMMARY TUMOUR PHOSPHATIDYLCHOLINE 
FATTY ACID PROHLE FORM RATS FED CORN OIL, OLIVE 
OIL AND MAX-EPA DIETS 242
-  XV -
PAGE
TABLE 35: COMPARISON OF NORMAL MAMMARY TISSUE AND ENU-
INDUCED MAMMARY TUMOUR PHOSPHATIDYL­
ETHANOLAMINE FATTY ACID PROFILE FROM RATS 
FED CORN OIL, OLIVE OIL AND MAX-EPA DIETS 243
TABLE 36: COMPARISON OF ERYTHROCYTE PHOSPHATIDYL­
INOSITOL FATTY ACID PROFILE FROM CONTROL AND 
ENU-TREATED RATS FED CORN OIL, OLIVE OIL AND 
MAX-EPA DIETS 244
TABLE 37: COMPARISON OF ERYTHROCYTE PHOSPHATIDYLCHOLINE
FATTY ACID PROFILE FROM CONTROL AND ENU- 
TREATED RATS FED CORN OIL, OLIVE OIL AND MAX-EPA 
DIETS 245
TABLE 38: COMPARISON OF ERYTHROCYTE PHOSPHATIDYL­
ETHANOLAMINE FATTY ACID PROFILE FROM CONTROL 
AND ENU-TREATED RATS FED CORN OIL, OLIVE OIL AND 
MAX-EPA DIETS 246
TABLE 39: COMPARISON OF THE RELATIVE PROPORTIONS OF
MAMMARY TISSUE AND MAMMARY TUMOUR MEMBRANE 
PHOSPHOLIPIDS FROM RATS FED A CORN OIL, OLIVE OIL 
OR MAX-EPA DIET 247
TABLE 40: COMPARISON OF THE RELATIVE PROPORTIONS OF
EYRTHROCYTE MEMBRANE PHOSPHOLIPIDS FROM 
CONTROL RATS AND ENU-INDUCED TUMOUR BEARING 
RATS FED A CORN OIL, OLIVE OIL OR MAX-EPA DIET 248
TABLE 41 : TRIGLYCERIDE AND CHOLESTEROL VALUES BEFORE
AND AFTER MARINE OIL SUPPLEMENTATION 254
TABLE 42: FATTY ACID PROFILE OF ERYTHROCYTE PHOSPHATIDYL­
INOSITOL BEFORE, AT WEEKS 1, 2, 3 & 4 DURING AND AFTER 
MARINE OIL SUPPLEMENTATION 255
-  XVI -
PAGE
TABLE 43: FATTY ACID PROFILE OF ERYTHROCYTE PHOSPHATIDYL­
CHOLINE BEFORE, AT WEEKS 1, 2, 3 & 4 DURING 
AND AFTER MARINE OIL SUPPLEMENTATION 256
TABLE 44: FATTY ACID PROFILE OF ERYTHROCYTE PHOSPHATIDYL­
ETHANOLAMINE BEFORE AND AT WEEKS 2 & 4 DURING 
MARINE OIL SUPPLEMENTATION 257
TABLE 45 : FATTY ACID PROFILE OF PLATELET PHOSPHATIDYL­
INOSITOL BEFORE, AT WEEKS 2 & 4 DURING AND 
AFTER MARINE OIL SUPPLEMENTATION 258
TABLE 46: FATTY ACID PROFILE OF PLATELET PHOSPHATIDYL­
CHOLINE BEFORE, AT WEEKS 2 & 4 DURING AND 
AFTER MARINE OIL SUPPLEMENTATION 259
TABLE 47: FATTY ACID PROFILE OF PLATELET PHOSPHATIDYL­
ETHANOLAMINE BEFORE, AND AT WEEKS 2 & 4 
DURING MARINE OIL SUPPLEMENTATION 260
TABLE 48: THE RELATIVE PROPORTIONS OF ERYTHROCYTE
MEMBRANE PHOSPHOLIPIDS BEFORE, AND AT WEEKS 
2& 4 DURING MARINE OIL SUPPLEMENTATION 261
TABLE 49 : THE RELATIVE PROPORTIONS OF PLATELET
MEMBRANE PHOSPHOLIPIDS BEFORE, AND AT WEEKS 
1 & 3 DURING MARINE OILSUPPLEMENTATION 261
TABLE 50: THE FATTY ACID PROFILE OF PHOSPHATIDYLINOSITOL
IN MALIGNANT, BENIGN AND NORMAL BREAST TISSUE 263
TABLE 51 : THE FATTY ACID PROFILE OF PHOSPHATIDYLCHOLINE
IN MALIGNANT, BENIGN AND NORMAL BREAST TISSUE 264
-  XVll -
PAGE
TABLE 52: THE FATTY ACID PROFILE OF PHOSPHATIDYLINOSITOL
IN ERYTHROCYTES FROM WOMEN WITH MALIGNANT 
OR BENIGN BREAST DISEASE OR HEALTHY CONTROLS 265
TABLE 53: THE FATTY ACID PROFILE OF PHOSPHATIDYLCHOLINE
IN ERYTHROCYTES FROM WOMEN WITH MALIGNANT 
OR BENIGN BREAST DISEASE OR HEALTHY CONTROLS 266
TABLE 54: THE RELATIVE PROPORTIONS OF MEMBRANE
PHOSPHOLIPIDS IN MALIGNANT BREAST LUMPS, 
BENIGN BREAST LUMPS AND NORMAL BREAST TISSUE 267
TABLE 55: THE RELATIVE PROPORTIONS OF ERYTHROCYTE
MEMBRANE PHOSPHOLIPIDS FROM WOMEN WITH 
MALIGNANT BREAST DISEASE, BENIGN BREAST 
DISEASE OR HEALTHY CONTROLS 267
TABLE 56: HISTOPATHOLOGICAL AND CLINICAL DIAGNOSIS
OF EXCISED BREAST TISSUE 269
-  X V lll -
LIST OF FIGURES
PAGE
figure 1 : Structure of Alveolus 10
figure 2 : Schematic diagram showing possible growth regulatory
pathways in human breast cancer 16
figure 3: The Major Biosynthetic Pathway of the Long Chain
Polyunsaturated Fatty Acids 20
figure 4: Receptor Stimulated Inositol Phospholipid Breakdown 26
figure 5: Phosphatidylinositol Phosphorylation 28
figure 6 : Schematic Diagram of the Analytical Steps Involved in
Phospholipid Analysis 33
figure 7: Diagram of a Thin Layer Chromatography Plate Showing
the Phospholipid Separation 39
figure 8 : Saponification and Méthylation of Phosphatidylcholine 41
figure 9: Schematic Diagram of an Ideal Column in which the
Sample is Distributed in Dynamic Equilibrium between
the Gas and Liquid Phase 42
figure 10: Simple Schematic Diagram of a Gas Chromatogram 44
-p^Ltru IOa : Bcampk of Acfd Trace ^ 5-
figure 1 1 : Phosphate Standard Curve Prepared from Known Volumes
of Phosphatidylcholine Standard 53
figure 12: Cholesterol Standard Curve 58
figure 13: Glycerol Standard Curve 59
figure 14: Mean Body Weight of Rats Fed Com oil, Olive oil and
MaxEPA Diets 70
-  XIX -
PAGE
figure 15: The Relative Proportions of Mammary Tissue Phospholipids
From Rats Fed Com oil, Olive oil and MaxEPA Diets 80
figure 16: The Relative Proportions of Erythrocyte Phospholipids
From Rats Fed Com oil, Olive oil and MaxEPA Diets 81
figure 17: Body Weight of ENU treated and Control Rats Fed
Com oil, Olive oil and MaxEPA Diets 98
figure 18: Cumulative Number of Rats Bearing Tumours in Each of
the Dietary Groups: Corn oil, Olive oil and MaxEPA 100
figure 19: Mammary Tissue Phosphatidylinositol Fatty Acid Profile
From Rats Fed Com oil, Olive oil and MaxEPA Diets 106
figure 20: Mammary Tissue Phosphatidylcholine Fatty Acid Profile
From Rats Fed Com oil, Olive oil and MaxEPA Diets 107
figure 21: Mammary Tissue Phosphatidylethanolamine Fatty Acid
Profile From Rats Fed Com oil, Olive oil and MaxEPA 
Diets 108
figure 22: Erythrocyte Phosphatidylinositol Fatty Acid Profile From
Rats Fed Corn oil, Olive oil and MaxEPA Diets 109
figure 23: Erythrocyte Phosphatidylcholine Fatty Acid Profile From
Rats Fed Corn oil, Olive oil and MaxEPA Diets 110
figure 24: Erythrocyte Phosphatidylethanolamine Fatty Acid Profile
From Rats Fed Com oil, Olive oil and MaxEPA Diets 111
figure 25: Relative Proportions of Phospholipids from Mammary
Tissue and ENU-Induced Tumours from Rats Fed Corn oil,
Olive oil and MaxEPA Diets 112
-  XX -
PAGE
figure 26: Relative Proportions of Phospholipids from Erythrocytes
from Rats Fed Com oil, Olive oil and MaxEPA Diets 113
figure 27: Percentage Change in the Relative Proportions of
Erythrocyte Phospholipids in Women After 2 Months
on a Low-Fat Diet 133
figure 28: Schedule of Blood Analysis 145
figure 29: Fatty Acid Profile of Erythrocyte Phosphatidylinositol
During Marine Oil Supplementation 151
figure 30: Fatty Acid Profile of Erythrocyte Phosphatidylcholine
During Marine Oil Supplementation 152
figure 31: Fatty Acid Profile of Erythrocyte Phosphatidyl-
Ethanolamine During Marine Oil Supplementation 153
figure 32: Fatty Acid Profile of Platelet Phosphatidylinositol
During Marine Oil Supplementation 154
figure 33: Fatty Acid Profile of Platelet Phosphatidylcholine
During Marine Oil Supplementation 155
figure 34: Fatty Acid Profile of Platelet Phosphatidylethanolamine
During Marine Oil Supplementation 156
figure 35: Relative Proportions of Erythrocyte Membrane
Phospholipids During Marine Oil Supplementation 157
figure 36: Relative Proportions of Platelet Membrane Phospholipids
During Marine Oil Supplementation 158
figure 37: Fatty Acid Profile of Phosphatidylcholine from Malignant,
Benign and Normal Breast Tissue 173
-  XXI -
PAGE
figure 38: Fatty Acid Profile of Phosphatidylinositol from Malignant,
Benign and Normal Breast Tissue 174
figure 39: Fatty Acid Profile of Erythrocyte Phosphatidylcholine
from Women with Malignant or Benign Breast Disease 
or Healthy Controls 175
figure 40: Fatty Acid Profile of Erythrocyte Phosphatidylinositol
from Women with Malignant or Benign Breast Disease 
or Healthy Controls 176
figure 41: Relative Proportions of the Major Breast Tissue Phospholipids
from Women With and Without Breast Disease 177
figure 42: Relative Proportions of the Major Erythrocyte Phospholipids
from Women With and Without Breast Disease 178
- XXII -
FATTY ACID NOMENCLATURE
The shorthand system now commonly used for designating particular fatty acids is 
based on the notation n:xvvy, where n is the number of carbon atoms in the fatty 
acid chain and x the number of ethylenic double bonds, wy denotes the number of 
carbon atoms from the centre of the double bond farthest removed from the 
carboxyl group to and including the terminal methyl group and thus gives the 
position of this double bond in the fatty acid chain. It is assumed that all 
ethylenic double bonds in polyunsaturated fatty acids are cis in structure and will 
be methylene interrupted (Stubbs & Smith, 1984).
SYSTEMATIC COMMON ABBREVIATION
NAME NAME
hexadecanoic palmitic 16:0
9-hexadecanoic palmitoleic 16:l>v9
octadecanoic stearic 18:0
9-octadecanoic oleic 18:lu/9
9,12-octadecadienoic linoleic 18:2w6
6,9,12-octadecatrienoic X -linolenic 18:3w6
9,12,15-octadecatrienoic cy-linolenic 18:3w3
8,11,14-eicosatrienoic dihomo- y -linolenic 20:3iv6
5,8,11,14-eicosatetraenoic arachidonic 20:4w6
7,10,13,16-docosatetraenoic adrenic 22:4w6
5,8,11,14,17-eicosapentaenoic timnodonic 20:5vv3
4,7,10,13,16-docosapentaenoic docosapentaenoic 22:5w6
7,10,13,16,19-docosapentaenoic clupanodonic 22:5w3
4,7,10,13,16,19-docosahexaenoic cervonic 22:6w3
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DMBA
NMU
ENU
P:S
S :0
w6:w3
PUFA
MUFA
J
IG F - I
iG F-in
EQF
TGFp
p d q -f
E
ABBREVIATIONS
Dimethylbenz(ûf)anthracene
Nitro-methylurea
A^-ethyl-A^-nitrosourea
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CHAPTER ONE
GENERAL INTRODUCTION
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Breast cancer is the largest single cause of death from cancers in women in the 
United Kingdom, with about 24,000 new cases and 15,000 deaths every year 
(Kingman, 1987). However, little is known about the initiation and promotion of 
this disease, and prognosis depends upon early detection and removal of the 
tumour.
Biological analysis of breast cancer indicates that there are several different 
diseases encompassed within this term. For example, breast cancer can be 
hormone sensitive or hormone independent; individual tumours can be highly 
aggressive or slow growing; primary tumours can rapidly metastasize or remain 
local over a long time and tumour histology has shown a number of different cell 
types. Nonetheless, the vast majority of breast cancers are cancers o f epithelial 
cells and transformation of breast cells and promotion of tumour growth are 
thought to somehow involve promotion of DNA synthesis and cell division, 
(Boyle & Leake, 1988).
There are many risk factors thought to be involved in the aetiology of breast 
cancer; hormonal, genetic, and environmental. One of the more recent hypotheses 
is that a high fat diet may be a contributory factor in breast disease.
EPIDEMIOLOGY
Evidence supporting the proposal that dietary fat may be involved in breast cancer 
has largely come from epidemiological studies. In 1966, Lea found there to be a 
highly significant correlation between the consumption of fats and oils and the 
death rates of women over 55 years of age from neoplasms of the breast in 23 
different countries (Lea, 1966).
More recently, Carroll (1975) made a study of per capita consumption o f dietary 
fat (total, vegetable and animal) and compared this with the age-adjusted
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mortality from breast cancer in 40 different countries. There was no correlation 
between vegetable fat consumption and mortality from breast cancer, and 
although a positive correlation was seen with animal fat, the most significant 
correlation was with total dietary fat intake and age adjusted mortality.
Kolonel et ah, (1981) conducted a study of the dietary practices and breast cancer 
incidence of the five main ethnic groups in Hawaii. They showed that the ethnic 
specific incidence rates could be correlated well with the intake of total dietary 
fat.
Further evidence for an association between environmental factors, possibly 
nutritional, and breast cancer incidence has been afforded by ecological 
investigations of the changing incidence of the disease over time. Japanese 
women present the lowest incidence of breast cancer in the world (Berg, 1975). 
Nevertheless, the incidence of breast cancer has been increasing over the last 
thirty years. In Japan, mean per capita daily fat intake rose from 23g/day in 1957 
to 52g/day in 1973 (Hirayama, 1978). During the same period overall breast 
cancer mortality rose approximately 30%, with the sharpest increase (>50%) in 
women aged 45 to 54 years (Schatzkin et a l, 1989). In Iceland, changes in 
cohort-specific incidence rates for breast cancer have also resulted in the cross- 
sectional age specific curve shifting from a Japanese type pattern in the 1920s to a 
western type pattern in the 1950s (Miller, 1977). This change has followed the 
substantial westernization that has occurred in Iceland, an important aspect of this 
being changes in diet from that of a largely fishing and agricultural based 
community, to an industrial type community.
Furthermore, investigations of the changing incidence of the disease in Japanese- 
American women (Buell, 1973) is indicative of a role for environmental factors 
over a period of time. Mortality studies for the period around 1950-1960 showed
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breast cancer mortality rates of Japanese-American women to be only slightly 
above levels prevailing in Japan. However, by 1969-1971, the calculated breast 
cancer rates for Japanese-American women had closely approached those for the 
indigenous population. This increase reflected a higher incidence in the second 
generation rather than the immigrant generation, thus suggesting that dietary 
factors from an early age may be important.
In general, populations at high risk for breast cancer tend to have a high intake of 
dietary fat. Exceptions, nevertheless do occur. Most notable is the case o f the 
native Greenland Eskimo, whose diet is very high in fat but whose age-adjusted 
risk of cancer in general, and of breast cancer in particular, is very low (Kromann 
& Green, 1980). However, the Eskimo diet is clearly unusual in that fat is 
derived almost exclusively from fish and aquatic mammals and is therefore rich in 
highly polyunsaturated w3 fatty acids. Furthermore, Kaizer et a l, (1989) 
performed an ecological study which correlated international incidence and 
mortality from breast cancer with the proportion of calories derived from fish and 
other dietary components. The international variation in breast cancer risk could 
be explained, on statistical grounds, by a combination of dietary components of 
which percent calories from fish showed a significant inverse relationship with 
breast cancer incidence.
CASE CONTROL STUDIES
Case control studies have also provided evidence of a slight but significantly 
greater intake of nutrients, especially total fat, in both pre-menopausal and post­
menopausal women with breast cancer (Miller et a l, 1978). However, not all 
epidemiological studies have shown a positive relationship between dietary fat 
intake and breast cancer incidence or mortality (Enstrom, 1981; Graham et a l, 
1982). A  study of mortality among Californian Seventh Day Adventists 
compared with a socio-economically similar population, showed little difference
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in the breast cancer mortality rates (Phillips et a l, 1980). Furthermore, there was 
a higher breast cancer risk in vegetarian Seventh Day Adventists than in non­
vegetarian Seventh Day Adventists. Similarly, British nuns who eat either no or 
little meat presented no less risk of breast cancer than women in the general 
population (de Waard, 1975). However, there may be other risks for breast 
cancer which apply to this particular group which should be taken into 
consideration, such as nulliparity. Furthermore, it may be that dietary influences 
in early life, especially at puberty, are important determinants in breast cancer risk 
(Miller & Bulbrook, 1980). Nuns would usually have eaten a normal diet during 
this period of their life and only change their diet during adulthood. It should also 
be stated that a vegetarian diet is not necessarily associated with a lower intake of 
total fat but an increased unsaturated to saturated fat ratio.
Further evidence against a relationship between dietary fat and breast cancer is 
afforded by a recent prospective study in the United States, in which 90,000 
women completed a dietary history questionnaire and were followed up for four 
years (Willet, 1987). Those women who developed breast cancer during this 
period of follow-up did not show higher fat intakes than those women who did 
not develop breast cancer (relative risk was 0.82). However, the lowest fat intake 
was 33% of calories and the highest 42%. It has been suggested that such a 
difference in fat consumption is too small to produce a significant difference in 
relative risk. Furthermore, during the period of this study, the average figure for 
total fat intake in the United States dropped from 41% to 37% of total calories, 
further reducing the difference between the two extremes of total fat intake 
recorded at the beginning of the study.
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BODY WEIGHT AND OBESITY
A  direct association has been shown between body weight and cancer deaths, 
particularly death from hormone-dependent cancers in women (La Vecchia et a l, 
1982). A  number of case-control studies have also demonstrated a relationship 
between obesity and risk of breast cancer (Paffenbarger et a l, 1980; Helmrich et 
a l, 1983), although a few studies have found no association, or only a weak 
association between weight and breast cancer when the analysis is corrected for 
height (de Waard, 1975; Soini, 1977). An inverse association between weight and 
risk of premenopausal breast cancer has been demonstrated (Paffenbarger et a l, 
1980; Helmrich et a l, 1983), suggesting that the relationship between body 
weight and breast cancer risk may operate only for cancers presenting during the 
postmenopausal years.
The mechanisms by which being overweight may enhance risk of breast cancer in 
postmenopausal years, but provide protective effects in premenopausal years are 
not known. However, it is generally agreed that the effects of overweight in 
postmenopausal women are mediated through increased adiposity and thus 
increased capacity for peripheral synthesis of oestrogens in adipose tissue.
Obesity appears to influence not only the incidence of breast cancer but also the 
progress and severity of the disease. Obese patients with breast cancer have been 
shown to have more advanced disease on diagnosis (Rosen et a l, 1977) and 
higher rates of recurrence and shorter survival times (Abe et a l, 1976; Morrison 
et a l, 1977; Donegan et a l, 1978), than lean patients. Although it has been 
suggested that these variables may simply reflect a later stage of diagnosis in 
obese women in whom breast lumps are more difficult to detect (Willet, 1987), 
Verreault et a l (1988) have shown that in cases with oestrogen receptor positive 
tumours, the incidence of axillary node involvement (indicating more advanced 
disease), was four times higher in overweight than in lean women, even after
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adjustments for tumour size were made. Furthermore, in an examination of the 
relationship between breast cancer risk factors and subsequent prognosis, Boyd et 
ah, (1981) found body weight to be the only risk factor associated with survival.
Similarly, survival rates have been shown to be highest among women in areas 
where breast cancer rates are low (Wynder et a l, 1963; Morrison et a l, 1973). In 
a comparison of survival rates among patients with breast cancer in Boston and 
Tokyo the higher survival rates in Tokyo could not be explained by differences in 
age, stage, histology, parity or age at first full-term pregnancy (Morrison et a l,
1976). The major distinguishing variable between the Japanese and American 
women which is also thought to be a breast cancer risk factor, was dietary intake.
ANIMAL STUDIES
Animal feeding studies have provided additional evidence that dietary fat may be 
involved in breast tumourigenesis. Initial experiments using the spontaneous 
mouse mammary tumour model established that: (i) animals fed a high fat diet 
(12% by weight hydrogenated cotton-seed oil) exhibited tumours earlier and with 
more frequency than animals fed a low-fat diet (3% hydrogenated cotton-seed 
oil); (ii) the effect was not based on caloric intake, and (iii) the dose-response 
effect was non-linear with a plateau occurring in the region of 16% fat 
(Tannenbaum & Silverstone, 1953).
In 1970, Carroll and Khor studied the effect on DMBA (dimethylbenzanthracene) 
induced tumour yield of a 20% com oil diet compared with a 0.5% fat diet, in 
Sprague Dawley rats. They found that at three different dose levels o f DMBA the 
rats fed a high fat diet developed more tumours than those fed a low fat diet. 
They also reported that the greatest effect of the high fat diet was observed when 
the diet was introduced after DMBA administration, indicating that the effect was 
mainly exerted at the promotional stage of mammary carcinogenesis. This
- 7-
investigation was repeated by Chan and Dao (1981) using three different strains 
o f rats; Sprague Dawley, Fischer and Long Evans. In each strain, the high fat 
purified diet significantly enhanced mammary carcinogenesis.
The role of a high fat diet in mammary carcinogenesis was further investigated by 
feeding rats a diet containing either 20% com oil (rich in essential fatty acids) or 
20% coconut oil (low in essential polyunsaturated fatty acids) (Carroll et a l, 
1981). The former diet resulted in a higher tumour incidence than the latter and 
thus it was concluded that polyunsaturated fats enhance mammary tumourigenesis 
more effectively than saturated fats. Ip (1987) has recently demonstrated that 
tumour incidence is linearly related to dietary linoleate content up to a maximum 
level which lies between 4 and 5%. Once this level has been reached, the amount 
of fat fed is the determining factor in tumour incidence. The reason for the high 
dependence of mammary tumours on essential fatty acids is not known, but it is a 
phenomenon which has also been observed in transplantable tumour cells grown 
in culture (Kidwell et a l, 1978). Other studies in animals support the hypothesis 
that the type as well as the total amount of fat fed may be important in mammary 
carcinogenesis.
Ghayur and Horrobin (1981), have reported that administering evening primrose 
oil (9% gamma linolenic acid) to Fischer rats results in smaller tumours than in 
rats given olive oil. This result has been confirmed by Karmali et a l, (1985). 
However, in their laboratory, administration of pure gamma linolenic acid 
produced no reduction in tumour growth, suggesting that some factor in the 
evening primrose oil other than gamma linolenic acid may be responsible for the 
reduction in tumour growth. Studies on the effect of marine oils containing w3 
fatty acids, compared with the w6 containing vegetable oils, have shown that the 
former result in a lower tumour incidence as well as a smaller tumour size and 
weight, than the vegetable oils (Jurkowski & Cave, 1985; Karmali et a l, 1984).
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These protective effects operate at low dose levels (Karmali et a l, 1984), and 
remain even when the total fat content of the diet is high (Oza & Karmali, 1986).
Although extrapolation from animal studies to the human disease must be applied 
with extreme caution, the above studies do provide a body of evidence for the 
involvement of dietary fat in breast cancer. In terms of the types o f fatty acids 
which act to promote tumourigenesis, there is some conflict between animal 
studies and epidemiological evidence, however, there is also some degree of 
concordance. Animal feeding studies have indicated that the w3 fatty acids may 
be less likely to enhance tumour growth than the w6 fatty acids. In relation to the 
human disease those populations, e.g. Japanese and Eskimos, who consume a low 
fat diet, or a diet mainly of marine origin (Lands, 1986) which contain the w3 
fatty acids, have a much lower breast cancer incidence than those populations, 
such as the Western Europeans, who consume a high fat diet in which the 
polyunsaturates are comprised mainly of w6 fatty acids.
In summary, a diet high in fat, especially w6 polyunsaturated fatty acids, is 
thought from the results of epidemiology and animal studies, to influence the risk 
of breast cancer.
MECHANISMS
There are four cell types most closely involved in breast cancer, these being the 
glandular epithelial cells, the myoepithelial cells, the stromal cells and the fat cells 
(Boyle & Leake, 1988) (figure 1).
The growth of the glandular epithelium depends not only on the free hormonal 
content of the blood supply, but also on the output of the other cell types, either 
through direct functional contact (myoepithelium), secretion of growth factors 
(stroma), or activation of precursors (stromal and fat cells).
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figure 1: Structure of Alveolus.
Normal breast epithelial cells respond markedly at puberty and during pregnancy. 
The majority of ductal development and virtually all the development of glandular 
secretory components depends on hormonal changes at puberty. Full 
development of intralobular alveolar elements is not initiated until pregnancy. 
This indicates sensitivity to the hormones and growth factors whose 
concentrations change at these times and it is therefore likely that breast cancer 
cells will also respond to these same hormones and growth factors. Other 
treatments influencing hormone and growth factor levels (e.g. oral contraceptives, 
additive hormone therapy etc.) might also influence breast epithelial cell division 
and, therefore, increase or decrease the chances of cell transformation (Boyle & 
Leake, 1988).
Breast tumours are usually slow growing. It takes about 10 years (by 
extrapolation) for a tumour to grow from the initial transformation event until the 
time that it becomes palpable. This means that the metabolic and hormonal 
conditions which may be related to the incidence of breast cancer are those in 
existence at the time of transformation and these may not be the same as those at 
the time of diagnosis.
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STEROID HORMONES
The precise mechanism by which dietary fat may exert an effect on breast cancer 
is unknown at present. Several proposals have been made, including the 
suggestion that a high fat diet alters the levels of the circulating steroid hormones. 
A  link between steroid hormones and breast cancer was first suggested in 1896 
when Beatson (1896) discovered that oophorectomy resulted in a striking 
remission of advanced breast cancer in some pre-menopausal women. It is now 
known that about one third of patients with breast cancer will have temporary 
tumour regression following treatments designed either to lower the serum 
oestrogen level or to block its effect.
Further evidence for an association between ovarian activity and the genesis of 
breast cancer is afforded by the markedly reduced risk which follows menopause, 
induced either surgically or by radiation (MacMahon, 1979). The earlier the 
menopause is induced, the greater the reduction in risk.
The hormone dependency of breast tumours can be assessed by the quantitative 
determination of the oestrogen receptor content of an excised tumour specimen. 
Tumours which contain low or negligible amounts of oestrogen receptor rarely 
respond to endocrine ablation or other hormone therapy, whereas most, but not 
all, receptor-rich tumours benefit from endocrine treatment. There is now 
evidence that oestrogen has a direct effect on the proliferation of human breast 
cancer cells in culture (Lippman et a l, 1977; Lippman et a l, 1987). Endocrine 
ablation and anti-oestrogen therapy have become common treatments for those 
tumours found to be dependent on hormones for their growth and proliferation.
It has been suggested that a high level of circulating oestrogen for a long period 
during a woman's life may increase her risk of breast cancer and a recent proposal 
is that over nutrition in early life causes rapid growth which results in early
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menarche (Moore et al., 1983), which in turn increases pre-menopausal breast 
cancer risk. There is little available evidence on the effect of the level of dietary 
fat intake on circulating oestrogen levels, nor on the proportions of the various 
types of oestrogens; oestradiol, oestriol, and oestrone. However, a recent study 
has reported a 50% reduction in circulating oestradiol levels in women consuming 
a low fat diet (22% calories as fat) for a three month period (Rose et a l, 1987b).
The principal source of oestrogens in postmenopausal women is from the 
conversion of adrenal androgens by the enzyme aromatase in fat cells (Boyle & 
Leake, 1988). It is interesting to note that the steroid content of postmenopausal 
breast tissue reflects the plasma steroid content characteristic of premenopausal 
women. This implies that critical steroid metabolism or selective steroid 
concentration occurs in normal breast tissue. (Bertuzzi et a l, 1981). It is 
therefore possible that an increase of dietary fat, and particularly obesity, 
promotes oestrogen production in postmenopausal women via an increase in fat 
cells.
PROLACTIN
Another mechanism through which dietary fat may be involved in breast 
tumourigenesis is via prolactin. Prolactin, a polypeptide hormone, is produced by 
the anterior pituitary under inhibitory control by prolactin inhibitory factor with 
oestrogen having some effect on its release (Kubota et al, 1989). It is involved in 
the control of growth, development and differentiated function of the mammary 
gland. Both stress and opiate agonists are promoters of prolactin release, and 
dopamine has been shown to inhibit prolactin release. However, the inhibitory 
effects of dopamine can be reversed by oestrogen, acting either directly on the 
pituitary or via the hypothalamus (Boyle & Leake, 1988).
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Several studies have shown that prolactin concentrations are elevated in some pre­
menopausal women with breast cancer compared with normal controls and 
women with benign breast disease (Bani et al, 1986; Malarkey et a l, 1977; Ohgo 
et a l, 1976). This was particularly noticed in women with invasive or poorly 
differentiated disease (Bani et al, 1986).
A  direct mitogenic effect of prolactin has been shown on the human breast cancer 
cell line MCF-7 (Shafie & Brooks, 1977). These workers also demonstrated an 
indirect mitogenic effect of prolactin which was shown to induce an increase in 
available oestrogen receptors. Prolactin also has the ability to modulate gene 
transcription and mRNA stability, as has been reported for casein mRNA (Guyette 
et a l, 1979; Teyssot & Houdebine, 1980).
The specific effects of prolactin are very much dependent on the stage of 
differentiation of the mammary epithelium (Ways et a l, 1979; Houdebine, 1979; 
Ray et a l, 1981; Nicholas & Topper, 1980). Prolactin action is modified by 
changes in the levels of other hormones. For example, prolactin effects on lipid 
metabolism are dependent on the concomitant presence of insulin and 
glucocorticoid (Ollivier-Bousquet, 1978; Wang et a l, 1972; Speake et a l, 1975). 
Further, there is evidence of an indirect effect of oestrogen and a direct effect of 
progesterone on the number of available prolactin receptors (Djiane Durand,
1977).
Measurement of prolactin concentrations in women with breast cancer has yielded 
conflicting results which can partly be explained by the difficulties in assessing 
prolactin concentrations due to the numerous factors known to influence its 
secretion. These include the oestroprogestative endocrine balance, the time of day 
or night, stress effects, drug effects and diet. Furthermore, prolactin is secreted in
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a pulsatile episodic fashion, with a short half-life of about 20 minutes (L’Hermite 
& L'Hermite-Baleriaux, 1988).
Parity causes a decrease of serum prolactin (Bruning et a l, 1987) which is 
detectable even in postmenopausal women indicating that the decrease in 
prolactin is a life long effect (Wang et a l, 1988). The early establishment o f a 
lowered prolactin secretion could be a mechanism whereby early age of 
childbearing and multiparity lead to a diminution in breast cancer risk.
The effect of a high fat diet on prolactin secretion in women has to date been 
difficult to assess, however, preliminary results using a newly developed bioassay 
have indicated that dietary fat may influence prolactin secretion. A  study of 
patients with cystic breast disease placed on a low fat diet (20% of total calories) 
for three months showed a significant decrease in bioassayable prolactin levels 
(Rose et al, 1987c).
Animal studies have also given some support to the hypothesis that there is 
abnormal prolactin secretion in mammary tumourigenesis and that this may, in 
part, be mediated via a high fat diet. Chan and Cohen (1975) have demonstrated 
that a high fat intake elevates serum prolactin levels in rats, and also that the anti­
prolactin drugs CB-154 (Chan & Cohen, 1974) and ergocryptine (Chan & Cohen, 
1975) suppress the formation of all palpable mammary tumours in DMBA treated 
rats on both a high fat diet and a low fat diet. However, these results are 
somewhat controversial as two other groups of workers (Carroll et a l, 1981; Cave 
et a l, 1979) have failed to observe any effect of dietary fat on prolactin levels in 
rats.
The ambiguity in the results obtained so far may be related to the experimental 
method of detecting prolactin. Radioimmunoassay is the traditional method used.
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However, there is now evidence to suggest there are a number of cleaved 
prolactin molecules circulating in the bloodstream which may not be detectable by 
radioimmunoassay, but which may still be of functional, mitogenic significance. 
In the rat, one such 16K polypeptide cleaved prolactin was reported to exhibit a 
significant in vivo stimulatory effect upon DNA synthesis and cell division of 
mammary epithelial cells (Mittra, 1980b).
Recently a new bioassay for lactogenic hormones based on the Nb2 lymphoma 
cell culture has been described (Tanaka et a l, 1980). Using this assay. Love and 
Rose (1985) found elevated bioactive prolactin up to 15 times the levels detected 
by radioimmunoassay in eight women who had at least two first degree relatives 
with breast cancer and a history of familial breast cancer.
Further studies are required both in animals and humans, in order to clarify the 
precise effect of a high fat diet on circulating prolactin concentrations.
GROWTH FACTORS
It has been hypothesized that breast cancer cells function as 'mini' endocrine 
organs which can synthesize and secrete a number of polypeptide growth factors 
or growth factor-like activities (Lippman et a l, 1987). Using specific cDNA 
probes, mRNA transcripts for TGF-alpha, TGF-beta, IGF-I, IGF-II, pro-cathepsin 
D (52K protein), PDGF and others have been identified in RNA extracts from 
breast cancer cells and tissues, and biological or immunoreactive growth factor 
activities have been found in conditioned medium from these cells (Lippman et 
al, 1987; Coronado et a l, 1988; Huff et a l, 1988; Nunez et a l, 1987; Peres et 
al, 1987; Rochefort et al, 1987; Salomon et al, 1984).
While breast cancer cells may secrete peptides that can stimulate growth of 
stromal elements, the 'benign' stromal cells may produce diffusable products that
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enhance growth of the breast cancer cells (Picard et a l, 1986; Clemmons et a l, 
1986). Thus, conversation among the cellular elements o f a tumour may take 
place in the form of secreted polypeptide messengers acting via a paracrine loop.
Using two monoclonal antibodies (MAb-425 and 528) directed against epidermal 
growth factor receptor (EGF-R), Manni et a l, (1990) showed that in the NMU 
(nitro-methylurea) mammary tumour grown in soft agar, EOF and TGF-alpha 
related peptides are produced upon exposure of oestradiol and progesterone. 
These peptides were not produced following prolactin administration.
Cell division is an extremely complex event which occurs 15-20 hours after 
addition of growth factors and which often requires the continuous presence of the 
growth factor(s) for at least half this interval. Growth factors may stimulate a 
number of parallel and redundant signals each of which contribute to the growth 
response. Eliminating any one of these signals {e.g. protein kinase C) may have 
little effect on the overall cellular response.
IGF-I IGF-II EGF
Prolactin
InsP
Growth Factors
Other Organs mRNA
Estromedins
Secreted Growth Factors 
(e.g. TGRf, TGFp, IGF-I, IGF-II 
52K, PDGF)
ParacrineAutocrine
Breast Cancer Cell Stromal Cell
figure 2: Schematic diagram showing possible growth regulatory
pathways in human breast cancer.
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Two broad families of growth factor receptors have emerged; those which have 
intrinsic protein-tyrosine kinase activity and those which do not:
PDGF (c-sis)
EGF
IGF-I
CSF-I
Insulin
Tyrosine Kinase
Thrombin
Bradykinin
Bombesin
GTP (c-ras)
There is emerging evidence that receptors lacking intrinsic protein-tyrosine kinase 
activity activate associated protein-tyrosine kinases, and therefore, functional 
distinctions between these families are becoming vague (Gaudino et a l, 1988; 
Klausner et al, 1987).
It has been postulated that the receptors (or oncogene products) which do not 
possess intrinsic tyrosine kinase activity are linked to the phosphatidylinositol 
secondary messenger system. However, so far evidence for a direct biochemical 
link has been lacking. Although GTP analogues stimulate polyphosphoinositide 
specific phosphodiesterases, it has not been possible to isolate a GTP binding 
protein which directly couples this response to a growth factor receptor. In 
addition, PDGF and EGF, whose receptors have intrinsic protein-tyrosine kinase 
activity, both stimulate phosphatidylinositol turnover, but a direct biochemical
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link between these kinases and the regulation of phosphatidylinositol turnover 
remains to be established.
There is no evidence at present that dietary fat affects the amount, or the binding 
of growth factors directly. However, from figure 2 it can be envisaged that 
growth factors may act as an amplification system with relatively small increases 
in oestrogen resulting in a greatly increased production of growth factors, possibly 
triggering secondary messenger systems inside the cell such as cyclic AMP and 
phosphatidylinositol which are known to be involved in cell proliferation.
Although the role of growth factors in breast cancer has been little investigated, 
there is currently much research in this exciting area. However, the idea of 
autocrine and paracrine factors is not new, and factors such as prostaglandins have 
been known to be involved in breast cancer for some time.
PROSTAGLANDINS
Another line of investigation is related to the role of prostaglandins in breast 
cancer and the effect dietary fat may have on the production of these autocrine 
factors. Prostaglandins are produced by nearly every cell in the body from free 
(non-esterified) C20 fatty acids. They are very unstable with half-lives of 
between 30 seconds and 4 minutes and hence they are not stored in tissues, nor do 
they circulate in the bloodstream (Salmon & Flower, 1979).
Increased production of prostaglandins is usually associated with changes in 
intracellular concentrations of cyclic AMP and/or calcium and, amongst a wide 
variety of functions, they have been suggested to play a role in cell replication 
(Salmon & Flower, 1979). Suggestions of their involvement in breast cancer 
arose from studies which showed increased synthesis of prostaglandin material 
from malignant breast tumours compared with tissue from benign tumours and 
normal breast tissue (Bennett et a l, 1977; Salmon & Flower, 1979). Increased 
production of prostaglandins have also been suggested to be involved in
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hypercalcaemia accompanying breast cancer and in the metastatic spread of the 
disease, as the highest levels of prostaglandin metabolites have been detected in 
women with these conditions (Bennett et al, 1977; Salmon & Flower, 1979).
The relationship between prostaglandins and mammary cancer has been 
investigated in rodents with the administration of inhibitors of prostaglandin 
biosynthesis (Powles et a l, 1973; Tashjian et a l, 1973). In one study there was 
found to be a reduction in the size of chemically induced tumours and also 
reduced bone destruction through osteolysis in rodents given inhibitors of 
prostaglandins, compared with control animals (Carter et a l, 1983). However, 
the drugs used are known to be non-specific and block not only the prostaglandin 
biosynthetic enzymes but a variety of other enzymes (Levine, 1981) and thus 
these experimental studies cannot be used as definitive evidence for involvement 
of prostaglandins in the development of tumourigenesis. Nevertheless, there is 
convincing evidence of elevated levels of prostaglandins in tumours obtained 
from experimental animals and women with breast cancer. Their significance and 
the mechanism responsible for their production remain to be elucidated. With 
reference to the relevance of prostaglandins in the aetiology of breast cancer and 
the effect of dietary fat, the influence of the total amount and types of dietary fatty 
acids on prostaglandin production in mammary tissue, also requires further 
clarification.
There are three series of prostaglandins, each derived from a different precursor 
fatty acid (figure 3). It has been suggested that dietary fat may influence 
prostaglandin production by alterations in precursor fatty acid availability. The 1, 
2 and 3 series prostaglandins have different and often opposite actions in 
regulating cell function (Karmali, 1980) and thus major changes in diet, 
particularly between the w6 and w3 fatty acids, could lead to alterations in 
prostaglandin biosynthesis. Thus, animal feeding studies which showed a 
reduction in tumour size when rats were fed marine oil containing w3 fatty acids
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compared with tumour size of rats fed com oil containing mainly w6 fatty acids 
was associated with an increased production of the 3 series prostaglandins which 
act antagonistically to the 2 series, levels of which are known to be increased in 
malignant breast tumours (Karmali et al., 1984). However, this view is highly 
speculative and is an area needing much more research. These findings have not 
yet been confirmed by other workers and it is as yet not clear whether alterations 
in the various prostaglandin families in response to w3 fatty acids is the cause of 
tumour reduction in these studies. The fatty acids required as precursors to 
prostaglandin biosynthesis are not stored in the non-esterified form in body 
tissues. The main sources of these precursor fatty acids are the 2' position of 
membrane phospholipids, release primarily being via the enzyme phospholipase 
A2 (Rubin & Laycock, 1978). Attention has therefore also been focussed on the 
fatty acid composition of membrane phospholipids, dietary influences on the fatty 
acid composition, and the desaturase and chain elongase enzymes involved in 
long chain polyunsaturated fatty acid biosynthesis.
MEMBRANE FATTY ACIDS
It is thought that dietary manipulation of cell membrane phospholipid fatty acid 
composition may have a variety of consequences and not all o f these may be due 
to alterations in prostaglandin production. For example, altered membrane 
fluidity may affect the conformational state of membrane receptors, and activities 
of those membrane bound enzymes which have a specific requirement for 
phospholipids for full activity. Alteration in mammary membrane fatty acid 
composition has been proposed as a possible locus for the tumour enhancing 
effects of dietary fatty acids (Williams & Dickerson, 1987).
Dietary modification of membrane phospholipid fatty acid composition has been 
little investigated in human subjects, although, it has been shown to occur in rat 
cell membranes. Rats fed diets rich in polyunsaturated fatty acids showed an 
increase in the content of polyunsaturated fatty acids in a variety of membranes,
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including endoplasmic reticulum, plasma membrane and mitochondrial membrane 
(Innis & Clandinin, 1981; Wahle, 1983). The change in diet also produced rapid 
and reversible changes in the fatty acid composition o f the membrane 
phospholipids which correlated with the fatty acids of the dietary lipid.
Further animal studies have also shown dietary manipulation of mammary tumour 
phospholipids. A  significant reduction in weight and volume of the rat R3230AC 
mammary tumour was observed after four weeks of supplementing normal rat 
chow diet (5% fat) with marine oil rich in w3 fatty acids (Karmali et al., 1984). 
The fatty acids 20:5w3 and 22:6w3 were found to be significantly increased in the 
phosphatidylcholine fraction of the mammary tumour membranes of rats given 
marine oil compared with those without marine oil supplementation.
These dietary induced alterations in membrane phospholipid fatty acids, 
associated with corresponding changes in tumour incidence and tumour size, 
strongly support an involvement of membrane fatty acids in tumour proliferation 
but such studies do not provide conclusive evidence, nor do they indicate the 
mechanism(s) involved.
The fatty acyl components of the phospholipid molecule have short half-lives and 
exhibit turnovers independent of the entire molecule. The fatty acid composition 
can be continually modified according to the profile of fatty acids which are 
available for incorporation into membrane lipids (Wahle, 1983). The relative 
availability of saturated and unsaturated fatty acids for membrane phospholipid 
synthesis can be manipulated by dietary means, but is also dependent upon the 
activity of membrane bound desaturases. Both nutritional and hormonal factors 
have been found to influence desaturase activity in animal tissues, although the 
results gained so far are controversial with regards to the effects of different types 
of dietary fat on the desaturase enzymes (Hagve & Christophersen, 1984; Pugh & 
Kates, 1984). The hormones insulin, glucagon and adrenaline have all been
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shown to affect desaturase activity (de Gomez Dumm et a l, 1975 & 1976). 
Adrenaline and glucagon both decrease delta-6 desaturase activity without effect 
on the delta-9 and delta-5 desaturases. Insulin increases delta-6 desaturase 
activity.
Chain elongation enzymes which add two carbon units at a time are not rate 
limiting (Bernert & Sprecher, 1975) and have not been well studied.
One interesting feature of desaturase enzyme studies and fatty acid profile studies 
has been the apparent abundance of arachidonic acid. This fatty acid is found in 
high levels in animal phospholipids and decreases only very slowly when the diet 
is deficient in the w6 fatty acids (Iritani & Narita, 1984). In children the 
percentage of saturated and monoene fatty acids in serum decreases significantly 
from <1 to 10 years of age. Linoleic acid and arachidonic acid increase 
significantly during this time, which correlates with an increase in linoleic acid 
consumption (Soderhjelm et al, 1970).
The cell membrane readily produces arachidonic acid (20:4w6) from linoleic acid 
(via gamma-linolenic acid and dihomo-gamma-linolenic acid) but this does not 
readily proceed further along the biosynthetic pathway to 22:4w6 suggesting that 
arachidonic acid is fundamental to body function (Hagve & Christophersen, 
1984).
Arachidonic acid is now believed to be the truly physiological in vivo essential 
fatty acid. It is known to be a precursor of prostaglandins of the 2 series. It is 
also released during hormone-induced phosphatidylinositol hydrolysis and in 
relation to this particular pathway, has been suggested to be involved in the 
initiation of cell proliferation which follows the hydrolysis o f this minor 
membrane phospholipid (Berridge et al, 1985a; Berridge et a l, 1985b).
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PHOSPHATIDYLINOSITOL
Phosphatidylinositol, a minor phospholipid in eukaryotic cells, and its 
phosphorylated derivatives, phosphatidylinositol-4-phosphate and 
phosphatidylinositol-4,5-bisphosphate, have a very characteristic fatty acid pattern 
in which a large proportion of the molecules contain stearic acid at position 1 and 
arachidonic acid at position 2 (Michell, 1975).
Initial studies in 1953 (Hokin & Hokin, 1953) showed that phosphatidylinositol 
metabolism was greatly stimulated by carbamylcholine or acetylcholine. Further 
work in the 1970s led Michell to suggest that phosphatidylinositol cleavage may 
ultimately be involved in the mechanisms whereby some cell surface receptor 
mechanisms transmit extracellular information into the cell interior (Michell, 
1975). This proposal was supported by evidence that although 
phosphatidylinositol is synthesized de novo at the endoplasmic reticulum, the cell 
surface is the site of a significant proportion of headgroup metabolism; and also 
those systems which show phosphatidylinositol metabolism do not show a cyclic 
AMP increase as their early response to hormonal stimulation and vice versa.
It is now known that a variety of neurotransmitters, hormones and growth factors 
invoke the turnover of the phosphoinositides, with a concomitant increase in 
intracellular calcium concentration which may be responsible for cell proliferation 
and cell secretion (Adamo et a l, 1985; Berridge et a l, 1985a & 1985b; Creba et 
al, 1983; Fain & Berridge, 1979; Hokin-Neaverson, 1974; Jones & Michell, 
1974; Siess & Binder, 1985). Furthermore, Kubota et a l, (1989) have recently 
demonstrated that oestradiol treatment can enhance the phosphoinositide 
metabolism in pituitary cells of ovariectomized rats, although this system did not 
appear to be tightly coupled to a greater production of prolactin release.
Recent evidence indicates that the gating of calcium is not regulated by a direct 
hydrolysis of phosphatidylinositol but by the hydrolysis of its phosphorylated
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derivative phosphatidylinositol-4,5-bisphosphate (Berridge et a l, 1985b; Joseph, 
1984). Changes in the level of phosphatidylinositol occur indirectly as it is 
consumed to replace the polyphosphoinositides. Abdel-Latif et a l, (1977 & 
1980) have shown that in iris smooth muscle, acetylcholine stimulates the 
breakdown of phosphatidylinositol-4,5-bisphosphate (mediated by a 
phosphodiesterase) with a concomitant accumulation of the water soluble 
metabolite inositol-l,4,5-trisphosphate in addition to inositol phosphate. The 
accumulation of inositol-l,4,5-trisphosphate has also been shown to occur upon 
stimulation of various other tissues (Agranoff et al, 1983; Berridge et a l, 1983).
The main products of phosphatidylinositol-4,5-bisphosphate hydrolysis are 
inositol trisphosphate and diacylglycerol. These are both thought to act as second 
messengers (Berridge, 1984). They both possess the properties of classical second 
messengers, being produced very rapidly, acting at low concentrations and having 
specific mechanisms for removal once the external signal is withdrawn. Each 
inositol trisphosphate molecule is thought to release about 20 calcium ions 
(Berridge & Irvine, 1984) probably from a vesicular store of intracellular calcium 
located in the endoplasmic reticulum (Prentki et al, 1984; Streb et a l, 1983).
Diacylglycerol is normally almost absent from membranes (Nishizuka, 1984), but 
a very rapid increase has been measured upon stimulation of a variety of cell 
types, including blood platelets, mast cells, thyroid, pituitary and liver cells 
(Igarashi & Kondo, 1980; Kennerley et a l, 1979; Prescott & Majerus, 1983; 
Rebecchi et a l, 1983; Thomas et a l, 1983). It acts as a second messenger within 
the plane of the membrane to stimulate protein kinase C, which is an ubiquitous 
enzyme present in all cells, particularly those of the brain (Berridge, 1984). The 
activation of protein kinase C requires both calcium and phosphatidylserine as co­
factors (Berridge, 1984; Nishizuka, 1984), and when activated, the kinase 
phosphorylates seryl and threonyl residues of specific cellular proteins that then 
lead to the initiation of various physiological processes (particularly cell secretion
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and proliferation), especially those that occur either independently o f calcium or 
at very low levels of calcium. It has been suggested that diacylglycerol may also 
increase cytoplasmic pH. An increase in pH is thought to have an important role 
in stimulating cell growth as it is a characteristic feature o f growth factor 
stimulation. It has been known for some time that growth factors cause changes 
in inositol lipid metabolism, but the link between these events at the plasma 
membrane and the onset of cell proliferation is not yet fully understood.
The activation of protein kinase C by diacylglycerol appears to be a prerequisite 
but not a sufficient requirement for physiological responses of target cells, 
because the cellular responses to synthetic diacylglycerol are always incomplete. 
Protein phosphorylation by protein kinase C and mobilization o f calcium, both of 
which are evoked by a single extracellular messenger, appear to be equally 
indispensable and synergistically effective for causing full physiological responses 
(Berridge, 1984; Nishizuka, 1984).
As yet very little is known about the control of phosphatidylinositol-4,5- 
bisphosphate hydrolysis, and the way this cell signalling system may be involved 
in abnormal cell proliferation. A link has recently been found between oncogenes 
and the inositol lipids, but research in this area is still in its early stages (Berridge, 
1984; Berridge & Irvine, 1984; Michell, 1984).
The stimulated hydrolysis of phosphatidylinositol-4,5-bisphosphate is dependent 
upon its availability. It is not stored in large quantities in the cell and must 
therefore be synthesized rapidly when required for hydrolysis (Berridge & Irvine, 
1984). Membranes contain a phosphatidylinositol kinase which specifically 
phosphorylates the hydroxyl on the 4-position of phosphatidylinositol to produce 
phosphatidylinositol-4-phosphate. A  phosphatidylinositol-4-phosphate kinase 
phosphorylates the hydroxyl on the 5-position to form phosphatidylinositol-4,5- 
bisphosphate (figure 5). The conversion of phosphatidylinositol to these two
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polyphosphoinositides can be reversed by two phosphomonoesterases that 
specifically remove phosphate from the 5- and 4- positions. The kinases and 
phosphomonoesterases that maintain this dynamic equilibrium are some of the 
most active enzymes in the cell (Berridge & Irvine, 1984).
ATP
Phosphatidyl­
inositol
Pi
ATP
Phosphatidyl 
inositol 4- 
phosphate
Phosphatidyl­
inositol 4,5-
bisphosphate
c
phosphatidylinositol kinase 
phosphatidyinositol 4-phosphate kinase 
phosphatidylinositol 4,5-bisphosphate phosphomonoesterase 
phosphatidylinositol 4-phosphate phosphomonoesterase
figure 5: Phosphatidylinositol Phosphorylation
Phosphatidylinositol itself is formed via the following biosynthetic reactions:
Phosphatidic acid + CTP —--------->  CDP-diacylglycerol + pyrophosphate
CDP-diacylglycerol + inositol --------------- >  phosphatidylinositol + CMP
These reactions are catalysed by the enzymes CTP phosphatidate cytidyl 
transferase and CDP-diacylglycerolphosphatidate transferase respectively 
(Berridge & Irvine, 1984; Hawthorne, 1982).
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In many tissues phosphatidylinositol has considerably more stearic and 
arachidonic acids than the phosphatidic acid from which it is synthesized. The 
enrichment is produced by déacylation and reacylation cycles of the phospholipid, 
and thus it can be envisaged that dietary modification of the fatty acyl species 
may occur according to the fatty acids available.
Specific dietary modification of mammary membrane phosphatidylinositol fatty 
acid composition is a completely uninvestigated area. However, a recent study of 
vascular smooth muscle cells showed that a refined preparation of fish oil and w3 
eicosapentaenoic acid, thought to be the particularly active component of fish oil, 
affected the phosphoinositide metabolism (Locher et a l, 1989). The fish oil and 
w3 eicosapentaenoic acid blunted the LDL-mediated stimulation of 
phosphatidylinositol turnover and thus it was hypothesized that the beneficial 
effect of these fatty acids on blood pressure and atherosclerotic events could be 
explained by their ability to attenuate the phosphatidylinositol turnover activity of 
the vascular muscle cell. If, as this study would suggest, phosphoinositide 
metabolism can be altered via administration of specific dietary fatty acids, then it 
may be envisaged that this could be via an alteration of the fatty acyl components 
of the phosphoinositide molecule.
In view of the proposed importance of this phospholipid in hormone induced 
signal transduction and cell growth, and in view of our incomplete understanding 
of the interaction between dietary fatty acids and hormones in mammary 
tumourigenesis, it is suggested that further investigation of the effect of changes 
in dietary fat on the composition and content of this phospholipid in mammary 
tissue is warranted.
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GENERAL AIMS
This study was concerned with investigating the dietary manipulation of
membrane phosphatidylinositol and to ascertain whether there are any
abnormalities in the relative proportion and fatty acid composition o f this minor
phospholipid in malignant breast tissue.
The aims were as follows:
1. To develop suitable methods for separation and fatty acid analysis of 
phosphatidylinositol from various tissues.
2. To determine the fatty acid profile of phosphatidylinositol in normal 
erythrocytes.
3. To determine the fatty acid profile and relative proportion of 
phosphatidylinositol in normal human breast cell membranes.
4. To ascertain whether there are changes in the fatty acid composition and 
relative proportion of phosphatidylinositol in malignant and benign breast 
tissue.
5. To investigate dietary modification of platelet and erythrocyte 
phosphatidylinositol fatty acid composition and relative proportion of total 
phospholipids in human volunteers.
6. To investigate the dietary modification of mammary cell membrane 
phosphatidylinositol in tumour and non-tumour bearing animals.
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CHAPTER TWO
MATERIALS AND METHODS
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INTRODUCTION
Methods have been developed in order to make an investigation into the fatty acid 
composition and relative proportions of phosphatidylinositol in membrane 
phospholipids of red blood cells, platelets and mammary epithelial cells. Lipid 
extraction, phospholipid separation and gas chromatography techniques for fatty 
acid analysis have been developed over many years, essentially for the study of 
total phospholipids and phosphatidylcholine. Phosphatidylinositol is a minor 
phospholipid in eukaryote cell membranes and has been little studied, largely 
because of difficulty in its separation from other phospholipids, particularly 
phosphatidylserine. A  further problem is that because of the small amount present 
in most membranes, analytical methods used must be very sensitive. These 
problems have necessitated a thorough investigation and development o f the most 
appropriate and effective methods for phospholipid separation, fatty acid analysis 
and phosphorus determination.
Phosphatidylcholine, an intensively studied phospholipid has also been analysed 
in the present study to enable results for this phospholipid to be compared with 
those obtained by many other laboratories. Furthermore, both 
phosphatidylcholine and phosphatidylethanolamine are of interest in the dietary 
modification of breast tissue with regard to their possible involvement as stores of 
arachidonic acid for prostaglandin synthesis in breast disease and hence analysis 
of these two phospholipids was undertaken in some of the studies in this thesis.
The analytical steps involved in phospholipid analysis have been outlined 
diagrammatically in figure 6.
32-
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X
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figure 6: Schematic diagram of the analytical steps involved in phospholipid 
analysis.
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CHEMICALS
Most of the solvents used were purchased from May and Baker Ltd., (Dagenham) 
and were Analar grade. Hexane was HPLC grade. Sodium chloride, Analar 
grade, was obtained from Fisons, (Loughborough, Leics.). Vanadium pentoxide, 
(laboratory grade); tri-sodium citrate, potassium chloride, perchloric acid (Analar 
grade); sodium hydroxide and hydrochloric acid (Aristar grade) were all 
purchased from BDH (Poole, Dorset). Fiske and Subbarow reducer, phospholipid 
standards for thin layer chromatography and fatty acid methyl ester standards for 
gas liquid chromatography were obtained from Sigma Chemical Company Ltd.,
(Poole, Dorset). Glass gas liquid chromatography columns packed with either 3% weight for 
PEGA (polyethylene glycoladipate) coated on chromasorb G AW-DMCS, mesh 
100-120 or 10%^Silar IOC (3-cyanopropyl silicone) coated on Gas chrom Q, mesh 
100-120 were purchased from Phase Separations Ltd., (Queensferry, Clwyd).
GENERAL PRECAUTIONS TAKEN IN LIPID ANALYSIS
Plastic apparatus and containers other than Teflon were avoided. Plastic screw 
caps to the glass tubes were Teflon lined. Glassware was cleaned by soaking in 
Decon 90 (Deacon Laboratories Ltd., Hove, E. Sussex) for at least 24 hours, 
rinsed in distilled water several times and dried in an oven overnight.
The antioxidant 2,6-di-tert-butyl-p-cresol (butylated hydroxytoluene, BHT) was 
added to all solvents at a concentration of 50mg/l; and 500mg/l to all thin layer 
chromatography solvents, in order to minimise auto-oxidation of polyunsaturated 
fatty acids. Further precautions were taken by storing the lipid extracts in 
chloroform under nitrogen at -20°C and methyl esters in hexane under nitrogen at 
-20°C.
PREPARATION OF PLATELETS
A tube containing 10 volumes of whole blood, anticoagulated with tri-sodium
citrate (13mmol/l) was spun at 280g (Beckman J6-B centrifuge) for 14 minutes at
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2°C. The platelet rich plasma was separated from the packed red blood cells and 
spun at 1120g (Beckman J6-B) for 15 minutes at 2°C. The platelet poor plasma 
was removed and stored at -80°C for future analyses.
The platelet pellet was washed with 2 volumes Tris buffer (15mmol/l Tris/HCl; 
134 mmol/1 NaCl; 5 mmol/1 KCl; pH7.4), spun at 1120 g under previous 
conditions and resuspended in 2 volumes Tris buffer.
PREPARATION OF LIPID EXTRACTS
Lipid extraction from cell membranes is achieved with the use of both an organic 
solvent and an alcohol. The alcohol is essential for disruption of the lipid-protein 
complexes, dissolution of the lipids and inactivation of the degradative enzymes. 
However, alcoholic solvents also extract cellular contaminants such as sugars, 
amino acids and salts (Kates, 1972). These can be removed via an aqueous wash; 
the alcohol partitioning into the aqueous phase leaving the lipid in the organic 
phase.
It is most common to use chloroform/methanol as the extraction solvent. 
However, for the lipid extraction of red blood cells, propan-2-ol is used instead of 
methanol as it extracts less haem protein (Broekhuyse, 1974) which would 
interfere with subsequent fatty acid analyses. The methods used for lipid 
extraction during the experimental work of this thesis are described below.
PLATELETS
5 volumes of methanol were added to the platelets suspended in Tris buffer and 
mixed end over end for 5 minutes. 5 volumes of chloroform were added and 
mixed for 5 minutes. The organic layer was removed. This procedure was
repeated twice. The amassed organic layers were evaporated to dryness under a
by voljume
stream of nitrogen and redissolved in 4 volumes chloroform/methanol (2:1^. The 
lipid extract was washed with 0.8 volumes potassium chloride (50 mmol/1).
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ERYTHROCYTES
Packed red blood cells were washed 3 times with an equal volume of 0.89% NaCl 
and the buffy coat was removed. An equal volume of distilled water was added. 
The cells were left to stand for 15 minutes and 6 volumes isopropanol were added 
slowly with mixing. After 1 hour with occasional mixing, 4 volumes chloroform 
were added, mixed and left at -20°C overnight.
The cells were filtered using Whatman No 1, 11 cm filter paper. The extract was 
transferred into an equal volume of chloroform/methanol (2:1 by volume) and 
washed with 0.2 volumes 0.05MKC1. The lower phase was collected, dried under 
a stream of nitrogen and stored in chloroform under nitrogen at -20°C.
MAMMARY EPTTHFJJTJM
The epithelium was cut into small pieces and homogenized in 6 volumes 
chloroform/methanol (2:1 by volume). 3 volumes 5% saline was added and 
mixed. After centrifugation at 300g (Beckman J6-B) for 10 minutes at 4°C, the 
chloroform layer was removed and dried under a stream of nitrogen and stored in 
chloroform, under nitrogen at -20°C.
LIPID SEPARATION
ACETONE REMOVAL OF NEUTRAL LIPIDS
The neutral lipids (e.g. cholesterol and triglycerides) and polar phospholipids are 
separated by a simple acetone extraction (Kates, 1972).
One aliquot of lipid was pipetted into a clean, glass tube and the solvent removed 
under nitrogen. 12 volumes of acetone were added, mixed, and the tube placed in 
ice for 1 hour. The acetone containing the neutral lipids was discarded leaving a 
white precipitate of the polar phospholipids. The phospholipids were redissolved 
in 1 volume chloroform prior to separation by thin layer chromatography.
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This technique was essential for the removal of the majority of the neutral lipids 
in mammary epithelium prior to thin layer chromatography.
PHOSPHOLIPID SEPARATION BY THIN LAYER CHROMATOGRAPHY 
Thin layer chromatography is a standard method for the separation o f neutral and 
polar lipids and the resolution of phospholipids into their individual classes. 
Methods are well established for the separation of the two major classes of 
phospholipids, phosphatidylcholine and phosphatidylethanolamine, however, the 
separation of phosphatidylserine and phosphatidylinositol has proved to be more 
difficult and has been little studied. The method relies on differing lipid polarity 
in the solvents used, the more polar lipids migrating up the plate more slowly. In 
the solvents commonly used for phospholipid separation, phosphatidylserine and 
phosphatidylinositol do not separate, and they migrate up the plate together. Most 
investigations into these phospholipids have therefore studied the combined 
fractions. A  number of different solvent systems for improving 
phosphatidylserine and phosphatidylinositol separation have been reported in the 
literature (Allan & Cockcroft, 1982; Broekhuyse, 1968; Cerbulis, 1983; Rouser et 
al., 1966; Skipski & Barclay, 1969), including the use of two dimensional 
chromatography (Dodge & Phillips, 1967). A  number of these methods were 
investigated as part of the present study with limited success.
An adaptation of the method of Allan and Cockcroft (1982) was found to give the 
most effective and consistent separation of the phospholipids. (Rf values: mean + 
SD; sphingomyelin, 0.05 + 0.009; phosphatidylcholine, 0.095 + 0.007; 
phosphatidylserine, 0.13 + 0.01; phosphatidylinositol, 0.18 + 0.02;
phosphatidylethanolamine, 0.36 + 0.01; phosphatidic acid, 0.46 + 0.03).
Two tanks were prepared with fresh solvent each week. The first solvent system 
was hexane/acetone (75:25 by volume). The second was chloroform/methanol/
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/acetic acid/water (75:45:3:1 by volume). At least one hour was required to create 
a solvent saturated atmosphere before the plates were run.
20 X 20 cm glass plates were used with 0.25 mm silica gel 60 (Merck). A  line 
was drawn 2 cm from the bottom of the plate and divided into 5 bands, 2 cm wide 
and 1.5 cm apart. 50 ug of individual phospholipid standards and 200-400 ul 
membrane lipid extracts were applied to the bands and dried with an electric 
hairdryer. The plate was run in the first solvent system until it could be seen that 
all the remaining neutral lipids in the cell extracts had moved to the top o f the 
plate. This was to help prevent the triglyceride interfering with the phospholipid 
separation. After drying the plate thoroughly with an electric hairdryer, the plate 
was run in the second solvent phase to separate the phospholipids into their 
individual classes. When the solvent front had reached 2 cm from the top o f the 
plate, the plate was removed, dried and placed in another tank with iodine 
crystals. The iodine vapour stained the phospholipids brown. The separated 
phospholipids were marked and scraped off into glass tubes.
-38
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PI standard Sample A PC/SP
standard
Sample B PS standard
(i) Phosphatidic acid (ii) Phosphatidylethanolamine (PE)
(iii) Phosphatidylinositol (PI) (iv) Phosphatidylserine (PS)
(v) Phosphatidylcholine (PC) (vi) Sphingomyelin (SP)
figure 7: Diagram of a thin layer chromatography plate showing the 
phospholipid separation.
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PHOSPHOLIPID SAPONIFICATION AND METHYLATION
Gas chromatographic analysis is achieved by the separation of thermally stable 
volatile compounds which are carried through the column, by the carrier gas, at 
different rates depending on their solubility in the stationary phase. Fatty acids, 
and in particular polyunsaturated fatty acids, are non-volatile and thermally 
unstable and cannot therefore be analysed directly by gas chromatography, they 
must first be derivatized to their methyl esters. This is achieved by a 
saponification step to cleave the fatty acids from the phospholipid molecules, 
followed by méthylation of the free fatty acids.
A  number of methods for the saponification and méthylation o f phospholipids 
have been reported in the literature (Bowyer et a l, 1963; Kates, 1964; Marinetti, 
1962; Morrison, 1964). Some of these achieve both reactions in one vigorous 
step, but this has the disadvantage of possible loss of the long chain 
polyunsaturated fatty acids. Two methods were studied as part of the present 
investigation (Hewlett Packard, 1986; Harbige, 1986). The former (Hewlett 
Packard, 1986) employed high temperatures for long time periods to ensure total 
saponification, however, difficulties were experienced in these initial studies with 
loss of long chain polyunsaturated fatty acids. An alternative method was 
investigated (Harbige, 1986), which involved a vigorous saponification step using 
NaOH in methanol and water which was then heated for 30 minutes, followed by 
a separate méthylation step employing HCl in methanol which required the use of 
lower temperatures and a shorter incubation period. This method was less likely 
to lead to significant oxidation of the long chain polyunsaturated fatty acid methyl 
esters.
METHOD
1 ml of 3.75 mmol/1 NaOH in methanol/water (1:1 by volume) was pipetted into
the tubes containing the phospholipid bands. The tubes were vortexed and placed
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(i) Saponification
O
H2Ç-O-C-R1
P
H-C-O-C-R,
OH
H2C-0-P-0-CH2-CH2-N(CH2)3 
O OH-
H2C-OH
H-C-OH
H2C-OH
Glycerol
Phosphatidylcholine
?  ?  
OH-C-Rj + OH-C-R2
Free fatty acids
(ii) Méthylation
OH +
0H-P-0-CH2-CH2-N(CH2)3
O OH-
Cholinephosphate
R-C-OH + CH3OH 
O
^  R-Ç-OCH3 +
t
H2O
Free fatty 
acid
Methanol Fatty acid 
methyl ester
figure 8: Saponification and Méthylation of Phosphatidylcholine
-41-
in a boiling water bath for 30 minutes with occasional mixing. The tubes were 
cooled, 2 ml of 6M HCl/methanol (13:7 by volume) was added, vortexed and 
placed in an 80 + 1®C water bath for 10 minutes.
1.25 ml of hexane/diethyl ether (1:1 by volume) was added to the cooled tubes 
which were then tightly capped and rotated end over end for 10 minutes to extract 
the methyl esters. The aqueous phase was discarded with a Pasteur pipette and 3 
ml of NaOH (300 mmol/1) was added to the remaining organic phase. The tubes 
were rotated end over end for a further 5 minutes. The organic phase was then 
transferred into a clean tube and a known volume taken, dried in a glass vial under 
nitrogen and then redissolved in 50 ul of hexane for gas liquid chromatographic 
analysis.
FATTY ACID ANALYSIS
After derivatization, the fatty acid methyl esters can be separated by gas liquid 
chromatography. The sample is injected into the injection port where it is rapidly 
vapourised and swept by the carrier gas onto the column which contains a liquid 
of low volatility held upon an inert support. On reaching this stationary phase, a 
major part of the vapour is adsorbed and a dynamic equilibrium is established 
between the adsorbed vapour and that remaining in the gas phase (Ambrose, 
1971; Braithwaite & Smith, 1985).
Liquid Phaseq
Gas Phasec
figure 9: Schematic Diagram of an Ideal Column in which the Sample is 
Distributed in Dynamic Equilibrium between the Gas and Liquid 
Phase.
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The portion of vapour in the gas phase is moved along by the gas flow; and the 
dynamic equilibrium between the stationary phase and the gas phase allows for 
the movement of the vapour down the column. The rate at which each component 
of a mixture moves depends upon its solubility in the liquid phase.
The ratio of the concentrations of a substance distributed between two 
equilibrated phases under certain conditions {i.e. at a particular temperature) is 
termed the distribution, or partition, coefficient {B). This is defined as:
B = q/c
where q is the concentration of the vapour in the liquid phase and c is the 
concentration of the vapour in the gas phase. The value of this constant 
determines the rate at which the zone of vapour passes through the stationary 
phase. Thus the larger the partition coefficient of a compound, the more readily it 
is adsorbed by the stationary phase and the slower it moves down the column 
(Keulemans, 1957).
Unsaturated fatty acid methyl esters cannot be separated on non-polar stationary 
phases and it is therefore necessary to use polar stationary phases such as DEGS 
(Diethyleneglycolsuccinate) or PEGA (Polyethyleneglycoladipate). It is
important to choose a polar column which can be heated to the temperatures 
required to elute the long chain methyl esters without degradation o f the column 
liquid phase.
The separated compounds are detected at the end of the column by a flame 
ionization detector. This operates by detecting the ions produced by combustion 
of carbon in a hydrogen-supported flame. The flame ionization detector requires 
a supply of hydrogen and of air, but the proportions of these gases are not too 
critical as long as they remain constant during an actual analysis (Ambrose, 
1971).
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figure 10: Simple Schematic Diagram of a Gas Chromatogram
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Initial studies were carried out using a 15%^DEGS (universal B 80-100) column, 
nitrogen flow rate 50 ml/minute and an oven temperature o f 180°C. 
Unsatisfactory separation and detection of the long chain fatty acid methyl esters 
was obtained and thus an alternative column packing material was sought. 
Further analyses were performed using a 3%^PEGA (chromasorb G AW-DMCS) 
column with a nitrogeti flow rate of 60 ml/minute and an oven temperature o f 
190°C (Harbige, 1986). This gave better separation o f the polyunsaturated fatty 
acid methyl esters, however, there was still unsatisfactory detection o f the C22 
fatty acids due to the long elution time for these methyl esters of 90 minutes.
The availability of a Varian 3400 gas chromatogram with full integration and data 
handling facilities together with microprocessor controlled operation o f gas flow 
rates and oven temperature greatly improved the reproducibility o f the method. 
However, the detection of the C22 fatty acid methyl esters remained
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unsatisfactory, and the use of another column packing material was sought. 
Analyses were finally performed on a 10%^Silar IOC (gas chrom Q 100-120) 
glass column (1.8 m length x 6 mm outside diameter) with a carrier gas 
( nitrogen) flow of 30 ml/minute and an oven temperature programming method 
to improve the separation of the shorter chain (C16-18) fatty acid methyl esters 
(Sanders, 1986). The initial temperature was 165°C which was held for 5 
minutes. The temperature was then increased to 200°C at a rate of 5°C/minute 
and held for 25 minutes. There was a further increase to 215°C at the end of the 
analysis which was held for 15 minutes in order to clean the column ready for the 
next analysis. The Silar IOC does not decompose at temperatures up to 225°C 
thus enabling an increase in the column temperature in order to decrease the 
elution time of the C20-22 fatty acid methyl esters and so improving their 
detection.
Methyl esters were identified by comparison of their retention times with those of 
authentic standards. Results were expressed as mol% and were calculated by the 
in board data processing from the area of the peaks, using the formula, peak area 
= height X width at half height. Quantification was checked using authentic 
standards of known composition. S ec-(q  a re  10 a  -for aa'diyace
EVALUATION OF THE SILAR lOC PACKED COLUMN FOR SEPARATION OF 
PHOSPHOLIPID FATTY ACIDS
The reproducibility of the gas liquid chromatography method of fatty acid 
analysis was determined by six repeated injections of a mixture known to 
comprise of approximately 20% each of five fatty acid methyl esters. The results 
(Table 1) show excellent reproducibility of repeated injections of a single mixture 
of standard methyl esters of chain length C16 to C18.
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Table 1: Repeated injection of a mixture of standard fatty acid methyl 
esters.
Fatty acid methyl ester Mean (mol%) + SD Coefficient of Variation (%)
16:0 21.1 + 0.02 0.09
18:0 20.9 ±  0.01 0.05
18:lw9 21.1 ±  0.02 0.09
18:2w6 19.4 ±  0.02 0.10
18:3iv3 17.5 ±  0.03 0.17
The reproducibility of the gas chromatography method was further assessed by
three repeated injections of a single methylated phosphatidylcholine standard.
The phosphatidylcholine standard (Sigma) was methylated according to the
method on page 40.
Table 2: Results from Three Repeated 
Phosphatidylcholine Standard.
Injections of Mlethylated
Fatty acid methyl esters Mean (mol%) + SD Coefficient of Variation (%)
16:0 15.9 + 1.3 8.2
18:0 32.1 ± 4.0 12.5
18:lw9 20.8 + 0.9 4.3
18:2iv6 12.2 ±  0.4 3.3
20:3w6 6.1 + 0.6 9.8
20:4w6 6.3 + 1.6 25.4
22:6w3 6.5 + 1.1 16.9
The coefficient of variation for each fatty acid was much higher than those seen in
the standard methyl esters. This may have been due to some possible
decomposition of the long chain polyunsaturated fatty acids during the
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méthylation process leading to a higher background noise and poorer separation 
o f the fatty acid methyl esters. There may also have been some column 
contamination between the analyses even though the column was left at high 
temperature for 15 minutes at the end of each analysis in order to remove 
contaminants. Leaving the column at higher temperatures or for longer periods of 
time at a high temperature was not acceptable as this would soon lead to column 
packing degradation.
The between day variability of the method was ascertained by analysing the 
phosphatidylcholine standard, methylated and analysed on Day 1, again on Day 2 
following careful overnight storage of the sample in hexane, under nitrogen at - 
20^C. Three further injections of this sample were made and the results compared 
with Day 1 (Table 3).
Table 3: Comparison of Repeated Injections of a Phosphatidylcholine 
Standard on Day 1 with Repeated Injections of the Same Standard 
on Day 2.
Fatty Acid Methyl Ester Mean (mol%) + SD Mean (mol%) + SD
Day 1 Day 2
16:0 15.9 ±  1.4 14.9 ±  2.4
18:0 32.1 + 4.0 31.8 ±  2.0
18:lw9 20.8 ±  0.9 21.9 ±  1.0
18:2w6 12.2 + 0.4 11.3 ±  0.8 *
20:3w6 6.1 + 0.6 7.3 + 0.6 **
20:4w6 6.3 + 1.6 7.9 + 0.8
22:6w3 6.5 + 1.1 6.8 ±  2.2
* p<0.05
** p<0.02
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The larger percentage of long chain polyunsaturated fatty acids may be due to an 
increased sensitivity of the gas chromatograph on Day 2 (Table 3.). The 
sensitivity of detection of these fatty acids is affected by the baseline noise level 
which alters day by day and is dependent upon a variety o f factors including 
column bleed (liquid phase decomposition), column contamination from previous 
samples and septum conditions. The differences in fatty acid profile from day to 
day were not generally found to be significantly different. Exceptions to this 
were the 18:2w6 (p<0.05) and 20:3w6 (p<0.02) fatty acids, however, the 
differences in mean from Day 1 to Day 2 were 1.1% and 1.2% respectively which 
are small differences. It is concluded that care must be taken when interpreting 
data analysed over several days, the magnitude of the differences between two 
comparative groups must be taken into consideration as well as the statistical 
significance level. When two groups of samples are to be compared, they should 
be analysed in parallel, i.e., a sample should be analysed from each group 
alternately, to minimize the effect of between day variation and to prevent bias in 
results due to analytical variation.
A  further validation experiment was aimed at assessing the variation o f the 
méthylation method. Six aliquots of phosphatidylcholine standard were 
methylated individually and analysed by gas liquid chromatography. The mean 
results and standard deviation are shown in Table 4.
The coefficients of variation were comparable in magnitude to those o f repeated 
injections of one methylated sample of phosphatidylcholine standard (Table 2), 
indicating that the méthylation method is reproducible and most of the variation 
occurs in the analytical stage.
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Table 4: Mean Phosphatidylcholine Fatty Acid Profile From Six Samples of 
Standard Methylated Individually.
Fatty Acid Methyl Esters Mean (mol%) ±  SD Coefficient of Variation (%)
16:0 14.1 + 2.6 18.4
18:0 36.3 + 0.2 0.6
18:lw9 20.4 + 0.2 1.0
18:2w6 10.6 + 0.3 2.8
18:3w3 2.7 + 0.2 7.4
20:3w6 6.2 + 0.8 12.9
20:4w6 5.2 + 0.6 11.5
22:6w3 4.0 + 1.1 27.5
The final validation experiment assessed the precision of the entire process. 60 
ml of blood was taken and divided into six aliquots. Each aliquot was separately 
taken through the lipid extraction and phospholipid extraction processes. The 
largest band was phosphatidylethanolamine and this was scraped from each of the 
thin layer chromatography plates, methylated and the fatty acids analysed (Table 
5).
The coefficient of variation for some of the fatty acid methyl esters was found to
be high, although it was acceptable (< 10%) for most fatty acids of interest,
except for 22:6w3. The coefficient of variation for 16:lw9 and 20:3w6 were
unacceptably high, and in the case of 20:3w6 this was almost certainly due to
difficulty in separating it from 18:3w3, and also because it is normally present in
mammalian tissues in very small amounts. It was concluded that any fatty acid
mol
detected which was present in amounts less than 1% of the total fatty acids
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detected would be classified as trace. Furthermore, during experimental analysis, 
any change or difference in fatty acid profile between the two groups of interest 
o f less than 1.5 mol%, even if found to be statistically significant, was considered 
of questionable biological significance due to the imprecision of the method. The 
high coefficient of variation found for this method means that biological 
differences in fatty acid composition due to effects of disease or diet, as 
investigated in this thesis, will be more difficult to demonstrate.
Table 5: Mean Phosphatidylethanolamine Fatty Acid Profile Analysed 
From Six Aliquots of Blood.
Fatty Acid Methyl Esters Mean (mol%) + SD Coefficient of Variation (%)
16:0 24.04 ±  0.77 3.2
16:lw9 4.29 ±  1.01 23.5
18:0 10.64 ±  0.85 7.9
18:lw9 18.98 ±  0.54 2.8
18:2w6 4.22 + 0.29 6.8
18:3w3 1.02 + 0.12 12.2
20:3w6 1.28 ±  0.67 52.51
20:4w6 14.95 ±  0.82 5.49
20:5w3 3.35 ±  0.20 6.1
22:4w6 2.00 ±  0.30 15.0
22:5w3 4.79 ±  0.36 7.6
22:6w3 2.26 + 0.31 13.8
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DETERMINATION OF THE RELATIVE PROPORTION OF PHOSPHOLIPIDS IN 
CELL MEMBRANES
PHOSPHORUS ASSAY
The relative proportion of phospholipids in cell membrane extracts were 
determined by separating the phospholipids by thin layer chromatography and 
then measuring the phosphorus content of each relative band by a 
spectrophotometric assay. The phospholipid bands were scraped from the silica 
plate and hydrolysed with acid to free the phosphorus from the molecule. The 
addition of a reducing agent forms a coloured compound which can be easily 
measured optically.
A  number of methods for achieving this have been reported in the literature 
(Anderson & Davis, 1982; Bartlett, 1959; Chen et a l, 1956; Dodge & Phillips, 
1967; Naito 1975; Rouser et a l, 1966). Several of these methods were 
investigated (Anderson & Davis, 1982; Bartlett, 1959; Dodge & Phillips, 1967; 
Rouser et a l, 1966), however, problems were encountered with incomplete 
hydrolysis and interference of the assay by silica. It was therefore necessary to 
develop a method which would provide reproducible results taking into account 
the small amount of phosphatidylinositol present in membrane phospholipids.
The maximum hydrolysis was achieved by the use of a catalyst, vanadium 
pentoxide, with perchloric acid. The phospholipids were heated with the acid for 
two hours at 170°C which was found to be the optimal temperature and time.
Silica was present in the samples due to the separation of the phospholipids by
thin layer chromatography. The phospholipids were scraped from the plate into
clean tubes and hydrolysed directly. It was found that the silica partially
neutralized the perchloric acid and also interfered with the measurement o f optical
density. Eluting the phospholipids from the silica with chloroform was found to
result in unsatisfactory and unreproducible recovery. The problem was reduced
- 5 1 -
by using an optimal volume of perchloric acid (determined by variations in the 
volume used) and by removing the acid containing the free phosphorus from the 
silica following hydrolysis.
METHOD
The relevant phospholipid bands were scraped from the thin layer 
chromatography plates following separation and placed into clean glass tubes. 1 
ml of vanadium pentoxide/perchloric acid was added to each of the tubes which 
were then heated in a driblock heater for 2 hours at 170^C.
The tubes were centrifuged at 1,000 rpmjfor 5 minutes to enable the sample to be 
removed from the silica which falls to the bottom of the tubes. The samples were 
transferred into clean tubes and diluted with 4 ml deionized water. 1 ml 
ammonium molybdate was added to each tube and mixed, followed by 1 ml Fiske 
and Subbarow reducer. The tubes were heated in a boiling water bath for 10 
minutes, cooled and the optical density of each sample read at 660 nm.
A  standard curve was prepared from the analysis of known quantities of 
phosphatidylcholine standard (figure 11.)
A  validation experiment was carried out on this method. To assess the precision 
of the complete methodology for phosphate determination a red blood cell sample 
was divided into 6 aliquots. The lipids from each aliquot were extracted, 
separated into the phospholipid classes by thin layer chromatography and the 
phosphate content analysed (Table 6).
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Table 6: Relative Proportions of the Major Phospholipids in Red Blood 
Cells Determined by Phosphate Analysis of 6 aliquots of Blood
Phospholipid Mean (mol%) + SD Coefficient of Variation (%)
Sphingomyelin 25.00 + 3.28 13.0
Phosphatidylcholine 11.83 + 1.86 15.7
Phosphatidylserine 20.00 + 4.87 24.4
Phosphatidylinositol 12.48 + 1.15 9.2
Phosphatidylethanolamine 30.58 + 1.17 3.8
The coefficient of variation is usually considered acceptable if below 10%. The 
coefficient of variation for sphingomyelin and phosphatidylcholine was just above 
this level and would indicate that there may not be a particularly good separation 
of these phospholipids on the thin layer chromatography plate. The coefficient of 
variation for phosphatidylserine was also unacceptably high and was also 
probably due to the difficulties in separating this phospholipid from 
phosphatidylinositol. The high coefficient of variation found for some o f the 
phospholipids means that caution must be used when interpreting biological 
differences in phospholipid composition due to effects of disease or diet, as 
investigated in this thesis.
QUANTITATIVE ANALYSIS OF NEUTRAL LIPIDS IN PLASMA
TOTAL CHOLESTEROL
Cholesterol reacts with strong, concentrated acids as a typical alcohol, and the 
products are coloured substances. In all procedures, acetic acid and acetic 
anhydride are used as solvents and dehydrating agents and sulphuric acid is used 
as a dehydrating and oxidising agent.
A range of cholesterol standards (0.5 - 2.5 mg/ml glacial acetic acid) were 
prepared. 0.1 ml of either distilled water (blank), cholesterol standard, or plasma
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sample was pipetted into a cedi tube and 2.5 ml cholesterol reagent (0.05M 
dimethylbenzene sulphonic acid/glacial acetic acid/acetic anhydride, 1:1:3 by 
volume) was added to each tube and mixed. The tubes were placed in cold water 
for 5 minutes and then 0.5 ml concentrated sulphuric acid was added slowly. The 
tubes were mixed vigorously using a vortex mixer. The solutions were cooled for 
10 minutes and then poured into dry cuvettes and the optical density of the 
standards and test samples were read against the blank at 570nm. A  standard 
curve was prepared (figure 12) and the concentration of total cholesterol in the 
plasma samples calculated.
HDL CHOLESTEROL
HDL cholesterol was measured as above after the removal of LDL cholesterol and 
chylomicrons. These were removed by precipitation with sodium 
phosphotungstate solution (40 g phosphotungstic acid/1 of 16 parts IM  NaOH/84 
parts distilled water). 0.1 ml sodium phosphotungstate solution was added to 1 ml 
of serum and hand mixed. 0.025 ml magnesium chloride was added (40.7 g 
MgCl2.6H20) and vortex mixed. The solution was centrifuged at 1500 g at 4°C
for 30 minutes and the supernatant assayed for cholesterol as before. 
TRIGLYCERIDES
Triglycerides were measured using a Boehringer Mannheim Kit assay. An 
enzymatic colorimetric method was used based on the following test principle:
esterase
Triglycerides + 3 H2 O  >  Glycerol + 3RCOOH
glycerol kinase
Glycerol + ATP — -------------------------- >  Glycerol-3-phosphate + ADP
glycerol-3-phosphate oxidase
Glycerol-3-phosphate ------------------------------------ ------ >  dihydroxyacetone phosphate
+  O 2  + H 2 O 2
H2 O2  + 4-aminophenazone ->  4-(p-benzoquinone-monoimino)-
+ 4-chlorophenol phenazone + 2 H2 O + HCl
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The reagents provided in the kit were:
1. Tris buffer: 0.15 mol/1, pH 7.6; magnesium sulphate: 17.5 mmol/1; EDTA, 
disodium salt: 10 mmol/1; 4-chlorophenol: 3.5 mmol/1; sodium cholate: 
0.15%; potassium hexacyanoferrate (II): 6 umol/1; hydroxypolyethoxy-w- 
alkanes: 0.12%
2. ATP > 0.5 mmol/1; 4-aminophenazone: 0.35 mmol/1; lipase > 3 U/ml; 
glycerol phosphate oxidase > 2.5 U/ml; glycerol kinase > 0.2 U/ml; 
peroxidase > 0.15 U/ml.
A  bottle of each reagent was mixed together immediately prior to performing the 
assay. 0.02 ml of glycerol standard (range 2.6 mg glycerol/100 ml distilled water) 
or serum sample was mixed with 2.0 ml of the reagent mix and incubated at 20 - 
25°C for 10 minutes. The absorbance of the samples (Asample) and standards
were read against a reagent blank at 546 nm within 60 minutes and a glycerol 
standard curve was prepared which demonstrated the linearity of the assay over 
the range measured (figure 13).
The concentration (c) of triglyceride in the sample could be calculated as follows: 
c (mmol/1) — 11.9 X
QUANTITATIVE ANALYSIS OF PLASMA HORMONES 
PLASMA OESTROGEN
Plasma oestradiol-17B was determined by a radioimmunoassay method using a 
commercially purchased kit (Steranto Research Ltd.), routinely used in our 
Department. Analyses were carried out by the research team technician. All 
determinations were carried out in duplicate and internal quality control 
specimens were included at intervals in the batch assay.
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PLASMA PROLACTIN
Plasma prolactin was determined by a heterologous double antibody 
radioimmunoassay method in the Department of Clinical Biochemistry and 
Nutrition, St Lukes Hospital, Guildford. Ampoules of reference preparations 
were obtained from the RIA Unit, St Bartholemews Hospital, London, and these 
were used as standards. Rabbit anti-prolactin serum was obtained from Guildhay 
UK Ltd. Internal quality control specimens were included at intervals in each 
assay and the assay was carried out in duplicate.
ANTHROPOMETRIC AND DIETARY DETERMINATIONS
BODY FAT
Body fat was determined by the measurement of skin fold thickness at four sites 
(biceps, triceps, suprailiac and subscapular regions) and substitution o f the mean 
values into the equation derived by Dumin and Rahaman (1967). Three repeated 
measurements of skin fold thickness were taken at each site using Harpenden skin 
fold callipers and the average value used.
NUTRIENT INTAKE MEASUREMENTS
Intake of major nutrients were determined in volunteers by seven and four day 
weighed dietary intake records. Daily intakes of individual nutrients were 
calculated using the Compeat programme (Nutritional Lifeline Services Ltd), 
which uses a nutrient data base based on the Food Composition Tables of 
M^Cance and Widdowson (Paul & Southgate, 1978).
The above anthropometric and dietary determinations were carried out by two 
undergraduate students of the BSc Nutrition course, as part of their final year 
project work.
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CHAPTER THREE
AN INVESTIGATION OF THE EFFECT OF DIET ON THF. 
PHOSPHOLIPID HEAD GROUP COMPOSITION AND FATTY ACID 
PROFILE OF PHOSPHATIDYLINOSITOL, PHOSPHATIDYLCHOLINE 
AND PHOSPHATIDYLETHANOLAMINE IN NORMAL RAT 
MAMMARY TISSUE AND ERYTHROCYTES
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INTRODUCTION
For many years after the identification of phospholipids in membranes, it was 
believed that they were purely inert, structural components of the cell membrane. 
It is now known, however, that they are neither 'inert' nor 'purely structural'. 
Membrane phospholipids constantly undergo de-and re-acylation reactions, so that 
their constituent fatty acids may be renewed according to specific tissue needs, 
and the fatty acids available. In this way phospholipid fatty acid composition can 
have profound effects upon the physical and functional properties of cell 
membranes.
Alterations of the membrane lipid environment have been shown to effect changes 
in the kinetic parameters of the membrane bound Na+, K+ -ATPase (Solomonson 
et a l, 1976), cell permeability and nutrient transport systems (Kaduce et a l, 
1977), and membrane fluidity (Berlin et a l, 1980; King et a l, 1977). It has also 
been suggested that the specific fatty acid composition of the phospholipids is 
important in protein conformation and receptor function (Wahle, 1983; Cave & 
Erickson Lucas, 1982).
Furthermore, phosphatidylinositol is now known to be involved in membrane 
signal transduction in a number of cells and it is believed that its characteristic 
fatty acid composition, with a preponderance of arachidonic acid (20:4^6) at the 
sn-2 position, may be vital for prostaglandin formation as part of the second 
messenger function of this phospholipid. With the development of 
chromatographic techniques for the separation and identification of phospholipids 
and their fatty acyl moieties, there has been an increase in the studies to elucidate 
the fatty acid profile of phospholipids in a variety of species and tissues and to 
investigate their susceptibility to dietary modification.
In comparing various laboratory animals and human tissues, Horrobin et a l, 
(1984) found major differences in the fatty acid profiles of total phospholipids
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from plasma, red blood cells and liver of different species. In all three tissues it 
was found that compared with humans, rat phospholipids contain at least twice as 
much arachidonic acid (20:4w6) and smaller amounts of palmitic (16:0), oleic 
(18:lw9) and w3 fatty acids. Conversely, rabbit tissues contained half as much 
arachidonic acid (20:4w6) in total phospholipids than did the human tissues.
In an investigation of phospholipid fatty acid profiles in different tissues in the 
rat, Gibson et al., (1984) found that the total phospholipid fractions from each 
tissue showed remarkably different fatty acid compositions. For example, brain 
phospholipids contained 8% arachidonic acid (20:4>v6) compared with 
approximately 20% in the phospholipids from plasma, red blood cells and liver. 
Alternately the brain phospholipids contained far higher quantities of 
docosahexaenoic acid (22:6w3). This difference in tissue membrane phospholipid 
fatty acid composition reflects the specific needs of the tissue. For instance, 
docosahexaenoic acid (22:6w3) is important in neurotransmission and is found in 
higher quantities in the brain and neurones. Arachidonic acid (20:4w6), however, 
is important in prostaglandin 2 series formation and is found in large amounts in 
platelets, where prostaglandins play an important secondary messenger role in the 
regulation of platelet aggregation.
Most studies of this kind have concentrated on total phospholipids and there is 
only limited information on the diversity of the individual phospholipid classes. 
However, Nakashima et al., (1984) have shown that the major phospholipid 
classes in the mouse have very different profiles from each other. For example, 
phosphatidylethanolamine contained more of the w3 fatty acid, docosahexaenoic 
acid (22:6w3), and also more arachidonic acid (20:4w6) than the other 
phospholipid classes in erythrocytes, plasma, liver and spleen. 
Phosphatidylcholine exhibited more palmitic acid (16:0) and linoleic (18:2w6) 
acid and the combined phosphatidylserine and inositol fraction showed a 
preference for stearic (18:0) and arachidonic (20:4w6) acids.
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Animal feeding studies have shown that the phospholipid fatty acid composition 
may be manipulated by dietary means. It has been demonstrated that feeding 
rodents diets rich in w3 fatty acids results in these fatty acids and their metabolites 
being incorporated into phospholipids with a subsequent reduction in the amount 
of w6 fatty acids, (Iritani & Narita, 1984; Weiner & Sprecher, 1984). Similarly 
feeding rats a diet rich in oleic (18:lw9) acid causes this fatty acid, and its 
metabolite, 20:3w9 to be incorporated into phospholipids (Weiner & Sprecher,
1984), 18:lw9 being incorporated mostly into phosphatidylcholine and the 
metabolite 20:3w9 predominantly in the other phospholipid fractions.
Although it has been shown that dietary fatty acids can be incorporated into 
phospholipids, this dietary effect has not been widely investigated in different 
tissues or indeed in different phospholipid classes. The limitations of such 
investigations apply particularly to the minor phospholipids, phosphatidylserine 
and phosphatidylinositol which are difficult to separate chromatographically. It is 
as yet unclear what physiological significance the characteristic fatty acid profiles 
o f the individual phospholipids confer, or indeed to what extent dietary 
modification of the fatty acid profile affects the function of the phospholipid 
moiety. However, it has been argued that each tissue has a specific fatty acid 
profile which reflects specific functional needs and that each phospholipid itself 
has a characteristic profile (Wahle, 1990). If this is so dietary modification may 
cause profound changes in the membrane functions of some tissues.
In view of the wide variation in both the fat content and fatty acid composition of 
human diets, and current interest in the role of dietary fat in the aetiology of 
chronic diseases of man, it is clearly important to establish the effects which 
dietary fat modification may have on membrane structure and function in 
different tissues.
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Although studies of effects of dietary fat modification have been carried out in a 
range of tissues in animals and humans, there has been little investigation of the 
effect of diet on breast (mammary) epithelial membrane phospholipid fatty acids.
It is envisaged that breast tissue phospholipids, being surrounded and possibly 
influenced by adipocytes, are likely to be affected by dietary modification. 
Furthermore, breast tissue is highly hormone responsive and therefore, it may be 
hypothesized that changes in phospholipid fatty acid composition may be 
particularly relevant to the effect of hormone action on breast tissue, with 
particular regard to receptor function and signal transduction mechanisms. With 
the current interest in the role of dietary fat in breast disease, together with the 
knowledge that dietary modification of phospholipids may cause functional 
changes of the cell membrane, it would seem pertinent to investigate the fatty acid 
profile and head group composition of mammary cell membrane phospholipids 
and their dietary modification.
Few investigations have concentrated on looking at the incorporation o f different 
fatty acids into individual phospholipid components of the cell membrane, 
however, some studies have suggested that phosphatidylinositol is less responsive 
to dietary manipulation than the choline and ethanolamine phospholipids in 
certain tissues. This study was therefore designed to investigate the dietary 
modification of phosphatidylinositol specifically in mammary tissue. Choline and 
ethanolamine phospholipids were also studied because they are the major cell 
membrane phospholipids, they have been more extensively studied and are 
therefore useful for comparisons. Also they are important cell sources of the 
prostaglandin precursor, arachidonic acid (20:4w6), the membrane content of 
which is thought to play an important role in breast disease.
Three diets were investigated, com oil which is rich in w6 fatty acids, fish oil 
(MaxEPA) which is rich in w3 fatty acids and 18:lw9 rich olive oil. The
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incorporation of the w6 and w3 fatty acids is of particular interest with respect to 
the hypothesis that w3 fatty acids may be protective against breast disease. Olive 
oil was studied because this oil has been little studied in relation to effects on 
mammary tissue and is relevant to the present study in view of the low incidence 
of breast cancer in Mediterranean countries.
Dietary modification of mammary tissue phospholipid fatty acid composition has 
never before been investigated and as such the speed and extent to which changes 
may occur is unknown. Erythrocytes on the other hand have been extensively 
studied and changes are known to occur within ten days of feeding rats different 
diets. Erythrocytes were studied in the current investigation in order to compare 
changes in red blood cells with those in the mammary cell membranes and to 
allow comparison of the data with that of other investigations.
Not only was the incorporation of individual fatty acids investigated, but also the 
resultant changes in polyunsaturatedisaturated fat ratio, and stearicroleic acid 
ratio. The rationale for this being that increased polyunsaturatedisaturated fat 
ratios lead to increased membrane fluidity which may affect cell function (Awad, 
1986). The stearicioleic acid ratio was examined because o f evidence of a 
decreased stearicioleic acid ratio in erythrocytes being associated with 
malignancies (Wood et al, 1985a).
The aims of this study were also to investigate the phospholipid composition of 
mammary and erythrocyte membranes. Little is known about phospholipid 
membrane composition, and the particular function for each phospholipid within 
the plane of the membrane. However, it would appear that different tissues 
possess very different phospholipid compositions probably depending on the 
protein structure and functioning of the membrane. It was therefore o f interest to 
see if the phospholipid composition of membranes could be modified by dietary
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means, or whether, as has been suggested (Wahle, 1990), this membrane 
characteristic is rigidly controlled.
METHODS
Forty eight, thirty day old, female Sprague Dawley rats, weighing approximately 
80g, were divided into two groups. One group was administered a carcinogen to 
study dietary effects o f tumour growth and the results of this experiment will be 
discussed in the following chapter. The remaining twenty four animals were sub­
divided into three dietary groups and were housed four per cage. All rats were 
supplied with water and food ad libitum. The diet was composed of starch (35% 
weight, BDH); sucrose (30% weight, household); casein (20% weight, G.Fiske & 
Co. Ltd., Richmond, Surrey); solka floe (4% weight, grade BW2030, Johnsen, 
Jurgensen & Wettre Ltd., Wokingham, Berks.); mineral mix (4% weight, 
CaHPO,, BDH; Na,HPO„ BDH; CaCO,, BDH; KCl, Fisons; MgSO,+H,0, BDH; 
ZnCOg, BDH; FeS0,.7H ,0, BDH; CuS0 ,.5H2 0 , BDH; KIO„ BDH; M nS0,.H ,0, 
BDH); vitamin mix (2% weight, nicotinic acid, calcium-^f-pantothenate, thiamine
Vitamin
hydrochloride, riboflavine, pyridoxine folic acid, J-biotin,^B12 and choline 
bitartrate, SIGMA; Vitamin K l, BP Nutrition; Rovimix E-50, A-500 & D-3500, 
Roche); methionine (0.2% weight, SIGMA) and either com oil (household), olive 
oil (household) or MaxEPA (British Cod Liver Oils, Hull) (4% weight). The fatty 
acid composition of each of the diets can be seen in Table 7. The diet was mixed 
weekly and stored at -20°C until required. The food pots were changed daily 
Sunday to Friday inclusive. Food intakes and weekly body weight were 
monitored for all the rats.
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Table 7. PERCENTAGE FATTY ACIDS IN THE CORN OIL, OLIVE OIL AND 
MAX EPA DIETS.
Results expressed as mol% of detected fatty acids.
Fatty acid Corn oil Olive oil MaxEPA
16:0 10.33 05.15 16.50
16:lw9 00.13 02.58 11.78
18:0 01.40 02.12 03.81
18:lw9 24.73 72.19 12.94
18:2w6 60.72 12.21 03.80
lS:3w3 01.24 00.91 03.14
20:3w6 00.16 00.50 06.51
20:4w6 00.06 00.00 00.72
20:5w3 00.61 00.42 19.41
22:4w6 00.06 00.69 01.26
22:5w3 00.00 00.14 01.50
22:6w3 00.22 00.25 10.23
The animals in this study were the control animals in a further study o f dietary 
modification in control and mammary tumour induced rats, described in Chapter 
4. Sacrifice of the animals therefore coincided with the sacrifice of an appropriate 
dietary paired tumour bearing animal. This protocol meant that data presented
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from animals described in the present study had been following the dietary regime 
for a period of not less than 16 weeks and not more than 20 weeks. The animals 
were killed by decapitation having first been anaesthetised with ether.
Blood was collected into tubes containing sodium citrate (lOg/1) and mammary 
tissue was excised. After weighing the tissue, the samples were taken to the 
laboratory for immediate extraction of lipids as previously described in Chapter 2 
(page 36).
After extraction of the lipids, thin layer chromatography was used to separate the 
phospholipid classes (Chapter 2, page 37). The inositol, choline and 
ethanolamine phospholipids were removed for fatty acid analysis (Chapter 2, page 
42), and all phospholipids were analysed for their composition of the membrane 
relative to the other phospholipids isolated by determining their phosphate content 
(Chapter 2, page 51).
Statistical analysis of the data was performed using the statistics program SPSS-X 
on the prime mainframe at the University of Surrey. The Duncan's range test was 
used for analysis of data between the three dietary groups and students paired t- 
test was used for within rat mammary versus erythrocyte analyses. Where data 
was found to have an unacceptable level of variance using Cochrans C, Bartlett- 
Box or Maximum/Minimum variance tests, statistical analyses were performed on 
log 1 0 , natural log or square root transformed data; p<0.05 was considered to be 
statistically significant.
The stearic (18:0) to oleic (18:lw9) acid ratio (S:0) and polyunsaturated to 
saturated fatty acid ratio (P:S) of each dietary group was also calculated and 
statistical analyses performed on the data.
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Some samples were lost at various stages through the procedures from lipid 
extraction to fatty acid analysis. In these instances the number of cases analysed 
was less than 8 , as indicated on the tables and figures.
RESULTS
The mean food intake for each dietary group is shown in Table 8 . The rats fed 
olive oil had a mean intake of 102 .8g/rat/week which was significantly higher 
than the intake of both the com oil and MaxEPA groups (p<0.05). The growth 
rate of the rats in each group can be seen in figure 14. The mean body weight of 
animals was not significantly different between the three dietary groups (Table 9).
TABLE 8. MEAN FOOD INTAKES (WEEKS 1 TO 15) IN ANIMALS FROM THE 
THREE DIETARY GROUPS.
Results expressed in g/rat/week (mean + standard deviation)
CORN OIL OLIVE OIL MAX EPA
n=8  n=8  n=8
93.8 + 6.35 102.8 + 6 .67*  95.7 ±8 .45
* p<0.05 compared with Corn oil and MaxEPA groups
TABLE 9. MEAN BODY WEIGHT AT TIME OF SACRIFICE FOR RATS IN THE 
THREE DIETARY GROUPS.
Results expressed in grams (mean + standard deviation)
CORN OIL OLIVE OIL MAX EPA
n= 8  n=8  n=8
266.5 + 16.46 277.13+ 16.18 274.75 + 18.36
Table 10 shows the mean age at sacrifice which was not significantly different 
between any group.
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TABLE 10. MEAN AGE AT SACRIFICE.
Results expressed in days (mean + standard deviation)
CORN OIL OLIVE OIL MAX EPA
n=8 n=8 n=8
100+ 12  120+ 15 110 + 45
Tables 11, 12 and 13 show the fatty acid profiles of inositol, choline and 
ethanolamine phospholipids respectively, from the rat mammary tissue in each of 
the three dietary groups. There were no differences in the phosphatidylinositol 
fatty acid compositions between the dietary groups (Table 11). 
Phosphatidylcholine (Table 12) showed small but significant differences between 
the dietary groups in palmitoleic (16:lw9) and linoleic (18:2w6) fatty acids 
(p<0.05). Phosphatidylethanolamine (Table 13) showed the greatest response to 
dietary modification, with linoleic (18 :21+6) acid being found in significantly 
higher amounts in the com oil group than in either the olive oil or the MaxEPA 
group (p<0.01). The MaxEPA group contained more docosapentaenoic acid 
(22:5iv3) than either the com oil or the olive oil groups (p<0.01) and more 
docosahexaenoic acid (22:6w3) than the com oil group (p<0.05). There were also 
higher amounts of arachidonic acid (20:4v+6) in the com oil group than the olive 
oil and MaxEPA groups, although this did not reach statistical significance.
The fatty acid profiles of red blood cells were more responsive to dietary 
modification than was the mammary tissue (Tables 14, 15 and 16). In all three 
phospholipids both linoleic (18:2>v6) and arachidonic (20:4>+6) acids were found 
in decreasing quantities in the groups com oil > olive oil > MaxEPA. Olive oil 
feeding did not result in oleic (18:lw9) acid being incorporated into any o f these 
phospholipids to a significant extent compared with feeding com oil or MaxEPA. 
In both phosphatidylcholine (Table 15) and phosphatidylethanolamine (Table 16) 
there was a significant decrease (p<0.01) in the polyunsaturatedisaturated fatty
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acid ratio, caused by an increase in saturated fatty acids and a decrease in 
polyunsaturated fatty acids, of which neither factor alone was significantly altered 
with diet. The MaxEPA group did not show significantly higher amounts of 
eicosapentaenoic (20:5i+3), docosapentaenoic (22:5>+3) or docosahexaenoic 
(22:6w3) acids than the other two groups in any of the three phospholipids, and in 
fact, in phosphatidylcholine there was significantly more of these fatty acids in the 
com oil group. In phosphatidylcholine and phosphatidylethanolamine there was 
significantly more of the saturated fatty acids in the olive oil and MaxEPA groups 
than in the com oil group and consequently significantly lower polyunsaturated to 
saturated fatty acid ratios (p<0.01).
The fatty acid profiles of mammary tissue and erythrocytes are very dissimilar in 
many respects (Table 17). In particular, the arachidonic acid (20:4>+6) content of 
all three phospholipids was much higher in erythrocytes than mammary tissue 
membranes although this difference only attained significance in 
phosphatidylinositol and phosphatidylethanolamine (p<0.05).
Diet had no significant effect on phospholipid headgroup composition in either 
the mammary tissue or erythrocytes (figures 15 & 16; Appendix I, Table 32). 
Also the phospholipid compositions of the two tissue membranes were very 
similar, the most marked differences being more phosphatidylcholine and less 
phosphatidylserine in the mammary tissue compared with erythrocytes. These 
differences, however, were not statistically significant due to the large variance. 
In the MaxEPA dietary group there were small but significant differences between 
mammary and erythrocyte phosphatidyl-inositol and phosphatidylethanolamine; 
the mammary tissue containing less phosphatidylinositol and more 
phosphatidylethanolamine (p<0.05).
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TABLE 11 : COMPARISON OF THE FATTY ACID PROFILE OF
PHOSPHATIDYLINOSITOL FROM MAMMARY TISSUE OF RATS FED
DIETS CONTAINING EITHER CORN OIL, OLIVE OIL OR MAX-EPA.
Results expressed as mol% (mean + standard deviation)
Fatty acid Corn oil Olive oil MaxEPA
n=8 n=7 n=6
16:0 22.99 ±  5.53 26.89 + 2.17 27.12 + 2.07
16:lw9 2.07 ±  1.92 2.13 + 1.58 1.15 + 1.58
18:0 31.09 + 8.16 28.31 ±  5.73 28.54 + 4.81
18:lw9 13.81 ±10.04 10.48 + 3.68 7.74 + 6.91
18:2w6 3.42 ±  3.03 1.87 + 0.68 4.09 + 6.91
18:3w3 2.30 ±  1.00 3.01 + 1.12 3.43 + 1.75
20:3w6 5.52 ±  6.91 5.33 + 1.81 4.67 + 1.68
20:4w6 7.52 + 3.77 7.27 + 1.87 9.08 + 3.50
20:5w3 1.19 + 1.44 1.63 + 0.94 1.62 + 1.07
22:4w6 0.89 ±  1.04 1.17 + 0.50 1.07 + 0.91
22:5w3 2.36 ±  1.23 2.75 + 0.74 3.75 + 2.17
22:6w3 3.02 ±  1.59 4.48 + 1.82 4.23 + 1.15
S :0 3.43 + 2.12 3.13 + 1.49 3.88 + 1.20
P:S 0.49 ±  0.13 0.51 + 0.13 0.58 + 0.12
Statistical analyses performed by Duncan's range test. 
No two groups differed significantly from each other.
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TABLE 12: COMPARISON OF THE FATTY ACH) PROFILE OF
PHOSPHATIDYLCHOLINE FROM MAMMARY TISSUE OF RATS FED
DIETS CONTAINING EITHER CORN OIL, OLIVE OIL OR MAX-EPA.
Results expressed as moI% (mean + standard deviation)
Fatty acid Corn oil Olive oil MaxEPA
n=8 n=8 n=5
16:0 46.42 ±10.64 51.95 ±  5.57 46.69 ±11.05
16:lw9 0.43 ±  0.49 0.77 ±  0.72 1.71 ±  0.99 b
18:0 19.29 ±  5.39 19.28 ±  3.81 19.62 ±  2.01
18:lw9 6.12 ±  3.56 8.13 ±  3.49 11.00 ±  5.66
18:2w6 5.21 ±  3.67 2.05 ±  1.39 a 3.74 ±  1.95
18:3w3 1.40 ±  1.90 1.09 ±  0.83 0.67 ±  0.31
20:3w6 4.09 ±  4.41 2.42 ±  1.50 1.24 ±  0.36
20:4w6 6.78 ±  4.18 4.33 ±  1.65 2.87 ±  1.80
20:5w3 0.65 ±  0.72 0.74 ±  0.97 2.13 ±  2.25
22:4w6 0.54 ±  0.64 1.10 ±  1.22 0.06 ±  0.13
22:5w3 3.70 ±  2.90 1.99 ±  0.76 2.08 ±  0.40
22:6w3 2.34 ±  0.97 2.26 ±  1.01 2.66 ±  0.75
S :0 5.08 ±  5.50 2.86 ±  1.47 2.65 ±  2.21
P:S 0.45 ±  0.37 0.23 ±  0.09 0.24 ±  0.14
Statistical analyses performed by Duncan's range test.
a = Com oil and Olive oil groups significantly different (p<0.05) 
b = Corn oil and MaxEPA groups significantly different (p<0.05) 
c = Olive oil and MaxEPA groups significantly different (p<0.05) 
A  = Com oil and Olive oil groups signficantly different (p<0.01)
B = Com oil and MaxEPA groups significantly different (p<0.01) 
C = Olive oil and MaxEPA groups significantly different (p<0.01)
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TABLE 13 : COMPARISON OF THE FATTY ACH) PROFILE OF
PHOSPHATIDYLETHANOLAMINE FROM MAMMARY TISSUE OF 
RATS FED DIETS CONTAINING EITHER CORN OIL, OLIVE OIL OR 
MAX-EPA.
Results expressed as mol% (mean + standard deviation)
Fatty acid Corn oil Olive oil MaxEPA
n=8 n=7 n=6
16:0 18.04 ±  2.90 21.35 ±  5.81 21.68 + 5.09
16:lw9 3.33 + 1.11 3.75 ±  1.51 3.16 ±  1.57
18:0 19.38 ±  3.81 20.04 ±  4.22 19.74 + 3.88
18:l>v9 14.21 ±  4.62 18.27 ±  2.20 14.78 ±  1.87
18:2w6 5.90 ±  3.00 2.59 ±  0.69 A 2.30 ±  0.65 B
18:3w3 1.46 + 2.18 1.68 ±  0.98 1.47 ±  0.75
20:3w6 6.97 ±  1.71 7.57 ±  1.20 8.68 + 2.14
20:4w6 13.27 ±  4.33 10.27 ±  5.21 7.78 ±  2.84
20:5w3 4.00 + 1.90 2.89 ±  1.96 5.91 ±  4.57
22:4w6 4.44 + 2.37 3.98 ±  2.82 1.40 ±  1.54
22:5w3 1.84 + 1.11 1.84 ±  0.75 3.89 ±  2.02 B,C
22:6w3 2.19 ±  0.66 2.63 ±  0.86 4.39 + 1.63 b
S :0 1.51 ±  0.58 1.12 + 0.32 1.34 ±  0.20
P:S 1.09 ±  0.26 0.87 ±  0.39 0.94 ±  0.47
Statistical analyses performed by Duncan's range test.
a = Com oil and Olive oil groups significantly different (p<0.05) 
b = Corn oil and MaxEPA groups significantly different (p<0.05) 
c = Olive oil and MaxEPA groups significantly different (p<0.05) 
A  = Com oil and Olive oil groups signficantly different (p<0.01) 
B = Com oil and MaxEPA groups significantly different (p<0.01) 
C = Olive oil and MaxEPA groups significantly different (p<0.01)
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TABLE 14: COMPARISON OF THE FATTY ACH) PROFILE OF
PHOSPHATIDYLINOSITOL FROM ERYTHROCYTES OF RATS FED
DIETS CONTAINING EITHER CORN OIL, OLIVE OIL OR MAX-EPA.
Results expressed as mol% (mean + standard deviation)
Fatty acid Corn oil Olive oil MaxEPA
n=7 n=7 n=6
16:0 16.91 ±  3.67 20.51 ±  4.65 22.72 ±  4.91
16:l>v9 1.20 + 0.45 1.95 ±  2.01 1.31 ±  1.29
18:0 35.68 ±  3.65 36.05 ±  7.47 44.83 ±13.13
18:lw9 8.46 ±  2.08 9.67 ±  3.74 6.25 ±  2.46 b
18:2w6 2.58 + 0.43 1.30 ±  0.49 A 1.07 ± 0 .2 0  B
18:3w3 1.42 ±  0.96 2.01 ±  1.47 1.42 ±  0.89
20:3w6 2.23 ±  1.51 3.32 ±  1.05 2.66 ±  1.44
20:4w6 22.32 ±  9.31 13.15 ±  7.80 7.50 ±  4.90 B
20:5w3 1.10 ±  1.40 1.47 ±  1.14 2.80 ±  3.30
22:4w6 0.99 ±  0.42 1.28 ±  1.05 0.60 ±  0.54
22:5w3 0.99 + 0.70 1.70 ±  1.12 1.88 ±  1.35
22:6w3 1.87 ±  0.74 3.41 ±  2.17 3.46 ±  1.89
S:0 4.45 ±  1.25 4.01 ±  1.03 9.44 ±  7.46
P:S 0.65 ±  0.17 0.51 + 0.24 0.35 ±  0.23
Statistical analyses performed by Duncan's range test.
a = Com oil and Olive oil groups significantly different (p<0.05) 
b = Corn oil and MaxEPA groups significantly different (p<0.05) 
c = Olive oil and MaxEPA groups significantly different (p<0.05) 
A  = Com oil and Olive oil groups signficantly different (p<0.01)
B = Com oil and MaxEPA groups significantly different (p<0.01) 
C = Olive oil and MaxEPA groups significantly different (p<0.01)
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TABLE 15: COMPARISON OF THE FATTY ACH) PROFILE OF
PHOSPHATIDYLCHOLINE FROM ERYTHROCYTES OF RATS FED
DIETS CONTAINING EITHER CORN OIL, OLIVE OIL OR MAX-EPA.
Results expressed as mol% (mean + standard deviation)
Fatty acid Corn oil Olive oil MaxEPA
n=7 n=7 n=5
16:0 31.55 ±10.07 46.98 ±  9.92 A 58.65 ±  5.61 B,c
16:lw9 0.90 ±  0.79 0.53 ±  0.66 0.68 ±  0.24
18:0 16.82 ±  8.92 27.81 ±  7.20 A 26.30 ±  3.57 b
18:lw9 7.13 ±  4.47 9.45 ±  3.02 5.83 ±  4.44
18:2w6 2.53 ±  0.77 2.33 ±  1.06 1.08 ±  0.75 B,c
18:3w3 3.19 ±  5.25 0.43 ±  0.31 0.21 ±  0.12
20:3w6 4.59 ±  2.67 1.89 ±  2.89 a 1.45 ±  0.34 B
20:4w6 13.59 ±  7.21 3.53 ±  1.72 A 1.44 ±  0.83 B
20:5w3 2.30 ±  2.37 0.60 ±  0.96 0.98 ±  1.17
22:4w6 1.07 ±  2.05 0.44 ±  0.20 0.40 ±  0.50
22:5w3 7.09 ±  3.45 1.45 ±  1.74 A 0.97 ± 0 .5 9  B
22:6w3 2.43 ±  0.77 1.13 ±  0.77 A 1.03 ±  0.37 b
S :0 4.39 ±  6.33 3.48 ±  1.99 11.63 ±12.91
P:S 1.04 ±  0.36 0.20 ±  0.23 A 0.08 ±  0.04 B
Statistical analyses performed by Duncan's range test.
a = Com oil and Olive oil groups significantly different (p<0.05) 
b = Corn oil and MaxEPA groups significantly different (p<0.05) 
c = Olive oil and MaxEPA groups significantly different (p<0.05) 
A = Com oil and Olive oil groups signficantly different (p<0.01)
B = Com oil and MaxEPA groups significantly different (p<0.01) 
C = Olive oil and MaxEPA groups significantly different (p<0.01)
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TABLE 16; COMPARISON OF THE FATTY ACH) PROFILE OF
PHOSPHATIDYLETHANOLAMINE FROM ERYTHROCYTES OF RATS 
FED DIETS CONTAINING EITHER CORN OIL, OLIVE OIL OR MAX­
EPA.
Results expressed as mol% (mean + standard deviation)
Fatty acid Corn oil Olive oil MaxEPA
n=6 n=7 n=6
16:0 18.15 + 1.61 27.91 ±  6.58 A 28.80 ±  5.54 B
16:lvv9 3.78 ±  0.92 2.98 ±  1.10 3.62 + 1.25
18:0 9.63 + 0.64 14.69 + 2.75 A 16.06 ±  2.63 B
18:lw9 14.73 ±  2.90 15.73 ± 4.61 11.82 ±  4.20
18:2w6 3.70 ±  0.53 2.16 ±  0.84 A 1.49 + 0.23 B
18:3w3 1.75 ±  0.40 2.58 ±  1.42 4.50 ±  1.59 B,c
20:3w6 6.33 ±  3.21 6.78 ±  2.49 7.91 + 1.67
20:41+6 20.37 ±  1.80 11.85 + 3.55 A 5.34 + 2.13 B,C
20:5w3 3.83 ±  2.76 3.97 + 2.10 6.05 + 4.17
22:4i+6 8.24 ±  1.92 2.40 ±  3.57 A 1.46 + 0.61 B
22:5i+3 1.36 ±  0.52 1.62 ±  2.32 2.47 + 2.39
22:6i+3 1.32 ±  0.62 2.25 ±  0.91 2.40 + 1.35
S :0 0.67 ±  0.12 1.03 ±  0.43 0.16 + 0.70 B
P:S 1.70 ±  0.20 0.84 ±  0.33 A 0.73 + 0.32 B
Statistical analyses performed by Duncan's range test.
a =vCom oil and Olive oil groups significantly different (p<0.05) 
b = Corn oil and MaxEPA groups significantly different (p<0.05) 
c = Olive oil and MaxEPA groups significantly different (p<0.05) 
A  = Com oil and Olive oil groups signficantly different (p<0.01)
B = Com oil and MaxEPA groups significantly different (p<0.01) 
C = Olive oil and MaxEPA groups significantly different (p<0.01)
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DISCUSSION
The mean food intakes (g/rat/week) shown in Table 8 indicate that the olive oil 
group ate significantly more per week than the com oil and MaxEPA groups 
(p<0.05). This is reflected in a numerically larger mean body weight at sacrifice. 
However, this was not significant and should not adversely affect the 
interpretation of the results.
This is the first study of the fatty acid profile of phosphatidylinositol in rat 
mammary tissue and as such direct comparisons with findings from other 
laboratories are not possible.
The results presented in Table 11 demonstrate that this minor membrane 
component was not modified by diet in the mammary tissue, possibly indicating 
that there is very tight control of the fatty acid profile of this phospholipid. 
However, the results of the present study do show fatty acid modification of 
phosphatidylcholine (Table 12) and phosphatidylethanolamine (Table 13). 
Similarly, in human platelets, Galloway et al, (1985) have demonstrated that after 
fish oil supplementation, eicosapentaenoic acid (20:5w3) was incorporated into 
phosphatidylcholine and phosphatidylethanolamine to a considerable degree but 
showed no incorporation of these polyunsaturated fatty acids into 
phosphatidylinositol or phosphatidylserine. Galloway et a l, (1985) showed the 
incorporation of eicosapentaenoic acid (20:5w3) was concomitant with a decrease 
in the amount of arachidonic acid (20:4w6) in the two phospholipids concerned. 
The displacement of arachidonic acid (20:4w6) by eicosapentaenoic acid (20:5w3) 
is a well reported phenomenon in platelets (Galloway et a l, 1985), red blood cells 
(Popp Snijders, 1986), rat liver and mammary tumours (Jurkowski & Cave, 
1985), and rat brain and neurones (Philbrick et al, 1987). In contrast to these and 
our own findings Glenn and Dam (1965) demonstrated that arachidonic acid 
(20:4w6) content of chick liver phosphatidylinositol was decreased by feeding 
linseed oil, and both the docosapentaenoic acid (22:5w3) and docosahexaenoic
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acid (22:6w3) content increased. Weiner and Sprecher (1984) have shown that 
diet can cause a significant change in rat platelet and liver phosphatidylinositol. 
For example, the arachidonic acid (20:4w6) content of platelets ranged from 18.2 
mol% to 40.3 mol% depending on the dietary fat, and similarly for liver the 
arachidonic acid (20:4w6) content ranged from 6.7 mol% to 39.7 mol%. 
However, in their study, Weiner and Sprecher used purified fatty acid ethyl esters 
as the sole fat source and thus only one fatty acid was found in the diet whereas 
most animal feeding studies use a mixed fatty acid fat source. Other discrepancies 
may be due to length of feeding, sex of animals and tissues studied - liver tissue 
being particularly susceptible to dietary fatty acid modifications.
The results presented here clearly show that diet had no effect on the fatty acid 
profile of m am m ary phosphatidylinositol during a 16 week period o f feeding. 
However, phosphatidylinositol in erythrocytes from animals fed olive oil and 
MaxEPA contained significantly less linoleic (18:2w6) and arachidonic (20:4w6) 
acids than did the erythrocyte phosphatidylinositol from animals fed the com oil 
diet. Erythrocyte phosphatidylinositol from the MaxEPA group also contained 
significantly more palmitic acid (16:0) than the com oil group. Nevertheless, it is 
noticeable that in both tissues, the phosphatidylinositol showed a lesser degree of 
dietary modification of its fatty acid profile than did the phosphatidylcholine and 
phosphatidylethanolamine fractions. These results may reflect stricter control of 
this functionally important membrane component.
There are only a few studies investigating the effect of diet on individual 
phospholipid fatty acid compositions, and these are diverse in terms o f tissues and 
species. However, it is clear from a number of studies on human red blood cells 
(Popp Snijders et a l, 1986), human platelets (Galloway et a l, 1985), chick liver 
(Glenn and Dam, 1965) and rat liver (Iritani et a l, 1988), that feeding fish oils or 
diets rich in w3 fatty acids, causes a decrease in the w6 fatty acids, linoleic 
(18:2w6) acid and arachidonic acid (20:4w6), and an increase in the w3 fatty acids
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docosapentaenoic (22:5w3) and docosahexaenoic (22:6w3) acids in both 
phosphatidylcholine and phosphatidylethanolamine. Dietary changes are readily 
apparent in the latter phospholipid when experimental diets are compared with a 
normal diet or a com oil rich diet. The results of the present study show that the 
mammary tissue phosphatidylethanolamine fraction (Table 13) responded to fish 
oil feeding since there was significantly more docosapentaenoic (22:5w3; 2.05 
mol%) and docosahexaenoic (22:6w3; 2.2 mol%) acids in the fish oil group than 
the com oil group, with less linoleic (18:2w6), arachidonic (20:4w6) and 
docosatetraenoic (22:4w6) acids (3.6 mol%, 5.49 mol% and 3.04 mol% 
respectively). However, in erythrocytes (Table 16), although there was much less 
arachidonic acid (20:41+6; 15 mol% less) in this phospholipid on feeding fish oil 
compared with com oil, and also significantly less linoleic acid (18:2w6; 2.21 
mol%), there was only a slight increase in the w3 fatty acids which, apart from 
linolenic acid (18:3i+3; 2.75 mol%) were not significantly increased. There was, 
however, a significantly greater amount of palmitic acid (16:0; 10.65 mol%) and 
stearic acid (18:0; 6.43 mol%).
These data suggest that, in mammary tissue, changes in phosphatidylethanolamine 
fatty acid composition reflect displacement of arachidonic acid (20:4>+6) with a 
corresponding increase in the desaturation and chain elongation products of 
eicosapentaenoic acid (20:5i+3). However, in erythrocytes the changes are more 
complex and less predictable from a knowledge of the fatty acids fed in the 
different diets. In general feeding fish oils resulted in an increase in the saturated 
fatty acids, whilst also decreasing w6 fatty acids with no effect on w3 fatty acids. 
The net effect was a significant decrease in the P:S ratio of 
phosphatidylethanolamine.
Mammary tissue phosphatidylcholine (Table 12) did not appear to be much 
affected by diet. The only significant difference between the com oil and 
MaxEPA groups was the latter contained 1.14 mol% more palmitoleic acid
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(16:l>+9). On the other hand, erythrocyte phosphatidylcholine showed
significantly more saturated fatty acids, (27.1 mol% palmitic (16:0) acid and 9.48 
mol% stearic (18:0) acid) in the fish oil group compared with the com oil group. 
As expected there was also less linoleic (18:2w6) and arachidonic (20:4w6) acids 
(1.45 mol% and 12.54 mol% respectively) in the fish oil group. Surprisingly,
however, there were less eicosapentaenoic (20:5w3) (1.32 mol%; NS)
docosapentaenoic (22:5w3) (6.12 mol%) and docosahexaenoic (22:6w3) (1.4 
mol%) acids in the fish oil group than in the com oil group, a reflection o f the 
much greater incorporation of saturated fatty acids into this phospholipid in the 
MaxEPA group. Thus a similar trend is apparent in red blood cell
phosphatidylcholine as in phosphatidylethanolamine with fish oil causing a 
marked increase in palmitic (16:0) and stearic (18:0) acids and a decrease in 
arachidonic (20:4w6), docosatetraenoic (22:4w6) and linoleic (18:2w6) acids, but 
no significant effect on eicosapentaenoic (20:5w3) acid. Thus the response is not 
a simple displacement effect, but involves compensatory changes in saturated 
fatty acids.
The dietary effect of olive oil on membrane phospholipid fatty acid composition 
has not previously been extensively investigated. Dougherty et a l, (1987) have 
shown in a comparison of the fatty acid profiles of red blood cells and platelet 
phospholipids of men from three different countries, that phospholipids of men 
from Italy, where consumption of olive oil is high, contain more oleic (18:lw9) 
acid and less stearic (18:0) acid than phospholipids of men from America and 
Finland. This effect was particularly noticeable in red blood cell phosphatidyl­
serine and phosphatidylethanolamine and platelet phosphatidylinositol and 
phosphatidylethanolamine. Also, there were less v+6 fatty acids in the 
phospholipids from the Italian men compared with Finnish and American men.
Weiner and Sprecher (1984), showed that feeding a diet containing oleic acid 
(18:lw9) ethyl ester caused this fatty acid to be incorporated into the
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phosphatidylcholine and phosphatidylserine fractions of rat platelets and liver to a 
greater extent than rats fed chow. This fatty acid was not so prevalent in the 
phosphatidylethanolamine and phosphatidylinositol fractions. They found there 
was less arachidonic acid (20:4w6) in all phospholipid fractions on feeding oleic 
acid (18:lw9) ethyl ester as the dietary fat. In the present study, feeding olive oil 
(72% oleic acid) resulted in oleic acid (18:lw9) being higher in mammary tissue 
phosphatidylethanolamine compared with feeding MaxEPA (18.27 mol% in the 
olive oil group compared with 14.78 mol% in the MaxEPA group), although this 
was not statistically significant. There was no significant effect of olive oil on the 
arachidonic acid (20:4w6) content of the tissues. No other phospholipid in either 
tissue showed a significantly greater degree of oleic (18:lw9) acid incorporation 
in response to the olive oil diet. However, in erythrocytes the arachidonic acid 
(20:4w6) content of all three phospholipids was lower from rats fed olive oil 
compared with rats fed com oil (significant in phosphatidylcholine and 
phosphatidylethanolamine only, p<0.01), these results being consistent with those 
of Weiner and Sprecher (1984) for platelets and liver. In all three phospholipids 
the arachidonic acid (20:4w6) content of erythrocytes was even lower in animals 
fed MaxEPA although this only attained a statistically significant difference from 
the olive oil group in phosphatidylethanolamine.
It can be seen from Tables 11 and 16 that in both rat mammary tissue and red 
blood cells, the fatty acid profile of phosphatidylinositol, choline and 
ethanolamine differ greatly from one another. For instance in both tissues, 
phosphatidylethanolamine has a much higher polyunsaturated fatty acid to 
saturated fatty acid ratio, phosphatidylinositol contains more stearic acid (18:0) 
and phosphatidylcholine contains larger amounts of palmitic acid (16:0).
Furthermore, the fatty acid profiles of the individual phospholipids are markedly 
different in the two tissues studied (Table 17, com oil diet only shown). In 
particular, in all three phospholipids, arachidonic acid (20:4w6) levels were higher
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in erythrocytes than in mammary tissue, although this was only significant in the 
phosphatidylinositol and phosphatidylethanolamine fractions.
The demonstration in this study that each phospholipid class has a characteristic 
fatty acid pattern which differs from one tissue type to another would be in 
agreement with all the literature to date, in many species. Nakashima et a l, 
(1984) have shown that sphingomyelin, phosphatidylcholine, 
phosphatidylethanolamine and phosphatidylserine/inositol fractions all have 
different fatty acid profiles in mouse liver, spleen and brain. In particular, 
phosphatidylethanolamine contained more w3 fatty acids than the other 
phospholipids. The phosphatidylserine and inositol fraction (these two 
phospholipids were not separated), incorporated more docosahexaenoic acid into 
the brain tissue (20.5%) compared with liver (9.2%) and spleen (9.0%) with a loss 
of arachidonic acid (20:4v+6; 8.65% in brain compared with liver 22.8% and 
spleen 19.0%).
Phosphatidylethanolamine has been shown to incorporate the long chain w3 fatty 
acids eicosapentaenoic acid (20:5w3), docosapentaenoic acid (22:5w3) and 
docosahexaenoic (22:6w3) acid as well as the w6 arachidonic acid (20:4w6) to a 
greater extent than phosphatidylcholine in a variety of tissues such as human red 
blood cells (Manku et a l, 1983), rat liver and platelets (Iritani & Narita, 1984) 
and rat brain (Baker & Thompson, 1972). Phosphatidylcholine on the other hand 
contains more total saturated fatty acids, particularly palmitic acid (16:0), and also 
more linoleic (18:2w6) acid. This difference in fatty acid composition may reflect 
specific tissue needs.
There were far more differences in relation to diet among the red blood cells than 
the mammary tissue. This may be due to the relatively short life of the red blood 
cells, making them more responsive to the dietary fatty acid milieu as new cells 
are formed. It may also be due to a greater degree of homeostasis among the
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functionally important mammary membrane phospholipids, where small changes 
in the fatty acid composition of the phospholipids could affect membrane fluidity, 
receptor protein conformation and functioning, and activities o f membrane bound 
enzymes.
One important difference between the response of the two tissues to diet is that 
there was no alteration of the P:S ratio in mammary phospholipids, whereas in red 
blood cell phosphatidylcholine and phosphatidylethanolamine, the P:S ratio 
decreased in the order com oil>olive oil>MaxEPA, with the com oil group being 
significantly greater (p<0.01) than the olive oil and MaxEPA groups. An 
increased P:S ratio usually results in an increase in membrane fluidity which may 
be beneficial to red blood cell membranes, enabling them to squeeze through 
small blood vessels more easily. However, it is curious that in this study the com 
oil fed animals had a higher P:S ratio than the MaxEPA fed animals as part of the 
beneficial effects of marine oils are thought to be due to an increased membrane 
fluidity, and it may be that several factors act together in altering the viscosity of 
the membrane, not just the degree of unsaturation of the fatty acids. It is possible 
that fish oil feeding may also result in changes in membrane cholesterol content 
and that the increase in saturated fatty acids is a compensatory change to ensure 
membrane stability and cell shape.
Figures 15 and 16 show that there were no significant differences in the 
proportions of the phospholipids in either mammary tissue or erythrocyte 
membranes respectively, with dietary manipulation. Curiously, although different 
membranes are known to possess different proportions of the phospholipids, in 
the com oil and olive oil dietary groups, there were no significant differences 
between mammary tissue and erythrocyte membrane phospholipid composition. 
In the MaxEPA group, the phosphatidylinositol content of mammary tissue was 
significantly lower than the phosphatidylinositol content of erythrocytes. 
Conversely, phosphatidylethanolamine was significantly higher in mammary
tissue than red blood cells in the MaxEPA dietary group. Whether these 
differences have any functional significance, and why they should only be 
apparent in the MaxEPA group is not clear.
Several studies have previously shown that phospholipid composition is resistant 
to dietary fatty acid changes (Awad & Spector, 1976; Bums & Spector, 1987; 
Farquar & Ahrens, 1963). It has been demonstrated that the phospholipid fatty 
acid composition of the plasma membrane of different tumours can be modified, 
but there are no changes in membrane phospholipid or cholesterol content, or in 
phospholipid headgroup composition. Therefore, what occurs is a substitution of 
fatty acyl groups within the same phospholipid framework of the membrane.
In conclusion, it can be seen that the susceptibility to dietary modification varies 
amongst phospholipid classes, with phosphatidylethanolamine > phosphatidyl­
choline > phosphatidylinositol in both tissues. It can also be seen from this study 
that the fatty acid profiles of mammary tissue and erythrocyte phospholipids are 
very different, particularly with respect to arachidonic acid (20:4w6) content. The 
red blood cell phospholipids are more responsive to dietary manipulation than the 
mammary tissue phospholipids, with phosphatidylethanolamine responding most 
and phosphatidylinositol being the least responsive in both tissues studied. Red 
blood cell membranes are also more responsive to incorporation of 
polyunsaturated fatty acids than mammary tissue, particularly the w6 arachidonic 
acid (20:4w6), thus increasing the P:S ratio particularly in the com oil fed rats 
and, possibly, membrane fluidity. The phospholipid composition of erythrocytes 
and mammary tissue membranes is very similar, and is not responsive to dietary 
manipulation in either tissue.
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CHAPTER FOUR
AN INVESTIGATION OF THE EFFECT OF DIET ON ENU INDUCED 
TUMOUR INCIDENCE, AND A COMPARISON OF PHOSPHOLIPID 
CONTENT AND PHOSPHATIDYLINOSITOL, CHOLINE AND 
ETHANOLAMINE FATTY ACID PROFILES OF ERYTHROCYTES AND 
MAMMARY TISSUE MEMBRANES FROM ENU DOSED RATS AND 
NORMAL HEALTHY CONTROL RATS.
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INTRODUCTION
Initial experiments in 1953 established that animals fed a high fat diet exhibited 
tumours earlier and with more frequency than animals fed a low-fat diet 
(Tannenbaum & Silverstone, 1953). Since then many investigators have 
confirmed that a high fat diet results in an increased tumour incidence (at a variety 
of sites), and a decreased latency period in different strains o f rats (Chan & Dao,
1981), at different dose levels of the carcinogen 7,12-dimethylbenz(a)anthracene 
(Carroll & Khor, 1970) and also using the carcinogen «-nitrosomethylurea (Cave 
et al., 1979).
In particular, a large number of studies have shown that mammary tumour 
incidence can be affected by the type of fat fed. Fish oils containing w3 fatty 
acids (Karmali et al., 1984; Jurkowski & Cave, 1985; Kort et al., 1987) and 
coconut oil which contains mostly saturated fatty acids (Gabor et al., 1985) both 
decrease tumour incidence and increase the latent period when compared with rats 
fed corn oil diets, or normal rat chow.
In vitro, Wicha et a l, (1979) showed that addition of linoleic acid to the growth 
medium of normal and neoplastic rat mammary epithelial cells caused an increase 
in the growth rates whereas saturated free fatty acids inhibited growth o f both 
normal and neoplastic cells. These findings suggest that dietary fatty acids may 
promote tumourigenesis via direct effects on the mammary epithelial cell 
membrane.
However, it has also been noted that a high dietary fat intake may promote tumour 
growth in vivo, via an increase in circulating prolactin concentrations (Chan & 
Cohen, 1975). Cave & Erickson-Lucas (1982) have also demonstrated that NMU 
induced tumours in animals fed a high fat diet exhibit a greater lactogenic 
hormone receptor binding capacity than tumours from animals fed a low fat diet. 
This greater lactogenic hormone receptor binding was thought to be due to
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prolactin receptor binding. They hypothesized that alterations to the membrane 
fatty acid milieu caused modification of the membrane prolactin receptor proteins, 
thus altering their binding capacities. These observations led to the proposal that 
effects of high fat diets on mammary tumourigenesis were due to increased 
hormonal stimulation both by virtue of increased circulating hormone 
concentrations and increased tissue responsiveness to hormonal stimulation 
(Welsch, 1987).
Recent studies have shown that adding marine oil to the diet o f rats carrying 
transplants of the R3230AC mammary adenocarcinoma causes a reduction in 
tumour weight and volume, accompanied by an inhibition in both tumour content 
(Karmali et al, 1984; Jurkowski & Cave, 1985) and in vitro synthesizing capacity 
of prostaglandins of the two series (Karmali et a l, 1984). This study suggested 
that inhibition of mammary tumourigenesis by marine oils may be linked to the 
inhibitory effects of the w3 fatty acids on arachidonic acid metabolism.
Despite a large number of studies carried out in animals the mechanism which 
leads to decreased tumour incidence in rats fed low fat diets, or diets o f altered 
fatty acid composition remains unclear. However, there is now considerable 
evidence to suggest that altered membrane function, via changes in prostaglandin 
efflux or altered protein function due to altered membrane fluidity, may play a 
major role in the promotional effect of dietary fat on tumourigenesis. Such a 
hypothesis is dependent upon demonstration of dietary fatty acid induced changes 
in mammary epithelial membrane fatty acid composition. It is therefore 
surprising to note that there have been very few studies of the fatty acid 
composition of membrane mammary lipids in tumour bearing animals, nor o f the 
effects of dietary fatty acid modification on tumour membrane composition.
The total lipids of mammary tumour microsomes have been investigated from rats 
fed a high fat diet compared with rats fed a low fat diet, the former showing
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significantly lower amounts of palmitic, palmitoleic, stearic, oleic and arachidonic 
acids, and 10 fold greater amounts of linoleic acid, (Cave & Erickson-Lucas,
1982). Feeding rats fish oils has been shown to increase the w3 fatty acids and to 
reduce w6 fatty acids in total lipids from tumour microsomes (Jurkowski & Cave,
1985). This data is consistent with suggested inhibitory effects of w3 fatty acids 
on arachidonate and thereby prostaglandin metabolism. However, Karmali et al., 
(1984) studied the phosphatidylcholine fraction and showed that this membrane 
fraction incorporates w3 fatty acids at the expense of stearic acid rather than the 
w6 arachidonic or linoleic acids. These results suggest that possibly one of the 
most important reservoirs of arachidonic acid, phosphatidylcholine, is resistant to 
dietary modification of the content of this fatty acid in the mammary epithelial 
cell. Tumour phosphatidylcholine also showed a much greater conversion of 
linoleic acid to arachidonic acid than in normal mammary tissue although this 
conversion was not affected by supplementing the diet with fish oils.
Bums & Spector (1987) showed that in L1210 leukemia and Erlich ascites 
carcinoma cells dietary modification of the phospholipid fatty acid composition 
could be achieved in culture by adding specific fatty acids to the growth medium 
and in vivo by feeding fat-supplemented diets to the tumour-bearing mice. In 
both cases they found the effects were confined to the total membrane fatty acid 
composition, and there was no change in membrane phospholipid content, 
cholesterol content or phospholipid head group composition. Furthermore, this 
alteration of fatty acid composition was sufficient to alter the physical properties 
of the membrane.
It would appear that dietary fat has an enhancing effect on mammary 
tumourigenesis in animals, (which has been described by Hicks (1983) as a 'co­
carcinogen' rather than a promotional effect), and that this action may be mediated 
at the site of the cell membrane. However, the precise mechanism of this 
relationship is unknown. My hypothesis is that alterations in dietary fat may
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result in significant alterations in the fatty acid profile of phosphatidylinositol, and 
may also lead to changes in the amount of phosphatidylinositol in mammary cell 
membranes, and that these changes may result in an alteration in the functioning 
of this important secondary messenger. Restriction of certain types of dietary fat 
may particularly affect mammary tumour growth via an alteration in this 
secondary messenger system. Tumour phosphatidylinositol composition has not 
previously been studied and it is therefore important to investigate further the 
dietary modifications of the fatty acyl components of individual membrane 
phospholipid classes, particularly the phosphoinositide fraction. Also any dietary 
modification of the relative proportions of, and the balance of saturated and 
unsaturated fatty acids within, the major phospholipids in mammary tumours may 
have profound effects on membrane fluidity and function and is worthy of 
investigation.
The objectives of this study were to investigate the differing tumour incidence in 
#-ethyl-#-nitrosourea (ENU) treated rats fed a corn oil, olive oil or MaxEPA diet; 
and to study and compare across dietary groups the fatty acid profiles of 
phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine o f the 
resulting tumours. The fatty acid profile of phosphatidylinositol, 
phosphatidylcholine and phosphatidylethanolamine were also measured in normal 
control mammary tissue following dietary modification (as described in Chapter 
3) and were compared with the fatty acid profile from the tumour phospholipids. 
A  further aim of the study was to determine whether there is dietary modification 
of the relative proportions of the phospholipids in the membrane of mammary 
tumours in rats compared with normal rat mammary tissue. Parallel 
investigations were performed using erythrocytes to determine whether dietary 
induced changes in the mammary tissue were reflected in erythrocytes also.
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METHODS
Forty eight, thirty day old, female Sprague Dawley rats weighing approximately 
80g, were divided into two groups. One group was administered the carcinogen 
#-ethy 1-jV-nitrosourea (ENU), (SIGMA chemicals, Dorset) dissolved in sesame 
seed oil at a dose of 180mg/kg intraperitoneally. Both the carcinogen 
administered group and the non-carcinogen group were sub-divided into three 
dietary groups and were housed four per cage. All rats were supplied with water 
and food ad libitum.
The diet was the same as that detailed in Chapter 3. The fatty acid compositions 
are shown in Table 7 (page 67). The diet was mixed weekly and stored at -20°C 
until required. The food pots were changed daily Sunday to Friday inclusive. 
Food intake and weekly body weight were monitored for all the rats.
Animals were sacrificed when palpable tumours could be felt at weekly 
examination. The animals were killed by decapitation following etherisation. 
The criterion for sacrifice in the tumour bearing animals was a palpable tumour of 
size 15 - 20 mm in diameter. A  control non-tumour bearing animal of 
approximately the same weight as the tumour bearing animal was sacrificed at the 
same time to eliminate any effect of duration of dietary exposure and body weight 
on the comparisons between the two groups. At 20 weeks all remaining animals 
were sacrificed and an autopsy performed to detect any tumours not palpated at 
weekly examination.
Blood, obtained by draining following decapitation, was collected into tubes 
containing sodium citrate (lOg/1) and the mammary tumour or tissue was excised. 
After weighing the tissue, the samples were taken to the laboratory for immediate 
extraction of lipids as described in Chapter 2 (page 35).
Phospholipid head group and fatty acid analyses were performed as detailed in 
Chapter 2 (pages 51 & 42 respectively).
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Statistical analysis of the data was performed using the SPSS-X program on the 
University of Surrey’s Prime Mainframe computer. The Duncan's range test was 
used to compare the groups of data and p<0.05 was taken as the level of 
significance. Where statistical analysis of the data showed lack o f variance 
homogeneity using the minimum/maximum variance, Bartlett Box or Cochran C 
test, the statistics were performed using log 10, natural log or square root data.
The data was analysed for comparison of the fatty acid profile of the 
phospholipids and also stearicioleic fatty acid ratios (S:0); 
polyunsaturatedisaturated fatty acid ratios (P:S); and w6:w3 fatty acid ratios were 
calculated and statistically analysed. Finally the relative proportions of the 
phospholipids were statistically analysed also using the Duncan's range test.
For analysis purposes, the animals were separated into three groups: (i) control, 
(ii) ENU treated tumour bearing and (iii) ENU treated non-tumour bearing. 
Statistical comparisons for fatty acid analysis and phosphate analysis were made, 
and the data presented, from the first two groups only.
One animal in the MaxEPA group died at 5 weeks; full autopsy was performed 
but no tumour was detected and death was from an unknown cause. This animal 
was excluded from the analysis of data, so that n=7 for ENU-treated MaxEPA 
animals. Some samples were lost during the procedures involved from lipid 
extraction to fatty acid and phosphate analysis. In these instances the number of 
cases analysed and indicated on the tables and figures is less than the total number 
of control or tumour bearing animals.
RESULTS
The mean food intakes for each of the dietary groups, both ENU treated and 
control animals can be seen in Table 18. There was no statistically significant 
difference between the ENU treated and control animals food intake within the 
dietary groups. The rats in the olive oil dietary group consumed more food than
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the com oil and MaxEPA fed animals although this was only significant between 
the control groups (p<0.05) and not the ENU treated groups of animals.. The 
body weight of each group of rats throughout the 15 week study can be seen in 
figure 17. Body weights of control animals were generally higher than of ENU 
treated animals although the difference was not statistically significant. The body 
weight at death between the ENU treated and control animals was not 
significantly different within the groups, nor was the mean body weight at death 
significantly different between the dietary groups (Table 19).
TABLE 18: MEAN FOOD INTAKES (WEEKS 1 TO 15) IN CONTROL AND ENU 
TREATED RATS FROM THE THREE DIETARY GROUPS.
Results expressed in g/rat/week (mean + standard deviation).
CORN OIL OLIVE OIL MAX-EPA
Mean SD Mean SD Mean SD
CONTROL (n=8) 93.8 + 6.35 102.8 + 6.9 * 95.7 ±  8.45
ENU (n=8) 99.4 ±  13.0 105.3 + 14.3 99.3 ±12.9
* p<0.05 compared with Corn oil and MaxEPA groups.
TABLE 19: BODY WEIGHT OF CONTROL AND ENU TREATED RATS AT 
SACRIFICE IN EACH DIETARY GROUP.
Results expressed in g (mean ±  standard deviation)
CORN OIL OLIVE OIL MAX-EPA
Mean SD Mean SD Mean SD
CONTROL (n=8) 265.6 ±16.1 275.9 ±15.8 274.0 ± 17 .4
ENU (n=8) 249.0 ±  33.8 256.4 ±  12.5 263.5 ±  19.5
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All animals were sacrificed by week 20 regardless of the presence of a tumour or 
of the tumour size if present. Hence some tumours detected at 20 weeks, and 
subsequently analysed, were smaller than the 15-20 mm specified in the sacrifice 
criterion.
TABLE 20: TUMOUR INCIDENCE IN THE RATS FROM THE THREE DIETARY 
REGIMENS.
Results expressed as % of rats bearing tumours 
(number tumour bearing animals/number surviving treated animals)
CORN OIL OLIVE OIL MAX-EPA
62.5% (5/8) 73.0% (6/8) 43.0% (3/7)*
* Significantly different from the other groups p<0.05 as analysed using the Chi- 
square test.
It can be seen from Table 20 that the tumour incidence in the MaxEPA dietary 
group was significantly lower than the tumour incidence in the com oil and olive 
oil groups (p<0.05). The incidence of tumours in the com oil and olive oil groups 
did not significantly differ. However, figure 18 shows the cumulative number of 
tumours over the 20 week period in each of the three dietary groups from where it 
can be seen that more of the ENU treated rats in the com oil group had developed 
tumours by week 16 than in either of the other two groups.
Figures 19, 20 and 21 show the profiles of the major fatty acids o f interest (18:0, 
18:l>v9, 18:2w6, 20:3w6, 20:4w6, 20:5w3, 22:6w3), and also the S :0 , P:S and 
w6:w3 ratios in normal mammary tissue and mammary tumour 
phosphatidylinositol (figure 19), phosphatidylcholine (figure 20) and 
phosphatidylethanolamine (figure 21) from rats following the three dietary 
regimens, com oil, olive oil and MaxEPA. The values for all fatty acids detected 
can be seen in Appendix II, phosphatidylinositol (Table 33), phosphatidylcholine 
(Table 34) and phosphatidylethanolamine (Table 35).
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In general the mammary tumour phospholipid fatty acid profiles did not respond 
to dietary modification. In phosphatidylinositol there was a significantly higher 
content of 22:5w3 in tumours from rats fed MaxEPA compared with rats fed olive 
oil (p<0.05). In phosphatidylcholine the tumours of rats fed MaxEPA contained 
more 16:lw9 than those from rats fed either com oil or olive oil (p<0.05). There 
were no significant differences in tumour phosphatidylethanolamine fatty acid 
profile between the dietary groups. There were no differences between dietary 
groups in the P:S and S :0  ratios in any of the three phospholipids studied. 
However, the w6:w3 ratio of phosphatidylcholine and phosphatidylethanolamine 
showed differences between the dietary groups. In phosphatidylcholine the 
w6:w3 ratio was greater in the com oil group than in the olive oil group (p<0.01). 
It was also numerically greater than the MaxEPA group although this did not 
attain statistical significance, probably due to the small sample size in this dietary 
group. In phosphatidylethanolamine, the olive oil group contained a higher 
w6:w3 ratio than the MaxEPA group (p<0.05).
One of the purposes of this study was to compare any differences in fatty acid and 
phospholipid composition between normal tissue and ENU induced tumour tissue. 
For this reason only data from the tumours themselves and not normal mammary 
tissue from non tumour bearing ENU treated animals was used for statistical 
analysis and hence the number of cases in the MaxEPA tumour group is only 2, 
one of the three tumours in this group being too small to analyse. The small 
number of animals developing tumours large enough for fatty acid analysis will 
limit the ability to demonstrate statistically significant differences between this 
group and the other two dietary groups; where clear trends are evident, these will 
be commented upon.
It can be seen from figure 19 that there are no statistically significant differences 
between normal and tumour tissue in the phosphatidylinositol fraction of 
mammary tissue phospholipids from rats fed a com oil diet. The 18:0 content of
- 1 0 1  -
this phospholipid was numerically higher in the tumour tissue but this difference 
did not attain statistical significance. In the phosphatidylcholine fraction (figure 
20), the 18:lw9 content of the tumours (13.89 mol%) was significantly higher 
(p<0.05) than the normal tissue (6.12 mol%). There were no other significant 
differences in the fatty acid profiles of normal and tumour mammary tissue 
phosphatidylcholine from com oil fed rats. The phosphatidylethanolamine 
fraction (figure 21) contained significantly less linoleic acid (p<0.05) in the 
tumour tissue than normal mammary tissue, and although it did not reach 
statistical significance the mean value for arachidonic acid (20:4w6) was higher in 
tumour than non-tumour tissue.
In the olive oil dietary group the phosphatidylinositol fraction of tumours 
contained significantly more 18:0 than the normal tissue (figure 19) (p<0.05). No 
other differences in the fatty acid profile of this phospholipid were detected 
between tumour and normal mammary tissue. Furthermore, there were no 
statistically significant differences between tumour tissue and normal tissue in 
either the phosphatidylcholine or phosphatidylethanolamine fractions, although 
the phosphatidylethanolamine fraction of olive oil fed rats (figure 21) contained a 
numerically greater amount of arachidonic acid in the tumour tissue than in the 
normal tissue. There were no statistically significant differences in any of the 
phospholipid fractions studied in the MaxEPA group. However, it is noteworthy 
that the phosphatidylcholine fraction exhibited a numerically greater amount of 
18:lw9 in the tumours than the normal tissue in both the olive oil and MaxEPA 
(figure 20) dietary groups.
A  study of the P:S, S :0  and w6:w3 ratios in each phospholipid in mammary 
tumours compared with normal mammary tissue for each of the dietary groups 
showed no statistical differences.
- 1 0 2 -
Figures 22, 23 and 24 show the fatty acid profiles of erythrocyte phospholipids 
from rats either non-ENU treated or rats bearing an ENU induced tumour from 
the three dietary groups (see also Appendix II, Tables 36, 37 & 38). The profile 
o f all the phospholipids studied differs greatly from the corresponding 
phospholipid from the mammary tissue as previously shown for normal mammary 
tissue in Chapter 3. The same trends were evident in the differences in 
erythrocyte phospholipid fatty acids from tumour bearing rats across the dietary 
groups as those seen in erythrocytes from control rats as described in Chapter 3.
Phosphatidylinositol was the least responsive phospholipid to dietary changes, 
with significant differences detected only in 18:2>v6 (com oil group contained 
more than the olive oil group, p<0.05); 20:3w6 (corn oil group contained less than 
the olive oil group, p<0.05); and 22:5>v3 (MaxEPA group contained more than 
both the corn oil and olive oil groups, p<0.05).
As in the control rats (Chapter 3), the erythrocyte phosphatidylcholine and 
phosphatidylethanolamine fractions showed greater variation in their fatty acid 
profiles across the dietary groups in tumour bearing animals. In 
phosphatidylcholine, 16:0 and 18:0 were found in lower amounts in the 
erythrocytes from com oil fed rats compared with MaxEPA fed animals (p<0.01 
and p<0.05 respectively). 18:0 was also less in the com oil group than in the 
olive oil group (p<0.05), as was 18:lw9 (p<0.05). 18:2w6 was found more
abundantly in the erythrocytes from the olive oil group than the MaxEPA group 
(p<0.01). There was more 20:3w6 in the erythrocyte phosphatidylcholine from 
com oil fed animals compared with MaxEPA fed animals (p<0.01) and there was 
more of both 20:4w6 and 22:5w3 in the com oil group compared with both the 
olive oil and MaxEPA groups (p<0.01), there being no significant difference 
between the olive oil and MaxEPA groups. The higher quantities of 
polyunsaturated fatty acids led to a higher P:S ratio in erythrocyte
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phosphatidylcholine from com oil fed rats compared with olive oil (p<0.05) and 
MaxEPA (p<0.01) fed rats.
In erythrocyte phosphatidylethanolamine there was less 16:0 and 16:lw9 in the 
com oil fed animals compared with the MaxEPA fed animals (p<0.01 and p<0.05 
respectively). There was also less 18:0 but more 18:2w6 in the com oil group 
compared with both the olive oil (p<0.05 and p<0.01 respectively) and MaxEPA 
(p<0.01) groups. Arachidonate (20:4w6) decreased in the order com oil>olive 
oil>MaxEPA although only the com oil and MaxEPA groups were statistically 
significantly different (p<0.01). However, the com oil group did contain 
significantly more 22:4w6 than the olive oil group (p<0.05). Conversely, the 
MaxEPA group contained more 22:6w3 than both the com oil group (p<0.01) and 
the olive oil group (p<0.05). The S :0  ratios decreased in the order 
MaxEPA>olive oil>corn oil, the MaxEPA group being significantly different 
from both the com oil and olive oil groups (p<0.05), and the P:S ratios decreased 
in the order com oil>olive oil>MaxEPA, in this case the com oil group being 
significantly different from the olive oil and MaxEPA groups (p<0.01). 
Furthermore, the com oil group had a significantly higher w6:w3 ratio than the 
MaxEPA group (p<0.05).
There were no statistically significant differences in the erythroctye phospholipids 
from tumour bearing animals compared with the corresponding control animal 
erythrocyte phospholipids within each of the dietary groups.
ENU-induced tumours did not possess a significantly different membrane 
phospholipid composition compared with normal, control mammary tissue for any 
dietary group (figure 25; Appendix II, Table 39). As discussed in the previous 
chapter, diet has no effect on the relative proportions of phospholipids in the 
normal mammary tissue membrane. Diet was also found not to significantly 
affect the phospholipid composition of mammary tumours, hence there were no
-104
differences with diet or treatment in mammary tissue membrane phospholipid 
composition.
In erythrocyte membranes there were no significant differences between the 
composition of membrane phospholipids from control rats compared with tumour 
bearing rats in any of the dietary groups (figure 26; Appendix II, Table 40). 
There was a numerically greater amount of phosphatidylcholine and less 
phosphatidylserine in the erythrocyte membranes of tumour bearing rats 
compared with control animals in the com oil dietary group, with the converse 
being true in the MaxEPA dietary group. These differences were not found to be 
statistically significant.
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DISCUSSION
The mean food intakes for each group of rats can be seen in Table 18. Both the 
control and ENU treated rats in the olive oil group ate more than the com oil and 
MaxEPA fed rats. In each dietary group the ENU treated rats consumed more 
feed than the control rats. However, this did not lead to a greater body weight at 
death. As can be seen from Table 19, body weights at sacrifice were lower 
among the ENU treated rats than the control animals, the increased food possibly 
being utilised as energy in the tumour bearing animals. The ENU treated animals 
in the com oil and olive oil dietary groups had a lower body weight at sacrifice 
than the ENU treated rats in the MaxEPA group even though their food 
consumption was higher. This is almost certainly because the com oil and olive 
oil dietary groups had a higher tumour incidence than the MaxEPA fed rats. 
These data support the concept that metabolic rate and energy requirements are 
increased in tumour bearing animals and represent part of the 'cancer cachexia' 
syndrome.
Although it has been known for some years that the amount of fat in the diet can 
influence tumour incidence and growth in rodents (Tannenbaum & Silverstone, 
1953; Carroll & Khor, 1970; Chan & Dao, 1981), the effect of different types of 
dietary fat is not clear. Recent studies to investigate the influence of dietary fats 
on mammary carcinogenesis have shown a reduction in the tumour incidence and 
latent period of carcinogen induced tumours of rats fed fish oil compared with 
feeding corn oil (Jurkowski & Cave, 1985), and inhibition of growth of 
transplantable mammary adenocarcinomas with w3 fatty acid supplemented diets 
(Karmali et a l, 1984; Kort et a l, 1987). The results of the present study are in 
agreement with these findings. The MaxEPA group exhibited a significantly 
lower tumour incidence (43%) compared with both the com oil (62.5%, p<0.05) 
and olive oil (73%, p<0.03) groups.
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It is worthy of note that, Hopkins et al., (1981), showed that feeding a coconut oil 
diet (rich in saturated fats) supplemented with either linoleic (iv6) acid or linolenic 
acid (w3) resulted in a similar tumour incidence in both groups of 
dimethylbenz(a)anthracene (DMBA) treated rats. It would therefore seem that 
eicosapentaenoic acid and docosahexaenoic acid, found mainly in fish oils, afford 
specific protection against tumour promotion, an effect apparently not shared by 
their w3 fatty acid precursor, linolenic acid. Possible reasons for this specific 
effect will be discussed later.
The effect of olive oil on tumour promotion in rats has not been widely 
investigated. The present findings indicated a tumour incidence similar to that 
obtained from feeding com oil. In agreement with the present investigations, 
Carroll and Khor (1971) reported olive oil exhibited tumour promoting properties 
similar to that of com oil. However, Cohen and Thompson (1984) showed olive 
oil to lack tumour-promoting action in the NMU-induced mammary tumour 
model. It has been suggested that these conflicting results stem from difference 
sources of olive oil, with different refining processes, such that some oils may be 
more pure than others, with less trans fatty acids which are also thought to 
promote carcinogenesis.
This study also investigated the effect of dietary fatty acid modification on 
membrane phosphatidylinositol, phosphatidylcholine and phosphatidyl­
ethanolamine fatty acid profiles in tumour and non-tumour mammary tissue, and 
on membrane phospholipid headgroup composition in both the mammary tissue 
and erythrocytes, measurements of which have not been carried out in previous 
studies.
One of the aims of this study was to determine whether there are any differences 
in membrane phospholipid fatty acid compositions in tumour and normal 
mammary tissue and also to determine whether tumour tissue responds in a
-115-
similar manner to normal tissue to dietary modification. Any differences 
observed may help to explain differences in tumour incidence found in the three 
groups of animals.
It is believed that one mechanism by which type of dietary fat may affect 
mammary carcinogenesis is via an alteration in the balance o f the prostaglandin 
families produced by the w3 and w6 precursor fatty acids. It has been shown that 
there is an increase in both tissue concentrations and synthesizing capacity of 
prostaglandins PGE2, PGFg cv , 6-keto-PGF^ , and TXB2 in NMU-induced
mammary tumours compared with normal mammary tissue (Karmali et al., 1983). 
These workers found that in general the tumour tissue content o f the four 
compounds were lower in rats given MaxEPA than in control rats. Furthermore, a 
high fat (18% com oil) diet resulted in a higher tumour incidence than a low fat 
(5% com oil) diet, but when the prostaglandin inhibitor indomethacin was 
included in the diet the tumour incidence in the high fat diet group was not 
significantly different from the low fat diet group (Carter et a l, 1983), indicating 
that suppression of prostaglandins results in a lower tumour incidence. However, 
care should be taken in interpreting the latter finding since indomethacin is not a 
highly specific drug and is known to inhibit a variety o f enzymes including 
phospholipase A2.
Further support for the prostaglandin hypothesis is afforded by studies which 
show that tumour content and in v/rra synthesis of prostaglandins of the 2 series 
(from arachidonic acid) are subject to dietary modification. A  decrease in PGE2
was demonstrated in rats fed a marine oil supplemented diet as opposed to a 
normal rat chow diet (Karmali et al, 1984; Kort et al, 1987). Marine oils contain 
eicosapentaenoic and docosahexaenoic acids which are potent inhibitors of 
prostaglandin 2 synthesis, and are also the precursors of prostaglandins o f the 3 
series which have different and often opposite metabolic effects from the 2 series 
prostaglandins. It has thus been suggested that the beneficial effect of marine oils
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may be due to their inhibitory and antagonistic effects on the 2 series 
prostaglandins. Similarly, it has been proposed that evening primrose oil, which 
has also been found to reduce transplanted tumour growth (Karmali et a l, 1985) 
may exert its protective effect via the inhibition of the 2 series prostaglandins.
The largest intracellular stores of arachidonic acid, the precursor fatty acid of the 
2 series prostaglandins are the choline and ethanolamine phospholipids. If 
sustained production of prostaglandins plays a part in maintaining malignant cell 
proliferation it might be expected that there would be an increased requirement 
for arachidonic acid. Tumour tissue may be expected to increase the acylation 
and incorporation of arachidonic acid into tissue phospholipids or increase 
desaturation and elongation of linoleic acid in order to build plentiful supplies o f 
this important fatty acid for growth and proliferation. In support of this 
hypothesis Tan et a l, (1975) showed significantly higher levels of 20:4w6 and 
lower levels of 18:2w6 in tumour tissue from DMBA treated rats. Karmali et a l, 
(1984) have also demonstrated a 6-fold increase in the arachidonic acid content of 
phosphatidylcholine in mammary tumours compared with normal mammary 
tissue. However, this increase in tumour phosphatidylcholine arachidonic acid 
content in tumours was not affected by supplementing the diet with marine oil. 
Although the tumours in the animals given marine oil did not grow at the same 
rate as the animals not given the marine oil supplement, the tumour membrane 
phosphatidylcholine fraction contained the same amount of arachidonic acid, 
suggesting that reduced tissue arachidonic acid content is not the mechanism by 
which w3 fatty acids reduce tumour incidence rates.
In the present study there was no demonstrable increase in the arachidonic acid 
content of phosphatidylcholine of mammary tumours in any of the dietary groups. 
However, there was a small but significant decrease in the linoleic acid content of 
mammary tumour phosphatidylethanolamine in the com oil dietary group with a 
concomitant increase in the arachidonic acid content of this phospholipid (not
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statistically significant), indicating that there may be a slight increase in 
desaturase and elongase enzyme activity in the tumour cell membrane in rats fed 
com oil. The phosphatidylethanolamine fraction from rats fed the olive oil diet 
also contained slightly more arachidonic acid in the tumours than normal 
mammary tissue. This difference was not significant but again may reflect a 
change in the uptake and desaturation/elongation of w6 fatty acids in tumour cell 
membranes.
In the present study numerically higher values for phosphatidylethanolamine 
arachidonic acid were found in tumours from animals fed com oil and olive oil. 
The failure to demonstrate statistically significant differences for 20:4iv6 in 
tumour compared with normal tissue is almost certainly due to the wide inter 
animal variation for this fatty acid. Whilst this variation may reflect true 
biological variation, the relatively poor analytical precision demonstrated for the 
measurement of this phospholipid in the Methodology section (Chapter 2) has 
contributed to this variation. Improvements in analytical precision and the use of 
a larger number of animals in each dietary group may have produced more clear 
cut findings.
None of the phospholipid fractions from any of the dietary groups showed 
significant differences in the content of w3 fatty acids in the tumours compared 
with the normal mammary tissue. Nor were there any significant differences 
between tumour and normal mammary tissue w6:w3 fatty acid ratio in any o f the 
phospholipids studied in any of the dietary groups. Thus mammary tumours are 
not associated with increased uptake into phosphatidylcholine, phosphatidyl­
ethanolamine or phosphatidylinositol of either w6 or w3 fatty acids. However, the 
ratio of these fatty acid families was altered by diet in both normal tissue and 
tumour tissue, the MaxEPA fed animal phospholipids containing the most w3 
fatty acids and the com oil fed animal phospholipids containing the most w6 fatty 
acids. Hence, diet may alter the availability of these fatty acids in the normal and
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tumour cell membrane phospholipids which may limit the potential for that cell to 
proliferate when stimulated by some other factor.
There were no statistically significant differences in S :0  ratios between the
of
mammary tumours and the normal mammary tissue ^rats in any o f the 
phospholipids studied for any of the dietary groups. Nor did the S :0  ratios in the 
erythrocyte membrane phospholipids differ from control animals erythrocytes 
compared with tumour bearing animal erythrocytes. Although there is no 
previous evidence which suggests that the S :0  ratio is altered in tumour bearing 
animals, there is evidence that in some human cancers, including breast cancer, 
there is a decrease in erythrocyte stearicioleic (S :0) fatty acid ratio (Wood et a l, 
1985a), possibly due to an increase in the rate of desaturation of stearic acid to 
oleic acid. The reason for such a decrease in the S :0  ratio is unknown and only 
limited evidence is available that this is a specific phenomenon of human cancers. 
This aspect of membrane fatty acid metabolism will be discussed in more detail in 
Chapter 7.
A  further mechanism by which dietary fat may affect mammary carcinogenesis is 
via alteration of membrane fluidity and in turn receptor function and enzymic 
activities. Increased unsaturation of membrane lipids generally leads to increased 
fluidity, although there are a number of complicating factors involved, including 
fatty acid interactions (Stubbs & Smith, 1984). Alteration in membrane fluidity 
has been shown to lead to changes in membrane receptor functioning and enzyme 
activities in a number of tissues and species (Stubbs & Smith, 1984; Wahle, 1983; 
Awad, 1986). Bums and Spector (1987) have shown that fatty acid modification 
o f several tumour membranes caused changes in the physical properties o f those 
membranes in particular in terms of amino acid and drug uptake. Furthermore, 
Cave and Erickson-Lucas (1982), have shown that altering the amount of fat in 
the diet can effect changes in lactogenic hormone receptor binding activity in rat 
mammary tumours which they attributed to changes in membrane desaturation.
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Unfortunately these investigators did not study the effect of different types of fat 
on this hormone receptor binding capacity. The results o f the present 
investigation indicate that there is no statistically significant alteration of 
mammary tumour membrane unsaturation in any of the phospholipids studied 
with either diet or treatment. The results of this study also indicate that there is no 
significant alteration in the relative proportion of membrane phospholipids in the 
tumour cell compared with the normal cell. The red blood cells also did not show 
any significant difference between the animal groups although there were trends 
towards increased phosphatidylcholine and decreased phosphatidylserine in 
tumour bearing animals. Therefore the present study does not provide evidence 
for changes in membrane phospholipid P:S ratios or phospholipid composition in 
rapidly growing mammary tumours. Furthermore, lack of an effect o f diet on 
these parameters suggests that dietary mediated changes in these membrane 
characteristics do not underlie different effects of dietary fatty acid on mammary 
tumour growth.
The central hypothesis under review in this thesis is that phosphatidylinositol is 
the locus for the effect of dietary fatty acids on membrane composition and on 
tumour incidence. This may be via an alteration in the amount of 
phosphatidylinositol present or via an alteration of its fatty acid composition 
which may in turn affect its functional properties. The results of this study show 
that there is no change in the amount of phosphatidylinositol present in the 
membrane in relation to the amount of the other phospholipids in mammary 
tumours compared with normal mammary tissue or in mammary tissue/tumours 
from animals on the three dietary groups. Attention is therefore focused on the 
fatty acid profile of this phospholipid, its alteration with diet and whether it is 
possible that the protective effects of marine oils, shown again in this 
investigation, are mediated via this minor membrane component.
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It is clearly shown in the results that in both tumour and normal mammary tissue, 
phosphatidylinositol is the least responsive of the phospholipids studied to dietary 
modification, particularly in terms of altering the content o f the w6 and w3 fatty 
acids. Unlike phosphatidylcholine and phosphatidylethanolamine, there was no 
increase in w3 fatty acids or decrease in w6 fatty acids in the phosphatidylinositol 
fraction of mammary tumours or control mammary tissue from rats fed a marine 
oil diet compared with rats fed a com oil or olive oil diet. Hence it seems 
unlikely that alteration in hormone signal transduction via the 
phosphatidylinositol turnover mechanism, through altered phosphatidylinositol 
arachidonic acid composition, is the mechanism by which dietary fatty acids 
influence mammary tumourigenesis. However, the present study has 
demonstrated an unexpected increase in the stearic acid content o f 
phosphatidylinositol in mammary tumours compared with control mammary 
tissue in rats on all three diets. This increase in stearic acid content was only 
statistically significant in the rats fed the olive oil diet (12 mol%; p<0.05) 
although a large increase was also seen in rats fed the com oil diet (>6 mol%) and 
only a small difference was seen in the MaxEPA fed animals which was <3 
mol%. Therefore, the extent of differences in stearic acid content is in line with 
the tumour incidence rates in the three dietary groups.
Changes in stearic acid content may have implications in terms of the membrane 
binding properties of phosphatidylinositol; enzyme binding during hydrolysis and 
perhaps other functionally important processes. Although the receptor binding 
properties o f phosphatidylinositol kinase have not been examined, nor have the 
transfer proteins in detail, it is thought that the fatty acid moieties o f the 
phospholipids can hinder the binding of the phospholipids to proteins such as 
phospholipid transfer proteins (Zborowski & Demel, 1982) and it is also possible 
that the fatty acid moieties affect the functional properties of the phospholipid 
within the membrane. Furthermore, the 1,2-diacyIglycerol produced from
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receptor mediated hydrolysis of phosphatidylinositol which is known to be 
involved in the activation of protein kinase C (figure 4; page 26) may also have 
specific fatty acid requirements for optimal activity.
In conclusion the present study suggests marine oils may limit the ability of 
mammary tumour cells to bring about alteration in fatty acid composition (relative 
to normal mammary tissue) in two ways:
(i) They may limit the capacity for linoleic acid depletion and arachidonic 
acid accumulation in phosphatidylethanolamine, since there was some 
evidence of increase arachidonic acid in phosphatidylethanolamine in 
tumours of com oil and olive oil but not marine oil fed animals.
(ii) They may limit the capacity for tumour cell phosphatidylinositol to 
undergo enrichment with stearic acid, an effect observed in olive oil fed, 
and suggested in com oil fed animals, but much less evident in marine oil 
fed animals.
It is possible that either or both of these processes may underlie the 
antitumourigenic effects of marine oils demonstrated by the present study. 
Suppressive effects of marine oils on 20:4w6 accumulation are consistent with 
action of this oil in other tissues and support the idea that alteration in 
prostaglandin metabolism underlie protective effects of w3 fatty acids. A t present 
there is no theoretical basis for the observed effects of tumourigenesis on 
phosphatidylinositol stearic acid content. However, it is pertinent to mention that 
Tinsley (1989) has shown that mammary tumour stearic acid content, unlike other 
major fatty acids, does not reflect surrounding adipocyte stearic acid content, and 
this suggests differences in stearic acid metabolism occur in mammary tumour 
cells.
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CHAPTER FIVE
THE EFFECT OF A LOW FAT DIET ON ERYTHROCYTE MEMBRANE 
PHOSPHOLIPID COMPOSITION IN HUMAN VOLUNTEERS
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INTRODUCTION
Over the last three decades it has become clear that there is a link between diet 
and breast cancer. However, the mechanism(s) of such a link have not been 
elucidated. Among the many alternative hypotheses, a role for membrane 
phospholipids has been suggested. Our understanding of the important role of 
membrane phospholipids as not only structural components of the cell membrane 
but also having vital biological functions in maintaining membrane fluidity and 
protein conformations, as co-factors, as fatty acid stores for eicosanoid production 
and also particularly the cell signalling system involving phosphatidylinositol has 
greatly increased over the past few years. Consequently there has been an 
increase in the research of phospholipids, their turnover rates, headgroup 
compositions and fatty acid profiles.
Animal and human studies have both indicated that altering the fatty acid 
composition of the diet can effect a change in the fatty acid composition of total 
membrane phospholipids. Several human studies have shown changes in the long 
chain polyunsaturated fatty acid content of the total red blood cells phospholipids 
(Sanders & Younger, 1981) and platelet phospholipids (Von Schacky et a l, 
1985), following marine oil supplementation. This modification was also found 
in plasma phosphatidylcholine (Sanders & Younger, 1981), platelet choline, 
ethanolamine and serine phospholipids (Von Schacky et a l, 1985) and 
erythrocyte choline and ethanolamine phospholipids (Popp-Snijders et a l, 1986).
Although it has been suggested that membrane phospholipids may be important in 
breast tumourigenesis, particularly in terms of eicosanoid production (Bennett et 
al, 1977; Salmon & Flower, 1979), it appears that research has largely 
concentrated on the effect of altering the fatty acid composition of the diet and 
studying either the phosphatidylcholine fraction which is believed to be the major 
cellular store of arachidonic acid, or the total phospholipids. Consequently our
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knowledge of the effect of low fat diets on the cell membrane phospholipids is 
very limited in terms of both fatty acid profile of individual phospholipids and 
indeed proportions of the phospholipids themselves.
In view of the recent investigations into the important role of phosphatidylinositol 
in cell signalling mechanisms, and the lack of knowledge about the fatty acid 
composition of this phospholipid and its dietary modification, it was considered 
important to study the fatty acid profile of this phospholipid and its response to 
changes in diet in human subjects. Phosphatidylcholine has been more widely 
investigated and is therefore useful to use as a reference. However, the changes in 
fatty acid profile of phosphatidylcholine in response to a low fat diet has not 
previously been studied.
Prolactin and oestrogen were also measured in this study. Many breast cancers 
are known to contain oestrogen receptors, and respond to endocrine ablation. 
Furthermore, there is evidence that high levels of circulating oestrogen for a long 
period during a woman's life may increase breast cancer risk (Moore et a l, 1983). 
Rose et a l, (1987b) have demonstrated that a low fat diet can reduce the amount 
of circulating oestrogen, thus possibly reducing breast cancer risk. There is also 
evidence that prolactin levels may be increased in patients with breast cancer 
(Bani et a l, 1986; Malarkey et a l, 1977; Ohgo et a/., 1976), and animal studies 
have shown that levels can be elevated in rats consuming a high fat diet (Chan & 
Cohen, 1974 & 1975). Furthermore, Rose et a l, (1987c) have shown that a low 
fat diet can cause a reduction in the amount of these hormones detected in the 
serum of women.
DESIGN OF STUDY AND DIETARY COMPLIANCE
Fifteen female subjects aged between 18 and 45 years agreed to follow a low-fat 
diet for a period of 2 months. All were healthy premenopausal women with 
regular menstrual cycles, recruited as volunteers from the University o f Surrey
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staff and student population. The study protocol had received consent from the 
University Ethical Committee. Subjects were selected from a group of volunteers 
who had completed a questionnaire on menstrual, reproductive and medical 
history, use of medications and dietary supplements. Subjects were excluded if 
they were taking oral contraceptives or other hormone preparations, or if they had 
ceased taking such preparations within the preceding 3 months. Subjects were 
also excluded if they regularly used dietary supplements containing w6 or w3 fatty 
acids. Other exclusion criteria were an ideal body weight <95% or >120%, or a 
history of diseases such as diabetes, arthritis, cancer and hypertension.
A  10ml blood sample was taken from each volunteer by venepuncture following 
an overnight fast on day 21 of their menstrual cycle, and placed into a blood tube 
containing heparin as anticoagulant. The plasma obtained from this sample was 
frozen for future hormone analysis. The red blood cells were taken immediately 
for phospholipid analysis.
Each subject was asked to carry out a weighed inventory of all food consumed for 
a seven day period. This data was collected and subsequently analysed for the 
nutrient content by use of the Compeat computer program (Lifeline Nutritional 
Services Limited).
Each volunteer was given information regarding methods for reducing fat 
consumption whilst maintaining her normal calorie intake. They were then asked 
to follow a low fat diet (25-30% total calories as fat) for two months. During this 
seven week period, weekly body weight and skinfold thickness at four sites 
(triceps, biceps, subscapula and suprailiac) were measured and recorded. Total 
body fat (g/kg) was calculated from the latter measurements according to the 
equation of Dumin & Rahaman (1967).
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A further blood sample was taken from each volunteer at the end of the study 
period. This second blood sample was also collected on day 21 of the menstrual 
cycle and was treated in an identical manner to the first.
Each of the women in the study carried out a further weighed inventory record of 
all food eaten for four days during the final week of the study. These records 
were also analysed using the Compeat computer program. Dietary compliance 
was assessed by random dietary 24-hour recall data, weighed food record sheets 
and questionnaires.
The methods used in analysing the fatty acid composition of erythrocyte 
phospholipids, and for determining the relative proportions of the phospholipids, 
and also the cholesterol, oestrogen and prolactin assays are detailed in Chapter 2.
Statistical analysis of data was performed using the SPSS-PC programme using an 
IBM compatible microcomputer. Values for parameters under investigation were 
shown to be normally distributed in most cases. When there was lack o f variance 
homogeneity the natural log of values was used and tested for significance using 
the paired Students't' test.
Samples from two volunteers were lost prior to fatty acid and phosphate analysis, 
and hence n=13 for all these analyses.
RESULTS
During the low fat regime, both the absolute quantity of fat and the percentage of
o
energy derived from fat was significantly reduced (p<0.01), (Table 21). There
was no significant change in the daily energy intake although the mean intake was
reduced by 200kCal/day. The P:S ratio was found to increase significantly for all 
0
subjects (p<0.01), largely due to a reduction in the intake of saturated fats. There 
was no significant change in carbohydrate or protein intake on the low-fat diet.
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but carbohydrate made a greater contribution to total energy intake. Fibre intake 
was higher but not significantly so on the low-fat diet.
Table 21: Daily dietary intake of major nutrients by women before and at
2 months after commencing a low-fat diet regimen.
(Mean values and standard deviations for fifteen subjects)
Pre-diet Diet for 2 months
Dietarv Intake (ner dav') Mean SD Mean SD
Energy (MJ) 7.79 1.82 6.06 * 1.72
Fat (g) 81 27 36 * 19
M UFA(g) 31 9 12 * 5
PUFA(g) 13 4 6 2
Saturated FA (g) 35 15 10 * 6
P:S ratio 0.38 0.18 0.61 *0.28
Carbohydrate (g) 221 60 224 80
Protein (g) 72 11 67 20
Dietary fibre (g) 22.2 6.42 27.9 10.67
Fat (%Energy) 37 6 21 * 7
Carbohydrate (%Energy) 44 7 56 12
Protein (%Energy) 16 3 18 2
* p<0.001 (Mean values significantly different from those for the pre-diet period).
Anthropometric measurements shown in Table 22, demonstrate that the reduced 
energy and fat intakes of subjects on the low-fat diet resulted in a significant loss 
of body-weight; that much of this weight loss represented loss of body fat is 
shown by the skinfold thickness and percentage body fat measurements made at 
the end of the dietary period. Mean weight loss was 1.76 kg and mean body fat 
loss was calculated to be 1.53 kg. The skinfold measurements show that the 
greatest percentage loss was on the biceps region (29%), less marked changes 
were observed on the triceps (14%), subscapular (17%) and suprailiac (12%) 
regions.
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Table 22: Anthropometric measurements on women before and at 2
months following the commencement of a low-fat dietary 
regimen.
(Mean and standard deviation for fifteen subjects)
Pre-diet Diet for 2 months
Characteristic Mean SD Mean SD
Body weight (kg) 
Skinfold thickness:
64.2 9.6 61.1 * 9.0
Biceps (mm) 12.1 5.7 8.5 * 3.28
Triceps (mm) 19.2 6.2 16.5 * 5.36
Subscapular (mm) 16.7 9.5 13.7 * 7.9
Suprailiac (mm) 22.2 7.3 19.5 * 6.1
Body fat (g/kg) 32.2 5.5 29.8 * 5.1
* p<0.001 (Mean values significantly different from those for the pre-diet period).
The fatty acid profiles of the two phospholipids studied showed little change with 
the diet. Arachidonic acid (20:4w6) increased significantly by 4.6% in the 
inositol phospholipids fraction (p<0.05). No other changes in the fatty acid 
composition of either phosphatidylcholine or phosphatidylinositol was significant 
(Tables 23 and 24 respectively), nor did the P:S ratio alter significantly in either 
phospholipid. Two samples were lost during the processes of lipid extraction to 
fatty acid analysis thus reducing the number of cases from fifteen to thirteen.
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Table 23: The fatty acid profile (mol%) of red blood cell membrane
phosphatidylcholine of women before and at 2 months following 
the commencement of a low fat dietary regimen.
(Mean + standard deviation for thirteen subjects)
Pre-diet Diet for 2 months
Fattv acid__________________ Mean SD Mean SD
16:0 37.2 4.9 37.6 5.3
18:0 12.5 4.0 10.2 1.7
18:lw9 19.9 6.9 18.7 1.8
18:2w6 19.0 5.8 20.9 4.9
20:3w6 1.1 0.5 1.2 1.5
20:4w6 3.7 1.3 4.0 1.5
20:5w3 0.4 0.3 0.8 0.6
22:5w6 0.1 0.2 1.0 3.1
22:5w3 1.3 0.5 1.3 0.9
22:6w3 3.3 3.5 3.0 3.5
P:S 1.1 0.3 1.1 0.3
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Table 24: The fatty acid profile (mol%) of red blood cell membrane
phosphatidylinositol of women pre-diet and after 2 months 
following a low-fat dietary regimen.
(Mean + standard deviation of thirteen subjects)
Pre-diet Diet for 2 months
Fattv acid Mean SD Mean SD
16:0 11.9 10.6 7.6 4.2
18:0 41.9 8.8 43.0 10.4
18:lw9 11.0 3.1 11.7 3.5
18:2w6 5.7 3.9 5.5 4.3
20:3w6 1.2 0.7 1.0 0.6
20:4w6 12.3 4.1 16.9 4.6 *
20:5w3 1.2 0.8 1.3 0.9
22:5w6 1.4 1.1 1.5 1.0
22:5w3 6.3 6.3 7.0 5.6
22:6w3 3.6 4.7 2.2 4.5
P:S 0.9 0.3 1.0 0.4
_= p<0.05 paired Students t-test.
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Values for the proportions of individual phospholipid classes of red blood cell 
membranes are shown in Table 25. There was a significant increase in the 
percentage o f phosphatidylinositol content of red blood cells in subjects after 2 
months on a low-fat diet. Percentage changes in individual phospholipids are 
shown in figure 27, and it can be seen that phosphatidylinositol showed a 40% 
increase in subjects on the low-fat diet, no significant changes in other 
phospholipids fractions were observed.
Table 25: Relative proportions (mol%) of erythrocyte phospholipids in
women before and at 2 months after commencing a low-fat 
dietary regimen.
(Mean + standard deviations for thirteen subjects)
Pre-diet Diet for 2 months
Phosnholinid Mean SD Mean SD
Phosphatidylethanolamine 25.4 3.7 26.6 2.3
Phosphatidylinositol 6.0 1.5 8.1 1.6*
Phosphatidylserine 12.6 1.9 12.0 1.9
Phosphatidylcholine 30.0 4.2 28.9 3.1
Sphingomyelin 26.0 5.6 24.7 3.3
= p< 0.02 Statistical test used was the Student's paired t-test.
Measurements of plasma prolactin, oestradiol, total cholesterol and HDL- 
cholesterol are shown in Table 26. There was no significant change in the mean 
prolactin concentration in subjects transferring to a low-fat diet, although two 
subjects in whom prolactin concentrations were elevated above normal on their
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customary diet showed normal values on the low-fat diet. These individual 
changes are reflected in the smaller standard deviation around the mean for 
prolactin concentrations in subjects on the low-fat diet. Luteal-phase oestradiol 
concentrations were significantly lower following the low-fat diet; in four subjects 
oestradiol concentrations decreased 100% on the low-fat diet. There was a 
significant reduction in total cholesterol on the low-fat diet, but HDL-cholesterol 
concentration remained unchanged.
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figure 27: Percentage Change in the Relative Proportions of Erythrocyte
Phospholipids in Women After 2 Months on a Low-Fat Diet. 
(Values are means with standard deviation represented by 
vertical bars, for thirteen subjects) *p<0.02.
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Table 26. Luteal-phase plasma oestradiol, prolactin and lipid
concentrations in women before and 2 months following the 
commencement of a low-fat dietary regimen
(Mean values + standard deviation for fifteen subjects)
Pre-diet Diet for 2 months
Serum constituents Mean SD Mean SD
Prolactin (uU/1) 331 237 318 125
Oestradiol-17B (pg/ml) 120 48.9 105 * 26.5
Total cholesterol (mg/1) 1600 300 1300 ** 290
HDL-cholesterol (mg/1) 410 78 430 116
* = p<0.05 
** = p<0.005
Statistical test used was the Students paired t-test.
DISCUSSION
Dietary modification of fat intake did not effect any significant alterations in red 
blood cell phosphatidylcholine content or fatty acid profile. However, small but 
significant changes were seen in both the content and fatty acid composition of 
phosphatidylinositol.
The phosphatidylinositol composition of membrane lipids has been little studied 
because of the difficulty of separating this minor phospholipid from 
phosphatidylserine. Nevertheless, studies of this phospholipid in platelets have 
shown that it constitutes between only 2.7% and 11.8% of total phospholipids 
(Owen et a l, 1981; Ahmed & Holub, 1984; Dougherty et a l, 1987). The pre-diet 
value of 6% reported here for red blood cell phosphatidylinositol is therefore in 
the same region as these values reported for this membrane component in 
platelets. Following the low-fat diet there was an increase in the inositol-
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phospholipid component of the red blood cell membrane. This increase, although 
small, was consistently found in all subjects, and represented a 40% increase in 
phosphatidylinositol. The functional significance of such a change and the 
mechanism by which it might have arisen is unknown.
The fatty acid profile of phosphatidylinositol has been a subject o f limited study 
for several years. Recent investigations in platelets have supported the traditional 
view that this phospholipid contains mainly stearic acid (approximately 40 mol%) 
and arachidonic acid (approximately 40 mol%), (Prescott & Majerus, 1981; 
Brockman et a l, 1981). However, Dougherty et a l  (1987) have demonstrated 
that the precise profile differs according to dietary habits. Rogiers et a l, (1980) 
and Williams et a l, (1966) have reported values for the fatty acid composition of 
red blood cell phosphatidylinositol, although values for a number of the major 
fatty acids reported by these authors differ from one another and from the values 
found in the subjects of this study. The most notable differences in fatty acids 
compared with the results of the present study were for 18:0 which was higher, 
and 20:4>v6 which was lower than values reported by both these authors. These 
differences may be attributed to age and sex differences in the subjects o f these 
different studies, since the studies of Rogiers et a l, (1980) were carried out on 
children, and that of Williams et a l, (1966) on adult male subjects. These 
between-study differences may also reflect differences in dietary fatty acid intake 
in subjects in these various studies. A  large number of dietary studies and 
investigations using fatty acid supplements have shown it is possible to alter the 
fatty acid composition of total phospholipids and individual phospholipid 
fractions of red blood cells and platelets by dietary means (Siess et a l, 1980; Brox 
et a l, 1981; Goodnight et a l, 1981; Sanders & Roshanai, 1983). In the present 
study the effect of more subtle dietary changes on red blood cell 
phosphatidylcholine and phosphatidylinositol were investigated. No significant 
changes in the fatty acid composition of phosphatidylcholine were observed on
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the low-fat diet. However, there was a significant increase in the 20:4w6 content 
o f the phosphatidylinositol on this diet. The mechanism of this change is unclear, 
since there was no increase in dietary 20:4w6 intake in subjects on the low-fat 
diet. The increase in 20:4w6 content may be explained by the decreased 
consumption of saturated fats, which are reported to suppress the conversion of 
linoleic to arachidonic acid (Holman, 1977).
This study showed no significant alteration in luteal-phase prolactin in women 
changing to a low-fat diet for a period of 2 months. Previous studies have shown 
that the relation between dietary fat intake and prolactin is complex. Gray et a l, 
(1981) found no significant alteration in plasma prolactin (measured by 
radioimmunoassay) in normal premenopausal women undertaking a 50% 
reduction in total fat intake for a period of 2 months, results which are entirely 
comparable with those found in the present study. Shultz et a l, (1987) showed no 
difference in luteal-phase prolactin (measured by radioimmunoassay) in 
vegetarians consuming a diet containing 28% energy as fat compared with non­
vegetarians whose diet provided 38% energy as fat. Conversely, Hill & Wynder 
(1976) reported a reduction in nocturnal prolactin concentrations in normal 
premenopausal women changing to a low-fat vegetarian diet from their customary 
diet (40% energy as fat), and measured elevated plasma prolactin in black 
vegetarian South African women when they transferred from their customary diet 
(15% energy as fat), to a diet containing 40% energy as fat (Hill et a l, 1980).
Shultz and Rose (1988) conducted a study on the effect of low (25% of calories) 
and high (46% of calories) fat diets on lactogenic hormone bioactivity compared 
with radioimmunoassay of prolactin and growth hormone in premenopausal 
women. Although they found no difference in the radioimmunoassay levels of 
prolactin or growth hormone, luteal-phase lactogenic hormone bioactivity 
appeared to be higher (averaging 28%; p<0.07) in response to high rather than 
low-fat diets.
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Rose et al. (1987a) have previously shown that prolactin and growth hormone 
measured by radioimmunoassay do not correlate well with the bioactivity of these 
hormones in patients with cystic breast disease. They suggested that an elevated 
level of a structural variant of high biological activity may explain the higher 
bioactivity compared with immunactivity of these hormones in cystic breast 
disease. Mittra (1980a) demonstrated that there are various forms of prolactin 
detectable by polyacrylamide gel electrophoresis, thought to be cleaved forms of 
the prolactin molecule. Furthermore, the cleaved forms were found to have 
mammary mitogenic activity in rats in vivo (Mittra, 1980b), Clapp et a l, (1988) 
have shown that a 16K fragment of prolactin has the same mitogenic activity but 
half the immunoactivity as the intact prolactin molecule and as such the functional 
significance of this and possibly other fragments may have been underestimated 
owing to a low radioimmunoassay activity. Further studies of the bioassayable 
form of prolactin, and the response of this fraction to dietary fat modification 
appears to be warranted.
Our study showed a small (12%) but significant decrease in oestradiol 
concentrations in women changing to a low fat diet for a period of 2 months, 
possibly reflecting the decrease in total serum cholesterol from which the steroid 
hormones are produced. Similarly Boyar et a l, (1988) found there to be a 
decrease in oestradiol concentrations in serum of women with breast cancer when 
they followed a low fat (21%) diet compared with their normal (34%) fat diet, 
although it was not until 5-6 months of following the low fat diet that there was a 
significant decrease (13%; p<0.025). They found no significant change in total 
oestrogen or oestrone levels.
Both the total fat intake and the percentage of energy derived from fat achieved
(y red u c e d
by the volunteers in this study was significant^and was accompanied by a mean 
weight loss of 1.76 kg. Furthermore, there was an increase in the P:S ratio from a 
pre-diet value of 0.38 to a value of 0.61 on the low-fat diet. Both increased P:S
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ratios and lower body weights are thought to result in lower total cholesterol 
concentrations of the serum (Nichaman & Hamm, 1987) and hence the significant 
decline in total cholesterol in our subjects following the low-fat diet was probably 
due to a combination of lower total fat consumption, lower body weight and an 
increased P:S ratio.
In conclusion, this study has shown that normal, healthy women show good 
compliance to a very low fat diet; compliance is confirmed by the observation of 
weight loss as fat and by lower serum cholesterol concentrations during the low 
fat regimen. Changes in erythrocyte phospholipid fatty acid composition and 
circulating hormone concentrations are small, with a moderate but consistent 
increase in erythrocyte phosphatidylinositol 20:4w6 content and total 
phosphatidylinositol composition, and an approximate 12% decrease in the mean 
oestradiol levels. Care should be taken in interpreting the biological significance 
of these data, particularly the values obtained for phosphatidylinositol 20:4w6 and 
total phosphatidylinositol content, since the differences observed, though 
consistent, were small. The wide assay variability for these measurements shown 
in Chapter 2, should be kept in mind when interpreting the data, although 
analytical imprecision should be expected to decrease rather than increase the 
likelihood of observing statistically significant data.
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CHAPTER SIX
EFFECT OF MARINE OIL SUPPLEMENTATION ON ERYTHROCYTE 
AND PLATELET INOSITOL, CHOLINE AND ETHANOLAMINE 
PHOSPHOLIPIDS IN HUMAN VOLUNTEERS
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INTRODUCTION
Marine oils, or w3 fatty acid rich preparations are coming under scrutiny as 
therapeutic agents in a variety of diseases (Sanders, 1985). The low incidence of 
coronary heart disease and thrombosis in Greenland Eskimos has stimulated 
interest in the possible protective nature of the Eskimo diet which is extremely 
rich in fish (Dyerberg et a l, 1978). Furthermore, Greenland Eskimos have a low 
incidence of breast cancer even though their diet is high in fat. It has been 
postulated that marine oil gives the Eskimos protection from this disease (Karmali 
et a l, 1987).
Altering the fatty acid profile of the lipid component of the diet has been shown to 
effect changes in the fatty acid profile of various membrane phospholipids 
(Stubbs & Smith, 1984). In rats such changes have been found to occur within 14 
days, modifications being detected in the phosphatidylcholine and 
phosphatidylethanolamine fractions of the rat liver, plasma, platelets and 
erythrocytes (Iritani & Narita, 1984).
Dietary manipulation of the fatty acid profile of human phospholipids is more
difficult to achieve and has been less extensively investigated. Studies involving
supplementation of the normal diet with marine oils such as cod liver oil and
MaxEPA have shown that increasing the proportion of eicosapentaenoic acid
(20:5w3) and docosahexaenoic acid (22:6w3) in the diet results in a significant
increase in the proportion of these fatty acids in total platelet phospholipids and in
the individual choline, ethanolamine, and serine phospholipid fractions (Von
Schacky et a l, 1985). In each of these phospholipids there was a concomitant
decrease in arachidonic acid (Ahmed & Holub, 1984; Sanders & Younger, 1981;
Von Schacky et a l, 1985). Similar changes have also been detected in plasma
phosphatidylcholine (Sanders & Younger, 1981) and erythrocyte
phosphatidylcholine and phosphatidylethanolamine (Popp-Snijders et a l,  1986).
Other phospholipid classes have been less extensively studied.
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Phosphatidylinositol, although a minor phospholipid in mammalian cell 
membranes, plays an important role in cell signalling systems in various cell types 
and is known to be involved in mediating platelet aggregation in response to 
extracellular stimulation (Rittenhouse-Simmons, 1979). Supplementing the diet 
with eicosapentaenoic acid and docosahexaenoic acid has been found to influence 
bleeding time (Sanders & Younger, 1981). It is suggested that this may be 
mediated through alterations in platelet aggregation secondary to changes in the 
fatty acid profile of platelet phosphatidylinositol.
Dietary modification of phosphatidylinositol in human tissues has been very little 
studied. Ahmed and Holub (1984) reported slight but significant increases in 
eicosapentaenoic acid in the phosphatidylinositol fraction of platelets of subjects 
taking dietary supplements with cod liver oil for two weeks. They did not detect 
docosahexaenoic acid in human platelet phosphatidylinositol either before or after 
cod liver oil supplementation. Conversely, Galloway et a l, (1985) and Gibney & 
Bolten Smith (1988) found no incorporation of eicosapentaenoic acid or 
docosahexaenoic acid into the phosphatidylinositol fraction of human platelets 
after four and six weeks of fish oil supplementation although the content of these 
fatty acids was increased in the phosphatidylcholine and phosphatidyl­
ethanolamine fractions. Similarly, the arachidonic acid content of 
phosphatidylcholine and phosphatidylethanolamine significantly decreased with 
no such decrease in this fatty acid in either the phosphatidylinositol or 
phosphatidylserine fractions. However, these authors also failed to detect any 
alteration in platelet aggregation or thromboxane synthesis following fish oil 
supplementation and it may be that the dose of eicosapentaenoic acid they gave 
their volunteers daily was insufficient to elicit the changes required to produce 
altered prostaglandin synthesis.
Thus, the effect of fish oil supplementation on human platelet and erythrocyte
phosphatidylinositol is unclear at present. The normal fatty acid profile of this
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phospholipid in human tissues is also poorly documented in the literature. 
Although the available evidence suggests that the fatty acid profile of this 
phospholipid is not subject to profound alteration in response to dietary 
modification in the short term, Dougherty et a l, (1987) have shown that the 
phosphatidylinositol fatty acid composition of platelets of men from different 
countries (America, Norway and Italy), who consume different dietary fats, varies 
according to the dietary fat consumed. In particular these authors reported much 
more oleic acid in the inositol phospholipid of platelets from men from Italy than 
the other two countries. Interestingly, they also noted that the relative proportions 
of erythrocytes and platelet phospholipids was significantly different from men 
from these three countries.
In view of the ambiguous results obtained from short term marine oil 
supplementation studies performed so far, it was decided that a further study of 
the effect of 3.3g eicosapentanoic acid plus 1.4g docosahexaenoic acid per day, on 
platelet and red blood cell phosphatidylinositol, phosphatidylcholine and 
phosphatidylethanolamine, monitored over four weeks would add to our 
knowledge of the relative susceptibility of these membrane components to dietary 
modification. Furthermore, an investigation of the effect o f marine oil on the 
relative proportion of phospholipids in platelets and erythrocytes has not been 
performed before and may add to our understanding of dietary manipulation of 
membrane phospholipids. It was therefore considered relevant to the present 
investigations of dietary modification of membrane phospholipids in breast 
disease, to look at the dietary modification of red blood cell and platelet 
phospholipids by marine oil in a group of healthy volunteers over a four week 
time span.
It has been reported (Phillipson et a l, 1985) that feeding marine oil to healthy
volunteers and hyperlipidaemic patients results in a lowering of serum triglyceride
and total cholesterol. It was decided that these biochemical parameters should be
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measured in this study in an attempt to assess volunteer compliance with the 
marine oil supplement.
STUDY DESIGN AND SUBJECTS
Nine healthy male volunteers and nine healthy female volunteers recruited from 
the Biochemistry department of the University of Surrey agreed to take 9 capsules 
per day of Super EPA 1200, (3 capsules 3 times per day with meals). Each 
capsule contained 1.2g of marine oil of which 48% was eicosapentaenoic acid 
(20:5w3) and docosahexaenoic aicd (22:6w3), (for composition, see Table 27). 
The study protocol had received consent from the University Ethical Committee. 
All subjects were asked to complete a questionnaire regarding special dietary 
habits and supplements, medication, a brief medical history and smoking history 
(Appendix IV). Each volunteer was weighed and given advice about reduction of 
fat intake by approximately lOg per day. All participants were also asked to try to 
consume more fish, particularly salmon, mackerel, pilchards and herring during 
the period of the study.
A  20 ml blood sample was taken from each volunteer by venepuncture following 
an overnight fast and placed into a glass vial containing trisodium citrate (3.8g/l). 
Platelet rich plasma and red blood cells were separated immediately, the lipids 
extracted, and stored in chloroform at -40°C until all samples had been collected 
as described in Chapter 2. Platelet poor plasma was frozen for subsequent 
cholesterol and triglyceride determinations.
The volunteers were asked to take the capsules for four weeks. A  10 ml fasting 
blood sample was taken from each subject every week and at 2 and 4 weeks post 
supplementation. All samples were treated in an identical manner to the first (see 
analysis schedule, figure 28). Body weight was also measured weekly.
All lipid analyses were performed at baseline and week 4 as the main time points
under investigation. Red blood cell phosphatidylinositol and phosphatidylcholine
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were also measured at weeks 1, 2, 3 and 8. Red blood cell 
phosphatidylethanolamine and platelet phospholipids were not measured each 
week due to lack of resources. The samples collected post supplementation were 
too small to be analysed for both erythrocyte and platelet phospholipid fatty acid 
composition. Furthermore, the samples were too small to be analysed for both 
phospholipid fatty acid composition and relative proportions of phospholipids 
each week and hence the proportions of phospholipids in the membrane could 
only be analysed on baseline and weeks 2 and 4 for the erythrocyte samples and 
baseline and weeks 1 and 3 for the platelet samples. A summary of the schedule 
for blood samples is shown in figure 28.
The methods used in the analysis of the fatty acid composition of the 
phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol fractions 
of erythrocyte and platelet phospholipids, and for determining the relative 
proportions of the phospholipids, as well as plasma cholesterol and triglyceride 
determinations are detailed in Chapter 2.
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ANALYSIS WEEK
0 1 2 3 4 6 8
Triglyceride X X
HDL-Cholesterol X X
Total-Cholesterol X X
RBC
Phosphatidylinositol X X X X X X
Phosphatidylcholine X X X X X X
Phosphatidylethanolamine X X X
Platelet
Phosphatidylinositol X X X X
Phosphatidylcholine X X X X
Phosphatidylethanolamine X X X
figure 28: Schedule of Blood Analysis
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TABLE 27: FATTY ACID COMPOSITION OF
F atty  acid moI%
16:0 00.05
16:liv9 02.04
18:0 01.10
18:lw9 02.66
18:2w6 12.15
18:3iv3 12.61
20:3w6 03.18
20:4 w6 09.39
20:5w3 35.11
22:6w3 13.39
The results of this study were analysed using the Wilcoxon matched pairs signed 
rank test which does not assume normal distribution of data. The level of 
significance was taken as p<0.05 although data has been shown using the p<0.02 
level of significance where appropriate.
RESULTS
All nine of the male volunteers complied with the study in taking the capsules and 
giving blood. Four female recruits withdrew from the study within the first week 
one due to unpalatability of the capsules, and three for personal reasons.
It can be seen from Table 28 that there were no unusual dietary habits o f any of 
the volunteers. One subject, HD, reported eating little red meat and two subjects 
took daily vitamin/mineral supplements. None of the volunteers took any 
supplement containing fatty acids. Two subjects smoked, one occasionally, the 
other daily. Nine of the fourteen volunteers took regular but not excessive 
exercise.
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TABLE 28: DEMOGRAPHIC DATA
Subject 5e» Age
HD F 24
SD F 25
MW M 21
MB M 40
JA M 30
MM M 26
JM M 22
MMu F 25
LD f  23
KM F 23
AS M 41
Weight
64.5
48.5 
63.9 
71.11
74.5
65.8
70.9
71.9 
56.4
59.5
73.4
SP M 20 6)-5
Smokes
0
0
0
0
0
0
0
Dietary habits and Supplements
Bats little red meat; Vitamin & Mineral 
supplements.
1 multivitamin tablet per day 
No unusual habits; no supplements 
No unusual habits; no supplements 
No unusual habits; no supplements
No unusual habits; no supplements
CB M 25
JW M 43
68.2
70.3
2-3cigarettes/
month
0
4-5/day
0
0
0
Exercise
Regular
No
Cycles 20 min/day 
No
Occasional squash 
& football
Football 2xAveek
No
No
Squash 40 mins/wk 
Swimming 
l-2hr/week 
Aerobics 1 hr/wk
No
Golf 4hrs/ week 
Running;
Football 1 hr/week 
Squash 40 min/wk 
Squash 90 min/wk
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Table 29 shows the body weights for the male and female volunteers at the 
beginning and end of the four week supplementation. Body weight did not 
change significantly in either group.
TABLE 29: BODY WEIGHT OF MALE AND FEMALE VOLUNTEERS BEFORE 
AND AFTER FOUR WEEKS OF FISH OIL SUPPLEMENTATION.
Results expressed in Kg (mean + standard deviation).
Male
Female
(n=9)
(n=5)
pre-study
70.09 + 6.98 
61.08 + 7.36
post-study
69.69 ±  7.63 
62.38 + 7.68
Table 30: PLASMA TRIGLYCERIDE AND TOTAL CHOLESTEROL
CONCENTRATIONS AT BASELINE AND AFTER FOUR WEEKS OF 
MARINE OIL SUPPLEMENTATION.
Results expressed in mmol/1 (mean + standard deviation)
Triglyceride
Total cholesterol
Baseline
n=14
1.93 ±  1.30
5.95 + 1.27
After Supplementation 
n=14
1.16 + 0.40 *
6.39 + 1.58
* Wilcoxon signed rank test p<0.05
Table 30 shows the mean plasma concentration of triglycerides and total 
cholesterol for the 14 volunteers who completed the study. The mean triglyceride 
concentration decreased significantly from 1.93 mmol/1 at baseline to 1.16 mmol/1 
at the end of 4 weeks of supplementation (p<0.05). The individual triglyceride 
values for 13 of the 14 volunteers decreased with marine oil supplementation 
(Appendix IV, Table 41). Mean plasma total cholesterol levels did not alter 
significantly with marine oil supplementation.
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In erythrocyte phosphatidylcholine (figure 30; Appendix IV, Table 43) there was 
a significant increase in 20:5>v3 after one week of marine oil supplementation 
(p<0.02) which was sustained until the fourth week of supplementation (p<0.05). 
A  significant increase in 22:6w3 also occurred after four weeks of marine oil 
supplementation (p<0.02). There were no significant alterations of any other fatty 
acid in this phospholipid fraction and all fatty acid values were similar to baseline 
values four weeks after the end of supplementation.
Neither erythrocyte phosphatidylethanolamine (figure 31; Appendix IV, Table 44) 
nor phosphatidylinositol (figure 29; Appendix IV, Table 42) showed increases in 
20:5w3 or 22:6w3 content, although there was a significant increase in 22:5w3 in 
phosphatidylethanolamine at two weeks (p<0.05) but not four weeks. In the 
phosphatidylinositol fraction there was a small, but significant alteration in the 
amount of w9 fatty acids, there being significantly less 16:lw9 after three weeks 
of marine oil supplementation (p<0.02) and less 18:lw9 after four weeks of 
supplementation (p<0.05).
Phosphatidylethanolamine showed increases in 18:lw9 and 22:5w3 and decreases 
in 18:3w3 and 20:3w6 after two weeks of supplementation (p<0.05). However, 
after four weeks of supplementation only the increase in 18:lw9 remained 
significant (p<0.02).
Platelets responded to the marine oil supplementation differently to erythrocytes. 
None of the phospholipids studied showed an increased incorporation o f 20:5vi^3 
or 22:6w3 (figures 32, 33 and 34; Appendix IV, Tables 45, 46, 47). After two 
weeks of supplementation there was a transient increase in 20:3w6 and also a 
decrease in the 22:4w6 content of phosphatidylcholine (figure 33; Appendix IV, 
Table 46) which attained statistical significance (p<0.05). There were no 
statistically significant differences in the fatty acid profile o f this phospholipid 
after 4 weeks of marine oil supplementation.
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In phosphatidylinositol there was a rise in 18:0 (p<0.02) and fall in 22:5w3 
(p<0.05) after two weeks of supplementation, but the fatty acid profile after four 
weeks of marine oil supplementation was not significantly different from the 
baseline profile (figure 32; Appendix IV, Table 45).
There was also a significant rise in 18:0 in platelet phosphatidylethanolamine after 
two weeks of supplementation with a decrease in 20:4w6 (p<0.05) (figure 34; 
Appendix IV, Table 47). Neither of these alterations in fatty acid profile were 
significant after four weeks of supplementation. However, there was a gradual 
rise in the content of 22:4>v6 which was statistically significant at weeks two and 
four (p<0.05).
Phosphate analysis of the individual membrane phospholipids showed that few
changes in phospholipid composition occurred during supplementation.
a
Erythrocyte membranes (figure 35; Appendix IV, Table 48) showed^small 
increase in which was significant at
week two only (p<0.02). Platelet membranes (figure 36;
Appendix IV, Table 49) also showed a small but significant increase in 
phosphatidylcholine after three weeks of marine oil supplementation (p<0.05). 
There was no significant change in the membrane content o f the other 
phospholipids.
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DISCUSSION
The participants of this study were healthy volunteers from the students, staff and 
relatives of the Biochemistry department of the University o f Surrey. Ethical 
committee approval had been obtained and questionnaires (Appendix IV) 
ascertained that no volunteers were suffering from diseases that may impair fatty 
acid metabolism or otherwise affect the results of the study. Table 28 shows the 
age and baseline weight for all volunteers as well as details o f smoking, dietary 
and exercise habits. None of the participants were vegan, vegetarian or followed 
other unusual dietary practices. None were obese or excessively underweight and 
body weight did not alter significantly over the study period.
Compliance was assessed by return of unused capsules and plasma lipid 
concentrations. Only occasional capsules were returned, and volunteers admitted 
to forgetting to take the capsules on rare occurrences. Marine oil supplementation 
is reported to decrease plasma lipid levels in normolipidemic subjects (Harris et 
a l, 1983), particularly triglycerides and VLDLs. In this study, total cholesterol 
was not reduced significantly by marine oil supplementation, but triglycerides 
decreased from 1.93 mmol/1 to 1.16 mmol/1 (p<0.05). The triglycerides decreased 
in 13 of the 14 volunteers indicating that compliance was high.
In this study it has been shown that feeding w3 fatty acids (eicosapentaenoic acid 
3.3g/day and docosahexaenoic acid 1.4g/day) resulted in a significant increase of 
these fatty acids in erythrocyte phosphatidylcholine.
The eicosapentaenoic acid content of erythrocyte phosphatidylcholine was 
significantly increased after one week of supplementation and remained at a 
significantly higher level than the baseline value throughout the study period. 
The docosahexaenoic acid content of erythrocyte phosphatidylcholine had also 
increased slightly by the end of one week of supplementation. However, this fatty 
acid did not increase significantly until after four weeks of supplementation.
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The increased incorporation of eicosapentaenoic acid and docosahexaenoic acid 
was not associated with a significant change in the content of any other fatty acid. 
In particular 20:4w6 remained constant throughout the study.
The incorporation of eicosapentaenoic acid into red blood cell 
phosphatidylcholine has previously been demonstrated by Popp-Snijders et a l, 
(1986). They also showed an increase in docosahexaenoic acid incorporation with 
a concomitant decrease in 18:2w6, but no significant change in any other fatty 
acid.
It is interesting to note that in our study the eicosapentaenoic acid was 
significantly incorporated into red blood cell phosphatidylcholine after only one 
week of supplementation, whereas it was not until the end of four weeks 
supplementation that there was a significant increase in docosahexaenoic acid. 
This is probably due to the fact that eicosapentaenoic acid was present at a higher 
concentration than docosahexaenoic acid in the marine oil supplement. However, 
it may also reflect a greater readiness for the cell membrane to accept 
incorporation of the less unsaturated fatty acid.
Popp-Snijders et a l, (1986) did not investigate the time-scale o f eicosapentaenoic 
acid and docoshexaenoic acid incorporation into the red blood cell membrane. It 
is therefore not known from their study how rapidly the relative uptake of these 
fatty acids into the membrane occurred. However, Von Schacky et a l, (1985) 
have suggested that it takes about 16 weeks to reach maximal amounts o f the w3 
fatty acids in erythrocyte membrane phospholipids and 12 -16 weeks in platelet 
membrane phospholipids.
The decrease in 18:2w6 shown in the study of Popp-Snijders et a l, (1986) was as
expected, as w3> fatty acids are believed to "displace" w6 fatty acids from the sn-2
position of phospholipids, thus maintaining a degree of homeostasis in terms of
membrane fluidity. However, it must be pointed out that this decrease in 18:2w6
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was observed after 8 weeks of supplementation. In our study there was a very 
slight decrease in 18:2w6 after the 4 week supplementation period, a trend which 
may have continued to significant levels had supplementation continued.
Contrary to expectations, erythrocyte phosphatidylethanolamine did not 
incorporate eicosapentaenoic acid or docosahexaenoic acid. There was, however, 
a significant increase in 18:lw9 and significant decreases in 18:3w3 and 20:3w6 
after 2 weeks of supplementation; the increase in 18:lw9 continued and was also 
significantly lower than baseline levels after 4 weeks of supplementation. There 
was also a transient rise in 22:5w3 at the end of week 2.
The changes in the content of 20:3w6 after weeks 2 and 4, and also of 22:5w3
after week 2 was less than 1 mol%. Also, the decrease in 18:3w3 at the end of
week 2 was only 1.35 mol%. These alterations are very small, and although
statistically significant, they are unlikely to represent functionally important
changes. They may even be artefacts due to the high coefficient of variation of
the method. However, the increase in 18:lw9 is consistent and sustained and is
likely to represent a true increase being >6 mol% after week 2 and >7 mol% after
week 4. The reason for this increase in 18:lw9 is unclear. It is also interesting to
note that, although not significant, 18:0 decreased by 1.2 mol% after 2 weeks of
supplementation and approximately 5 mol% after 4 weeks of supplementation.
The increase in 18:lw9 together with the decrease in 18:0 led to a lower stearic to
oleic acid ratio and may be due to activation of the delta 9 desaturase enzyme
which converts 18:0 to 18:lw9 or alternatively could be due to inhibition of the
delta 6 enzyme which converts 18:lw9 to 18:2iv9 (Kinsella et a l, 1990).
Although little attention has been paid to changes in stearic:oleic acids in response
to dietary manipulation. Wood et a l, (1985a) demonstrated that patients with
malignancies showed an decreased stearic:oleic acid ratio in their red blood cells.
As marine oils are thought to be protective against breast disease, this altered
stearic:oleic acid ratio in this major red blood cell membrane phospholipid would
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seem worthy of comment. The data also closely corresponds with that of Gibney 
& Bolton-Smith (1988) who showed reduced 18:0 and increased 18:lw9 in 
platelet phosphatidylethanolamine of subjects after 6 weeks supplementation with 
MaxEPA. Altered delta 6 desaturase activity is a likely possibility since a number 
o f studies have shown eicosapentaenoic acid and docosahexaenoic acid to inhibit 
conversion of linoleic acid to arachidonic acid (Kinsella et a l, 1990).
In contrast to the present study, Popp-Snijders et a l, (1986) showed significant 
increases in 20:5w3 (2.3 mol%) and 22:6w3 (1.7 mol%) in erythrocyte 
phosphatidylethanolamine. They also demonstrated concomitant decreases in the 
w6 fatty acids 18:2w6 (1.3 mol%) and 20:4w6 (1.7 mol%).
There were very few changes in erythrocyte phosphatidylinositol fatty acid 
composition. At the end of week 3 there was a significant decrease in 16:lw9 and 
at the end of week 4 there was a significant decrease in 18:lw9, the opposite 
change to that which occurred in the phosphatidylethanolamine fraction.
There were, however, no changes in the content of any of the w3 fatty acids. This 
phospholipid appeared to be the most conserved in terms of fatty acid changes in 
response to marine oil supplementation.
The incorporation of w3 fatty acids into erythrocyte phosphatidylinositol in 
human volunteers has not previously been investigated. Comparison of the results 
of this study for erythrocyte phosphatidylinositol with other laboratories can not 
therefore be made.
None of the three platelet membrane phospholipids investigated showed changes 
in w3 fatty acid content following marine oil supplementation. 
Phosphatidylcholine exhibited a transient increase in 20:3w6 and a decrease in 
22:4w6 after 2 weeks of supplementation which, although statistically significant 
were small and are unlikely to be of functional significance.
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Phosphatidylinositol also showed minor alterations in fatty acid content at week 2, 
with a small (<1 mol%) decrease in 22:5w3 and a significant increase in 18:0 
(approximately 6 mol%). This rise in 18:0 was also evident at the end of week 4 
(4 mol% increase from baseline value), but was not significant. The cause of such 
a change is not known and has not previously been reported.
Phosphatidylethanolamine 18:0 also increased significantly at the end of week 2, 
an increase which diminished and was not significant by the end of week 4. 
There was also a decrease in 20:4w6 (significant at the end of week 2) and an 
increase in 22:4w6 (significant at the end of week 4), which may indicate a slight 
increase in chain elongation. These results are in partial agreement with 
Galloway et a l, (1985) and Gibney & Bolton-Smith (1988) in that all three 
studies have shown no incorporation of w3 fatty acids into the 
phosphatidylinositol fraction of platelets after 4 weeks (Galloway et a l, 1985) 
and 6 weeks (Gibney & Bolton-Smith, 1988) of fish oil supplementation. 
However, these other studies did show an increase in the eicosapentaenoic acid 
content of phosphatidylcholine and phosphatidylethanolamine with a concomitant 
decrease in arachidonic acid. Galloway et a l, (1985) also showed a decrease in 
the 18:2w6 content of phosphatidylethanolamine after 4 weeks of 
supplementation, a finding not observed by Gibney & Bolton-Smith (1988).
The present results therefore contradict the above findings in that there was no 
incorporation of w3 fatty acids into the phosphatidylcholine and 
phosphatidylethanolamine fractions of platelets. These data are particularly 
unexpected in view of the consistent reports of reduced platelet aggregation and 
increased bleeding time observed with fish-oil supplements, effects which have 
been attributed to increased membrane concentrations of eicosapentaenoic acid 
and docosahexaenoic acid and altered platelet prostanoid metabolism.
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Contrary to expectation marine oil supplementation for four weeks did not elicit a 
significant incorporation of eicosapentaenoic acid and docosahexaenoic acid in all 
phospholipids studied. It would appear that there is a high degree of homeostasis 
in tissue membranes, and perhaps a more prolonged and more intense marine oil 
diet is necessary before these w3 fatty acids are incorporated into membrane 
phospholipids. Some of the differences between the present study and those of 
other reports are almost certainly due to differences in the duration and dose 
levels of supplements used and the influence of the subjects’ usual diets, a factor 
which has been shown to affect response to fish-oils in other studies (Sanders & 
Younger, 1981).
This study did provide support for conclusions drawn in the animal feeding 
studies which suggested that phosphatidylinositol is the least responsive of the 
three phospholipids investigated in terms of fatty acid incorporation. It also 
suggested that platelets are less susceptible to short term dietary modifications 
than are red blood cells.
The membrane composition of phospholipids (figures 35 and 36) were relatively
constant and unaffected by dietary manipulation. The only significant changes in
platelets between baseline and the end of study values (week 3) was in
phosphatidylcholine (figure 36). Erythrocyte phosphatidy-leheMne sffii
a
sphingomyelin showed ^transient but significant increase after 2 weeks of 
supplementation (figure 35). No phospholipid in erythrocyte membranes was 
significantly different at the end of the 4 weeks of marine oil supplementation 
compared with the baseline value. Overall, the membrane phospholipid 
composition showed a high degree of homeostasis. This is in agreement with the 
literature on animal studies which have shown phospholipid composition to be 
resistant to dietary modification (Awad & Spector, 1976; Bums & Spector, 1987; 
Farquar & Ahrens, 1963).
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In certain tissues where w3 fatty acids are functionally important, e.g. brain, nerve 
tissue and retina, ingestion of w3 fatty acids results in their rapid incorporation 
into both phosphatidylcholine and phosphatidylethanolamine (Philbrick et a l, 
1987). It would appear from the results of the present study that this response is 
not observed in all tissue types, and those tissues, e.g. red blood cells, which are 
not functionally dependent upon the provision of w3 fatty acids do not show an 
increased incorporation of eicosapentaenoic acid and docosahexaenoic acid into 
membrane phosphatidylethanolamine. The data obtained here for erythrocytes of 
human solyects are not inconsistent with those observed for effects o f MaxEPA 
on the rat erythrocyte, shown in Chapter 3, in which little incorporation of 
eicosapentaenoic acid and docosahexaenoic acid was found in a long term feeding 
study.
The changes in 18:lw9 found in erythrocyte phosphatidylethanolamine are worthy 
of further investigation. Most studies of fish-oil supplementation have 
concentrated on the measurement of increased eicosapentaenoic acid and 
docosahexaenoic acid content of platelet and red blood cell membranes and on 
corresponding displacement of 20:4w6, even though these changes when they do 
occur are often found to be small. Changes in 20:5w3 and 20:4w6 are particularly 
emphasised because of the role of these fatty acids as precursors for the 
prostaglandin 2 (PG2) and prostaglandin 3 (PG3) families. However, there is
much dispute as to the likely significance of altered membrane 20:4w6 and 
20:5w3 (Sanders & Roshanai, 1983). Changes in the membrane content of fatty 
acids other than 20:4w6 and 20: 5>v3 should not therefore be ignored, even though 
at present the physiological significance of such changes cannot be identified.
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CHAPTER SEVEN
ANALYSIS OF FATTY ACID PROFILE OF BREAST TISSUE AND 
ERYTHROCYTE PHOSPHATIDYLINOSITOL AND 
PHOSPHATIDYLCHOLINE FROM WOMEN WITH MALIGNANT AND 
BENIGN BREAST DISEASE AND IN NORMAL CONTROLS
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INTRODUCTION
The mechanism by which dietary fat may influence the growth of breast cancer is 
as yet unknown. Several hypotheses have been proposed, such as dietary 
influences on circulating oestrogens and prolactin and on receptor binding and 
prostaglandin synthesis (Welsch, 1987). We have also proposed that dietary 
modification of phosphatidylinositol may influence breast disease as this 
phospholipid is known to be involved in cell signalling in a number of secretory 
cells (Fain & Berridge, 1979; Siess et a l, 1986; Uhing et a l, 1986), with some 
evidence of its involvement, with prolactin, in breast tissue growth (Sharoni et a l, 
1986). However, there have been very few studies of the fatty acid profiles of 
tissue from patients with malignant or benign breast disease or normal breast 
tissue, and indeed none that have investigated the individual phospholipids.
It is ethically impossible to examine the effect of diet directly on breast tissue in 
humans, but corresponding rat studies have indicated that certain diets enhance 
tumour growth (Carroll et al, 1981) while others appear to abate growth (Karmali 
et a l, 1984; Jurkowski & Cave, 1985) and these effects are associated with 
modifications of the membrane phospholipid fatty acid profiles (Karmali et a l, 
1984). Also in humans dietary fatty acid modification has been shown to cause 
alteration in membrane phospholipid fatty acid composition of erythrocytes and 
platelets (Von Schacky et a l, 1985). In view of the close proximity of breast 
epithelial cells to surrounding mammary adipocytes, and since adipocyte 
triglyceride fatty acids reflect dietary fatty acids, it may be speculated that 
mammary epithelial cells could be particularly susceptible to effects of dietary 
fatty acids.
It has been reported that the stearicioleic acid ratio of red blood cell lipids may be 
decreased in women with breast cancer compared with normal controls (Wood et 
a l, 1985a), but this has yet to be confirmed, another study finding no difference
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between the two groups (Thomas et a l, 1988). The phospholipid arachidonic 
acid content of human breast tumours has also been found to be higher than the 
amount in adjacent reference breast tissue (Hietanen et a l, 1986).
Nothing is yet known about the fatty acid profile of individual phospholipids in 
human breast tumours, or indeed normal breast tissue. It was therefore deemed 
fundamental to establish the fatty acid profile of phosphatidylcholine, the major 
membrane phospholipid, and phosphatidylinositol, a secondary cell signalling 
messenger, in normal breast tissue and investigate any differences in the profiles 
of these phospholipids in malignant and benign breast tumours. It was also 
considered important to investigate the fatty acid profiles of the corresponding 
erythrocyte phospholipids to see whether any comparisons could be made with 
breast tissue, and to further investigate the altered stearicioleic fatty acid ratio 
reported in the study of Wood et a l, (1985a). Furthermore, as each phospholipid 
is believed to have a specific and important function in the membrane it would be 
of interest to know if the proportions of the phospholipids is different between 
malignant and benign breast tumours and normal breast tissue.
STUDY DESIGN
Access to tumour tissue obtained from patients undergoing lumpectomy for the 
treatment of malignant and benign breast disease at a Charing Cross hospital, 
London, was provided by the kind permission of the surgeons. Ethical consent 
for the study was obtained from the hospital Ethics Committee. Diagnosis was 
confirmed by histological examination of a portion of the same tissue 
(histopathological diagnosis is shown in Appendix VI, Table 56, page 269). 
Because of the difficulty of ensuring that 'normal' tissue obtained from a region of 
the breast unaffected by disease can be considered as representative of normal 
tissue, it was decided to obtain normal tissue for comparison from women 
undergoing breast surgery for cosmetic breast reduction at a private London 
hospital.
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Fifteen malignant breast tumours and twelve benign breast tumours were taken by 
the investigator from theatre at Charing Cross Hospital at the time of 
lumpectomy. A  10ml blood sample was also taken during the operation. Five 
samples of normal breast tissue were collected from the Harley Street Clinic from 
women undergoing breast reduction surgery. However, as these were private 
patients, clinical details and blood samples were not made available. Blood 
samples for the control group were taken from age matched normal healthy 
women from the general population at the University of Surrey, and from patients 
undergoing surgery for fractured neck of femur or total hip replacement at,the 
Royal Surrey County Hospital.
Details of age, weight and parity were obtained from the hospital patients 
wherever possible.
Lipid extraction of the breast tissue and red blood cells was performed on the 
same day as collection and the lipids were stored at -40®C under nitrogen for 
subsequent analysis. All methods for lipid extraction and analysis were as 
described in Chapter 2.
Statistical analysis of the results was performed using the SPSS-X program on the 
Prime Mainframe at the University of Surrey. The Duncans range test was used 
to analyse this data and p<0.05 was taken as the level of significance. Where data 
was found to have an unacceptable level of variance using Cochrans C, Bartlett- 
Box or Maximum/Minimum variance tests, statistical analysis was performed on 
loglO, natural log or square root transformed data.
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Table 31 shows the demographic data (age, weight and parity) from the groups of 
women in this study.
TABLE 31: A g e , w eigh t an d  n u m b er  o f  ch ild ren  (parity) a t  th e  tim e o f  lu m p ecto m y .
DIAGNOSIS AGE WEIGHT PARITY
MEAN SD MEAN SD MEAN SD
BENIGN (n = 1 2 ) 3 9 .3 8  1 3 .4 9  5 8 .5 8  1 2 .2 7  1 .7 8  1 .4 8
CANCER (n = 1 5 ) 6 1 .0 7  1 5 .7 5 *  6 3 .4 3  9 .0 1  1 .0 7  1 .3 9
NORMAL BREAST (n =  5 )  DATA UNAVAILABLE
NORMAL BLOOD (n = 1 5 ) 4 9 .4 2  2 2 .6 1  5 9 .3 9  1 6 .7 0  1 .0 0  1 .2 1
* p < 0 .0 5  ca n cer  group  v ersu s b e n ig n  group
The mean age of patients with a diagnosis of benign breast disease was 
significantly lower than the age of patients with breast cancer (p<0.05).
The fatty acid profile of normal breast phosphatidylcholine (figure 37; Appendix 
V, Table 51) shows a number of significant differences compared with both 
malignant and benign breast tissue. There was less 1 8 : 1 v p 9  (p<0.05) but more 
20:3uiband 20:4w6 in the control tissue (p<0.02 in both cases). The lower content 
of 18:lw9 in the normal tissue resulted in a higher stearicioleic acid ratio (18:0 to 
18:lvv9 ratio). This ratio was significantly increased in control tissue compared 
with benign breast tissue (p<0.05), but although there were similar trends in 
malignant tissue a comparison with control tissue did not attain statistical 
significance.
In the phosphatidylinositol fraction (figure 38, Appendix V, Table 50) the 16:0 
content of the control tissue was significantly higher than that of both malignant 
and benign breast tissue (p<0.05). Furthermore, stearic (18:0) acid was found in
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significantly greater amounts in malignant than both benign and control tissues 
(p<0.05). There were also differences in the content of w3 fatty acids between 
these three tissue groups. Normal breast tissue contained significantly more 
18:3w3 than malignant tissue, and significantly more 20:5w3 than both malignant 
and benign breast tissue (p<0.05). Benign tissue contained numerically more 
22:6w3 than both malignant tissue and control tissue. This together with the 
marked differences in 18:0 content between malignant and benign breast tissue 
led to a significantly higher P:S ratio in the benign tissue compared with the 
malignant tissue.
Erythrocyte fatty acid composition showed more differences between the three 
groups. The fatty acid profile of phosphatidylcholine (figure 39, Appendix V 
Table 53) contained more 18:0 and less 18:lw9 in the normal volunteers than in 
either the breast cancer (18:0 p<0.05; 18:lw9 p<0.02) or benign (p<0.05 for both 
fatty acids) breast disease groups. This led to a significantly higher 18:0 to 
18:1h»9 (stearicioleic) ratio in the control volunteer blood phosphatidylcholine 
(p<0.05). Other differences in this phospholipid were in the w6 fatty acids. 
There was less 18:2w6 acid in erythrocytes from the control group compared with 
the malignant (p<0.02) and benign (p<0.05) breast disease groups, but more 
20:3w6 (control greater than the malignant group p<0.05; control greater than 
benign p<0.02) and 22:4w6 (control greater than malignant and benign groups 
p<0.02). There was also more 20:4w6 in erythrocyte phosphatidylcholine from 
normal volunteers compared with erythrocytes from patients with either malignant 
or benign tumours, although this difference was only statistically significant 
between the control and benign groups.
In erythrocyte phosphatidylinositol (figure 40, Appendix V, Table 52) the fatty 
acid profile of the normal volunteers contained significantly more 16:lw9 and 
20:3w6 (p<0.02) and less 18:lw9 (p<0.02), 18:2w6 (p<0.02 when compared with 
malignant group; p<0.05 compared with benign group) and 22:6w3 (p<0.02) than
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either the erythrocytes taken from women with malignant breast disease or those 
taken from women with benign breast disease. Although the 18:lw9 content of 
erythrocyte phosphatidylinositol from control women was significantly lower than 
that o f women with breast disease, this did not lead to a significantly higher S :0  
ratio, almost certainly due to the high variation in this ratio seen in the control 
group. The 2 2 :61+3 content of erythrocytes from women with breast cancer was 
also significantly greater than the content of this fatty acid from women with 
benign breast disease (p<0.05).
The relative proportion of the phospholipids in breast tissue did not differ 
markedly in tissue in normal, benign or malignant breast tissue (figure 41; 
Appendix V, Table 54) for most of the phospholipids. However, there was a 
significantly greater content of phosphatidylserine in control breast tissue 
compared with malignant and benign breast tissue (p<0.01). There was 
numerically less phosphatidylethanolamine in control tissue than in malignant and 
benign breast tissue but this did not attain statistical significance.
There were less marked differences in the erythrocytes (figure 42; Appendix V, 
Table 55). Nevertheless, sphingomyelin was found in significantly greater 
amounts in erythrocytes from normal healthy volunteers than from women with 
either malignant or benign breast disease (p<0.01). There was also significantly 
less phosphatidylethanolamine in erythrocytes from normal controls compared 
with women with benign breast disease (p<0.05).
172
!£} ÇïS q
i i s
(N g)
V V c  a. CL ^  
_r -  VY c  c
rM
IT
C
Il II
c  c
2 2 ^  
i l l>» >. r=
§ c  ô
O) g) : :
Z= c  c
®  CD O
m  o
IlîliJ
Ê.3
so &3
&
50 â
&3 âs %
Cso 2 « . 1c
I 8 2 8
î i : H
c  = c  «  M so
l l î
Il II II
= C =
sc so so
i i s
n II
j2 u < =: U
o
g  g
C\J ^
L O O i O O i O O L O O i O OL O ü O ' ^ ' ^ C O C O Ç X j C X J v — lO o
t r
11 
. 1 1  I ;
<
c
<ü
i
a .
-D fTi
C  C  C:
aj etII
•u •ac
2 ^
x :c .
v;
Ê
E
c
D
B
■2 >
t>
m
t
3
5£
I l l
'  V
Ci 2  ir,
Il II IIc c c
c
03
C
03
l i i
i l l
c O
03 h so
■— c  c
0 3  ( D  O
^  OÛ O
I I I
s os o
111■o "O o u 
"3
ro «c  C c
60 50 so
111 
Il II II
ÇK
O
O  m
O  lO O
co C\j C\J
u3 O
I
93
"9c3
Su
Ë
c3
ëÎ3
*3
U
S ‘V
C
X)
Ë
O-
X)
c c
>
X»
"3
3
C
ce
X:
I I
t  I
X)
2
<
oc
m
t
3
C£
>
3"
II
c
c
(0
C
03
O
q qq C)
l î S VCL.
s i ? C € l5 H 2 2 X
l ê 2 ■3i  i3  -s 3 3  a 2-3
3
1»
3; = c 3 C
II s.5 .2 ImC
S 1 1 e 0>'J'.
■= tÆ C 3
03
C
(D
m
o
L_
C
Co
ô
2
►JQ SX) 3 te
S,I
■3
50“ •3Î
50 5
G so d 50
Mi l
« 5Ô.2P.2P.=P
E ^ =
Il II "X o <
c X  
Il II
= u
iX3 o  lO o  LT! o  UD o  u j 
( O ( O L C ü 3 ' ; T ^ C 0 C 0 C \ j
~ T ~
u “ : U . : -
c v
■r.
t
93
.=f
Ca>
93
% B
i l
H1) .;:a
ë  .2
2 X
tz:lî
o- ^
B £
ê  i
£  §II
x>
u
£  Bc  3
>L.a.
'U
<
>5.
OSfC
3
C£
V )
r '
s  S c
I Ic
C
CO
c
O)
c
O)
c
CD
m
lf2
IIc
O
i w .
c
o
O
T3
aK
o
&K.C 6.6.%
i i>> ±-
V c
l ê
_r V
II
f  1 - ^ 1 1 ^
3.1
5b .59
Û. Cm3
se 3
2
se so
c
-a •S3 cc 0C3 -3
« £c = cse c9 c?
' £
£
II II II
X -C
ÎI
c "%
-
-3 5
s  ^
II II
CO
UCO
CO —
CO
CO
i
o
00
(O
o
CO
10 o
10 LO
uo
'xj-
o LO O  
CO CO
10
CM
O  10 CO ^  CD
CM ^  ^
CM
CM
LO
0
CM
m
6
■ Q
!S
CM
Ü
ca 3
Æ
CO > O .•r.
0 CO ï“
CM u_
3CM > s ,
do Vr '
B
do u
T -
J J
0
do c
&.
!20 '3
CO <
1>
'■ t.Î30^
:ür \
' / 5
t
05
•rfs
A
1  s
11
a.
-  ^
É
E
c
D
E
3J
_2
CC>
oTf
t3Cl
IT)
IT
fN
I I
C
vn
I I
c
îîiH i
Hî
■3; 'c■A ^ tC
tc ^  g 
W) £ M{Î!
= c c to M) to
“O
=:3
I
yiffttmfm
"3
cu
5
CÛ
o .
1 >
H  - 5
>
"3
i ,  -C
g
c
E
c
CC
£
X)
>
J2
X )
ÛÎ
t
351
>
r-r-
Il
.o  c
T
c
o
II
c
1^ û- £  £
-3 >» — 
~  T 3il
s z
8 II
n
me
DISCUSSION
The women in this study with a diagnosis of benign breast disease had a mean age 
of 39.38 years compared with a mean age of 61.07 years (p<0.05) in the women 
with a diagnosis of malignant breast disease. It is well known that breast cancer is 
found mainly in peri- or post-menopausal women, whereas benign breast disease 
is much more common in younger women. This is reflected in the mean ages of 
the women in this study. There were no significant differences in body weight or 
parity between the two groups of patients.
Clinical data for the 5 women undergoing breast reduction could not be obtained. 
However, information was given by the surgeon that all these women were under 
30 years of age and none had a history of breast disease. Blood was obtained 
from volunteers at the University of Surrey and from patients at the Royal Surrey 
County Hospital. An attempt was made to match the volunteers with the patients 
for age. Although numerical differences in age are evident it can be seen from 
Table 31, the age, weight and parity of these women does not differ significantly 
from either the malignant disease or the benign breast disease groups.
Previous studies have investigated total phospholipid fatty acid composition of 
diseased breast tissue and that of surrounding tissue, assuming the latter to 
represent normal non-diseased tissue (Hietanen et al, 1986). There is some doubt 
as to whether this is a valid assumption, since diseased breast tissue has been 
suggested to influence the fatty acid composition of surrounding tissue (Tinsley, 
1989). To avoid this problem the present study has compared the phospholipid 
fatty acid composition of diseased breast tissue with that o f normal breast tissue 
removed during surgical breast reduction. Access to normal tissue from patients 
undergoing breast reduction was limited so that only five samples of normal tissue 
were available for analyses. A  further disadvantage of the use of this group of 
patients was that details of age, parity etc. could not be obtained.
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The present study has investigated the fatty acid composition of two phospholipid 
fractions, phosphatidylcholine and phosphatidylinositol, since studies in other 
tissues and other species have shown that the fatty acid compositions of the 
different phospholipid fractions are very different, and that they also differ in 
their response to diet and disease states.
A  previous comparative study of erythrocyte phospholipid fatty acid composition 
in normal women and women with benign and malignant breast diseases 
measured only total phospholipid fatty acid composition, and only reported values 
for the stearicioleic acid (18:0 to 18:lw9) ratio (Wood et a l, 1985a). The present 
study has compared erythrocyte phosphatidylcholine and phosphatidylinositol 
total fatty acid composition from these three groups, as well as measuring the P:S 
ratio and the stearicioleic acid ratio. A comparison of results from the present 
study with those of previous studies will firstly be undertaken before a detailed 
consideration of the present findings and their possible significance is discussed.
In the present study marked differences in oleic acid (18:lw9) and stearic acid 
(18:0) compositions were observed in phosphatidylcholine and 
phosphatidylinositol fractions of both erythrocytes and breast tissue from women 
with breast disease compared with normal women. The differences were most 
evident in the erythrocyte phospholipid fractions in which significantly higher 
stearicioleic acid ratios were found in phosphatidylcholine in cells from normal 
women compared with cells from women with malignant and benign breast 
diseases, and although not statistically significant, numerically higher stearicioleic 
ratios were also found in erythrocyte phosphatidylinositol from normal women 
compared with women with breast disease. These data are in part agreement with 
those reported by Wood et al, (1985a) in which mean erythrocyte total 
phospholipid stearic: oleic acid ratios of 1.57 and 0.79 were reported for healthy 
subjects and women with breast cancer respectively. Values for erythrocyte 
phosphatidylcholine stearicioleic acid ratios for normal versus breast cancer cases
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in the present study were 2.06 and 0.68, respectively, this difference was largely 
due to increased oleic acid (18:lw9) content of the phospholipid, although stearic 
acid (18:0) content was also decreased in erythrocytes from patients with breast 
disease.
There was a high degree of variability seen in the erythrocyte phosphatidylinositol 
stearic: oleic acid ratio so that although oleic acid (18:lw9) content was lower in 
red blood cells from controls, this phospholipid fraction did not show the same 
statistically significant differences between patients with breast disease and 
normal subjects. The present study also found marked differences in erythrocyte 
phospholipid stearicioleic acid ratios in women with benign breast disease 
compared with normals, an observation which was not found in the study of 
Wood et al., (1985a). In Wood's study women with benign breast disease had a 
mean erythrocyte phospholipid stearicioleic ratio of 1.45, a value which was very 
close to the value they reported in normal subjects (1.57). In the present study an 
erythrocyte phosphatidylcholine stearicioleic ratio of 0.70 was found in women 
with benign breast disease, considerably lower than the value of 2.06 found in 
normal women. Again the difference was largely due to higher 18ilw9 content of 
diseased compared with normal tissue.
It is noticeable that in Wood's study a comparison of stearicioleic acid ratios in a 
large heterogeneous group of patients with other non-malignant disease showed 
values intermediate between those of normal and malignant cases. This suggests 
that alterations in the stearicioleic ratio are not confined to malignant diseases 
alone and may represent a systemic response to tissue dysfunction and/or injury.
Differences in the findings of the present study and those of Wood et a l, (1985a) 
for benign breast disease, may be explained through a number o f possible causes 
but no definite conclusions can be drawn. It may be that in benign breast disease, 
alteration in phosphatidylcholine stearicioleic ratios are more marked than for
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other phospholipid fractions and that these differences are masked when total 
phospholipid fatty acids are determined, as in Wood's study. Alternately 
differences may be due to differences in the nature and duration of disease in the 
patients in the two studies, however, since no details of patients in the benign 
breast disease group of Wood et a l, (1985a) were given, this explanation must 
remain speculative. Differences are unlikely to be due to incorrect diagnosis and 
assignation of patients to benign rather than malignant groups in the present study, 
since clinical diagnosis of benign and malignant disease was confirmed by 
histopathological examination of excised tissue from all patients included in the 
present study (Appendix VI, Table 56). Furthermore, other differences in 
erythrocyte fatty acid composition between benign cases and normal subjects and 
corresponding differences in breast tissue fatty acid compositions between benign 
cases and normal subjects, support the conclusion that benign as well as malignant 
breast disease, result in changes not only in breast tissue phospholipids, but in 
erythrocyte phospholipids also.
Similarities were seen in the stearicioleic acid ratios between the erythrocytes and 
the breast tissue. In phosphatidylcholine, oleic acid (18ilw9) was significantly 
lower in normal breast tissue than in malignant and benign breast tissue (p<0.05). 
The stearicioleic ratio was numerically higher in control tissue than malignant and 
benign breast tissue although this only attained statistical significance between the 
control and benign breast tissue. These were the same trends as seen in the 
erythrocyte phosphatidylcholine. In phosphatidylinositol, the oleic acid (18ilw9) 
content of control breast tissue was not significantly different from that o f either 
malignant or benign breast tissue. However, it was numerically lower than results 
for both disease groups, again reflecting the erythrocytes for these three groups of 
women. Although in the erythrocyte phosphatidylinositol fraction there was no 
statistically significant difference in the stearicioleic acid ratio between the 
malignant, benign and normal groups, there was a trend towards a higher
- 1 8 2 -
stearicioleic acid ratio in erythrocytes from the normal volunteers. However, in 
breast tissue this trend was not evident even though there was less oleic acid 
(18ilw9) in the normal breast tissue, due to a markedly higher 
phosphatidylinositol stearic acid (I81O) content in the malignant breast tissue. 
Although the stearicioleic acid has not previously been studied in breast tissue 
phospholipids, it is an interesting observation that in general, the changes noted in 
erythrocytes from patients with breast disease are reflected in the diseased tissue 
itself, particularly in the phosphatidylcholine fraction.
In addition to differences in the w9 fatty acids the present study also found 
significantly higher 18i2>v6 and lower 20i3w6 in both erythrocyte phospholipid 
fractions of women with malignant and benign breast disease compared with 
normal breast tissue. Levels of 20i4>v6 were also significantly lower in 
phosphatidylcholine, but not phosphatidylinositol, of erythrocytes from women 
with benign breast disease.
Similar trends in the pattern of w6 phospholipid fatty acids were found in breast 
tissue as in the erythrocytes of women with breast disease. In breast tissue 
phosphatidylcholine levels of 18i2w6 were numerically higher in both malignant 
and benign tissues, although differences from normal tissue did not reach 
statistical significance. However, levels of 20i3w6 and 20i4w6 were significantly 
lower in tissue from both groups compared with normal. In phosphatidylinositol 
of diseased breast tissue, levels of 18i2w6 were higher and 20i3u/6 lower than in 
normal tissue, although these trends did not reach statistical significance. 
Notably, as was the case for erythrocytes, phosphatidylinositol 20i4w6 did not 
differ between the three groups of patients, and no trends were evident, suggesting 
that in this fraction 20i4w6 content is maintained.
The observation of lower 20i4w6 levels in phosphatidylcholine of malignant and 
benign breast tissue is in contrast with the findings of Hietanen et al., (1986) who
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found larger amounts of 20:4w6 in total phospholipids o f breast tumours 
compared with surrounding non-diseased tissue. This study also found large 
quantities of 20:3iv6 in tumour versus surrounding tissues. The limitations of 
studying apparently 'normal' tissue from the same breast as that of the diseased 
tissue has already been commented upon, so that only limited conclusions should 
be drawn from the study of Hietanen et a l, (1986). Nevertheless, it should also 
be pointed out that data from the present study conflicts with that of Karmali et 
a l,  (1984) who found six times higher arachidonate levels in mammary tumour 
phosphatidylcholine than in phosphatidylcholine from normal rat mammary 
tissue. However, in the animal study carried out by the present investigator 
(Chapter 4), there was no significant difference in the arachidonate content of 
mammary tumour phosphatidylcholine compared with the arachidonate content of 
this phospholipid in normal mammary tissue, although there were non- 
significantly higher amounts of arachidonic acid in phosphatidylethanolamine of 
mammary tumours.
These data draw attention to the discrepant findings which are evident in 
comparisons of human and experimental animal studies and also between 
different animal tumour models, Karmali et a l, (1984) having used a transplanted 
tumour, and the present investigator having used a chemically induced tumour 
model. It may also highlight the species differences in fatty acid uptake, 
déacylation and reacylation mechanisms and desaturase enzymes.
The data described above for erythrocytes and breast tissue suggest that in women 
with breast disease, pathways of w9 and w6 fatty acid metabolism are altered and 
that these alterations result in differences in membrane phospholipid fatty acid 
composition in erythrocytes, as well as in the diseased breast tissue itself. 
Reduced stearicioleic acid ratios, and reduced 20i3w6 and 20i4w6 in the presence 
of elevated 18i2w6 levels (most notably in phosphatidylcholine), suggest that 
these differences reflect alterations in the activity of the delta-9 and delta-6
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desaturase enzymes whose activities are the rate determining steps in the 
conversion of 18:0 and 18:2w6 to their desaturated, chain elongated metabolites 
(Gurr & James, 1980). Elevated levels of 18:2w6 together with reduced levels of 
its chain elongation and desaturation products 20:3w6, 20:4>v6 and 22:4w6 (see 
figure 3, page 20), suggests that there may be reduced activity of the delta-6 
desaturase enzyme in patients with breast disease. Higher 18:l>v9 levels in red 
blood cells and breast tissue of patients with breast disease may be explained 
either through increased activity of the delta-9 desaturase, or again through 
reduced activity of the delta-6 desaturase, since 18:lvv9, 18:2>v6 and 18:3tv3 are 
all co-substrates for this enzyme. The only exception to the trend for higher 
stearicioleic acid (18i0 to 18ilw9) ratios in erythrocytes and breast tissue of 
women with breast disease was in phosphatidylinositol from malignant breast 
tumours in which stearicioleic acid (18i0 to 18ilw9) ratios were similar in normal 
and malignant groups, despite lower 18il>v9 in normal subjects. These results are 
explained because of the markedly higher stearic acid (18i0) content of malignant 
breast tissue phosphatidylinositol. Possible mechanisms responsible for these 
effects on w9 and w6 fatty acids, and their significance to cell proliferative 
processes, will be discussed later.
Data from the present study also provides evidence of altered w3 fatty acid 
metabolism in membrane phospholipids of women with breast disease and again 
differences were more evident in erythrocytes than in breast tissue, but unlike 
previous data described above, in the case of this pathway, more differences were 
found in the phosphatidylinositol than the phosphatidylcholine fraction in tissue 
from patients than controls. In particular, levels of 22:6w3 were markedly higher 
in phosphatidylinositol of erythrocytes from women with benign (p<0.02) and 
malignant (p<0.02) breast disease compared with erythrocytes from normal 
women. Similar trends but less marked differences in phosphatidylcholine 
22:6w3 content were evident in erythrocytes of cases compared with normal
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controls. In breast tissue, levels of 18:3w3 were lower in breast tissue 
phosphatidylinositol from malignant cases than from normal subjects, and 
although there were higher levels of 22:6w3 in breast tissue phosphatidylinositol 
from malignant and benign cases than controls, these differences did not reach 
statistical significance. Taken together, these data are suggestive o f increased 
conversion of 18:3w3 to the final product of w3 elongation and desaturation, 
22:6w3. If this is so then it would suggest that the reduced activity o f delta-6 
desaturase acting against linoleic and oleic acids suggested above in erythrocytes 
and breast tissue of patients with breast disease, does not apply to the co-substrate 
alpha-linolenic acid (18:3w3). The data is also suggestive of increased activity of 
the delta-4 desaturase enzyme against 20:5w3. Overall the results indicate 
increased activity of delta-6 and delta-4 desaturase enzymes against w3 substrates, 
with reduced activity against w9 and w6 substrates in tumours and in erythrocytes 
from patients with malignant and benign breast disease compared with normal 
controls.
Other differences in fatty acid composition determined between the three groups 
include larger amounts of 16:0 in phosphatidylinositol of normal compared with 
malignant (p<0.05), and benign (p<0.05) breast tumours, and larger amounts of 
phosphatidylinositol 18:0 in malignant compared with either benign breast 
tumours (p<0.05) or normal tissue (p<0.05) (already mentioned). Although the 
biological significance of increased 18:0 content of malignant breast tumour 
phosphatidylinositol is not known it is interesting to note that this is one o f only 
three statistically significant differences between malignant and benign tumours in 
terms of fatty acid composition in the phospholipids investigated. This reiterates 
one of the most important, and surprising, findings of this study which was the 
very similar fatty acid compositions of both erythrocyte and breast tissue 
phospholipids from the two patient groups. A further unexpected finding was the 
observation that benign tumour phosphatidylinositol had a significantly higher
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polyunsaturatedisaturated (P:S) fatty acid ratio than malignant tumour 
phosphatidylinositol. The P:S ratio was also higher in benign tumour tissue than 
normal breast tissue, but this difference was not statistically significant. The 
major factor which contributed to the higher P:S ratio in benign tissue was the 
lower content of 18:0 compared with malignant tissue and higher 22:6w3 in the 
phosphatidylinositol fraction.
The relative proportions of the phospholipids were also measured in breast 
samples and erythrocytes from the three patient populations. The relative 
proportions of the phospholipids in the cancer and benign tumours did not differ 
significantly, nor did the proportions of the phospholipids in the erythrocytes 
from patients with malignant or non-malignant tumours.
The normal breast tissue, however, did show a significantly higher proportion of 
phosphatidylserine compared with the diseased breast tissue (p<0.05), no other 
phospholipids being different from the breast disease groups. This is the first 
demonstration of differences in the proportion of phospholipids in normal and 
diseased breast tissue and although the results of this investigation show a large 
difference in the content of phosphatidylserine from the normal and tumour tissue, 
the functional significance of this unknown.
The difference in phosphatidylserine content demonstrated in the breast samples 
was not reflected in the red blood cells of women from each group. There was 
significantly more sphingomyelin in the erythrocyte membranes from women 
without breast disease compared with women with malignant or benign breast 
disease (p<O.Ol), and significantly less phosphatidylethanolamine in the 
erythrocyte membranes from control women compared with women with benign 
breast disease (p<0.0[). These differences, however, were small and probably 
have no functional significance.
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Data obtained in the present study is suggestive of altered desaturase enzyme 
activity in women with benign and malignant breast disease. The pattern of 
phospholipid fatty acids found in erythrocytes and diseased breast tissue was 
consistent with increased conversion of 18:0 to 18:lw9 and/or decreased 
conversion of 18:lw9 to 18:2w9, and also decreased conversion of 18:2w6 to 
20:3w6. Generally these patterns were more dominant in the phosphatidylcholine 
than phosphatidylinositol fraction and in erythrocytes than breast tissue. 
Additionally, in the phosphatidylinositol fraction there was evidence of increased 
chain elongation and desaturation of w3 metabolites, most notable in the 
erythrocytes from women with malignant disease. Previous studies have reported 
reduced stearic (18:0) to oleic (18:lw9) acid ratios in erythrocytes of subjects with 
chronic leukaemia (Apostolov et al., 1985), in patients with various solid tumours 
(Wood et al., 1985a) and also in human malignant liver neoplasms (Wood et al., 
1985b). However, none of these studies reported consistent changes in other fatty 
acids and the study of Wood et al., (1985a) found abnormal stearic:oleic acid 
ratios only in women with malignant and not benign breast disease. These 
authors suggested that increased conversion of stearic (18:0) to oleic (18:lw9) 
acid in malignant cells may be a mechanism to achieve increased membrane 
fluidity, since as they stated, a larger incorporation of unsaturated fatty acids 
contributes to a higher membrane fluidity and increased metabolic activity of lipid 
dependent enzymes (Cooper, 1977; Sandemann, 1979).
Increased membrane fluidity has also been shown to be associated with a higher 
capacity for cell division (Cooper 1977). However, findings from the present 
study do not support the view that altered delta-9 desaturase activity may be a 
mechanism for increasing membrane fluidity, since the increased oleic acid seen 
in erythrocytes and breast tissue, was associated with depleted content o f the long 
chain polyunsaturated fatty acids of the w6 class, an effect which would be likely 
to decrease membrane fluidity. Calculation of the P:S ratios in the present study
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also provides little support for this concept. Although there were trends towards 
increased P:S ratios in the phosphatidylinositol fraction, which were significantly 
higher in benign breast tissue compared with malignant tissue, there were no 
significant differences in the P:S ratio of erythrocyte phosphatidylinositol or the 
phosphatidylcholine fraction in breast tissue and only a small difference between 
the cancer and normal groups in erythrocyte phosphatidylcholine (p<0.05). Since 
phosphatidylcholine is the major phospholipid class, effects on this component are 
likely to be of greater significance to total membrane fluidity than effects on the 
phosphatidylinositol fraction. Nevertheless, increased P:S ratios in 
phosphatidylinositol may be of considerable biological significance in view of the 
close structural and functional interaction of this membrane lipid with membrane 
bound enzymes and receptors.
Evidence for depletion of polyunsaturated fatty acids of the w6 class in human 
breast cells is supported by the study of Begin et a l, (1988). These authors 
compared rates of lipoperoxidation by exponentially growing human breast 
carcinoma cells with normal cells. When polyunsaturated fatty acids with 3-5 
double bonds were added to the medium there was a markedly higher rate of 
lipoperoxidation in the carcinoma cells than in the normal cells. Addition of 
polyunsaturated fatty acids with six double bonds (22:6w3) resulted in similar 
rates of lipoperoxidation in normal and tumour cells. In normal cells the rates of 
lipoperoxidation were proportional to the number of double bonds in the added 
polyunsaturated fatty acid, an observation consistently found by other workers 
(Wills, 1985), but in, malignant cells rates were highest in response to fatty acids 
with 3-5 double bonds. The authors concluded that there was a lack of the normal 
substrate, polyunsaturated fatty acids with 3-5 double bonds, in the tumour cells. 
This data is supported by the present study, in which depletion of 20:3w6 and 
20:4w6 was found in tumours and erythrocytes, whilst levels o f 22:6w3 were 
elevated. It has been suggested that depletion of 3-5 double bond polyunsaturated
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fatty acids may lead to reduced rates of lipoperoxidation. The ability to maintain 
lipoperoxidation may be important in preventing abnormal cell proliferation since 
lipoperoxides inhibit cell proliferation (Cornwall & Zhang, 1988) and also, it has 
been shown that the rate of lipid peroxidation is often low in tumours as compared 
with corresponding normal tissues (Cheeseman et a l, 1984).
Thus it may be hypothesized that reduced delta-6 desaturase activity may be an 
abnormal mechanism in rapidly dividing cells, which acts to maintain low levels 
of potentially oxidisable polyunsaturated fatty acids. Furthermore, it could be 
argued that increases in 18:lw9 through increased delta-9 desaturase, and possible 
increase in 22:6w3 through increased delta-4 desaturase, may be an adaptational 
response to depletion of w6 fatty acids in order to maintain membrane fluidity, 
rather than reduced delta-9 desaturase acting as the primary abnormal component. 
However, these suggestions must be considered as tentative since few studies of 
desaturase activities in tumour cells have been undertaken. Delta-9 desaturase has 
been shown in fast and slow growing hepatomas of rats and mice (Chiappe et a l, 
1974) and it is interesting to note that although delta-6 desaturase activity was 
measured in mouse hepatoma the level of activity was less than in host normal 
liver tissue (Chiappe et a l, 1974). Furthermore, delta-6 desaturase activity was 
found to be absent from heteroloid or transformed mouse fibroblasts (Dunbar & 
Bailey, 1975). It would appear that further studies of desaturase activity of 
diseased human breast tissues are required. The fact that abnormal fatty acid 
profiles are found in erythrocytes as well as breast tissues has led to the 
suggestion that a circulating agent, possibly released from breast tissue may be 
acting to bring about these alterations (Wood et a l, 1985a). Indeed, it is not 
known whether human breast tissues possess desaturase activity, so that 
differences in breast and erythrocyte membrane fatty acids, may reflect changes in 
hepatic fatty acids with tissue changes reflecting hepatic phospholipid fatty acids.
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Other mechanisms responsible for these abnormal fatty acid patterns must also be 
considered. It is known that human breast tumours synthesize large amounts of 
prostaglandins, most notably the PG2 family. Depletion of 20:4w6 may therefore
be the result of increased requirement for the substrate for prostaglandin 
synthesis, with other changes occurring as a secondary consequence to this. 
However, this would not explain the elevated levels of 18:2w6 in erythrocytes and 
breast tissue, which would also be expected to be lower if 20:4w6 depletion was 
the result of increased metabolism rather than decreased production.
In conclusion, the overall findings from this study are that malignant and benign 
breast tumours are extremely similar in phospholipid content and fatty acid 
profiles. However, they differ from normal breast tissue in terms o f decreased 
stearicioleic acid ratio in phosphatidylcholine, a phenomenon which is also 
reflected in the erythrocytes from women in the diseased groups compared with 
normal healthy women. Phosphatidylcholine from normal breast tissue and 
erythrocytes contains more 20:4w6 and 20:3w6 but less 18:2w6 than diseased 
tissue, a result also reflected in phosphatidylinositol regarding the latter two fatty 
acids, but not 20:4w6. The most notable effects on phosphatidylinositol were 
increases in long chain polyunsaturated w3 fatty acids in diseased breast tissue and 
erythrocytes from these women compared with normal control tissue. (A similar 
trend was observed in phosphatidylcholine). Additionally, in malignant tissue, 
phosphatidylinositol contained significantly more stearic acid (18:0). This data 
for stearic acid is of particular significance since (i) this was one o f the few 
differences between malignant and benign breast tissue, (ii) it was not observed in 
erythrocytes and appears to be a specific effect on mammary tissue rather than a 
general systemic response to disease, (iii) similar data was obtained for mammary 
tumour phosphatidylinositol in experimental animals in Chapter 4.
In terms of the relative proportions of the phospholipids, there was more 
phosphatidylserine in normal breast tissue compared with diseased breast tissue.
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Any biological effect of this is at present unknown. There were also some 
differences in the relative proportions of erythrocytes from the different groups of 
women, however, these were very small and may not be of functional 
significance.
From the results of this study it would appear that there is an alteration of the 
balance between the delta-9, delta-6 and delta-4 desaturase enzymes in diseased 
breast tissue. The functional significance of this cannot be determined as yet, 
however, it would appear not to relate simply to altered needs of arachidonate in 
quickly dividing cells or the needs of tumour cells in prostaglandin production. 
Studies of desaturase activity in breast tumours and other malignant tumours are 
needed to elucidate the function of the desaturase enzymes in breast disease. 
Further, stearic acid (18:0) is increased in phosphatidylinositol in malignant breast 
tumours, an effect which appears to be specific to this phospholipid, and may be 
due to increased stearoyl acyl transferase activity. Further investigation o f the 
mechanism underlying this accumulation of 18:0 and its significance to the 
malignant process would appear to be warranted.
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CHAPTER EIGHT
GENERAL DISCUSSION
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DISCUSSION
Phosphatidylinositol is a secondary messenger between receptor binding and 
events at the nucleus in a number of cells. It could be hypothesized that alteration 
in phosphatidylinositol fatty acids could influence the signal transduction function 
of this membrane phospholipid in a number of ways:
(i) In view of the suggested major role of phosphatidylinositol in hormone- 
stimulated arachidonic acid release and prostanoid synthesis in secretory 
cells, it could be speculated that dietary induced alteration in 
phosphatidylinositol sn-2, 20:4w6 content may alter cellular response via 
changes in the amount and/or potency of prostanoids released following 
cell stimulation.
(ii) Altered fatty acid composition of both sn-1 and sn-2 fatty acids on 1,2- 
diacylglycerol released upon phosphatidylinositol hydrolysis may 
influence the potency of this second messenger in protein kinase C 
activation.
(iii) Alteration in fatty acid composition may also alter the binding o f this 
phospholipid to the G protein which is thought to be the link between the 
membrane receptor and the phosphatidylinositol molecule, or it may alter 
the affinity of the specific phospholipase C enzyme involved in the 
receptor mediated hydrolysis of the phosphorylated derivatives of 
phosphatidylinositol through to inositol trisphosphate.
The aim of this thesis was to investigate in animal and human tissues, and 
particularly mammary tissue, whether it is possible to achieve major changes in 
phosphatidylinositol fatty acid composition. If this proved to be so, then further 
studies of altered phosphatidylinositol function could be undertaken.
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It was first necessary to develop methods for separating the membrane 
phospholipids into their individual classes, and for analysing the fatty acids within 
each specific phospholipid. One of the major limitations o f the present studies is 
the high variation in the gas chromatography assay technique, particularly for the 
minor fatty acids. However, small fluctuations in fatty acid profile are unlikely to 
be of much biological significance, and although high assay variability and small 
sample size limit the ability to detect small differences between groups, a number 
of interesting observations were made in each of the studies which were found to 
be statistically significant and are probably also of true biological significance.
The first observation was that of the three phospholipids investigated 
(phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamine), 
phosphatidylinositol was consistently the least responsive to dietary modification, 
both in rat and human cell membranes. Its fatty acid profile was not readily 
altered in response to administration of marine oils in rat mammary tissue 
(Chapter 3), rat erythrocytes (Chapter 3), rat mammary tumours (Chapter 4), 
human erythrocytes (Chapter 6) or human platelets (Chapter 6). In the human 
marine oil supplementation study (Chapter 6), there were few significant 
alterations of phosphatidylinositol fatty acids profile. In platelets there was a 
slight, but statistically significant increase in stearic acid and decrease in 22:5w3 
after 2 weeks of marine oil supplementation. However, these changes were 
transient and unlikely to have been of functional importance. In erythrocytes 
there were small but significant alterations in 16:lw9 and 22:4w6 during the 4 
weeks of supplementation. These changes were less than 1 mol% and may have 
been artefacts due to the high variation of the analytical method. In the rat study 
there were some differences in the phosphatidylinositol fatty acid profile of 
erythrocytes from rats fed a MaxEPA diet compared with rats fed a corn oil diet 
or an olive oil diet. Notably, there was a lower content of arachidonic acid and a 
higher content of the saturated fatty acids 16:0 and 18:0. These differences led to
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a decreased polyunsaturated to saturated fatty acid index, which was, however, 
not statistically significant. It is interesting to note that the rats fed the marine oil 
diet did not have an increase in the w3 fatty acids in their erythrocyte 
phosphatidylinositol, but they did contain less arachidonic acid. This 
phenomenon was not detected in the mammary tissue where there was no 
difference in the arachidonic acid content of phosphatidylinositol from rats from 
any of the three dietary groups. Furthermore, mammary tumour 
phosphatidylinositol was also found not to contain differences in w3 fatty acids, 
nor did it contain differences in arachidonic acid content in rats fed com oil, olive 
oil or MaxEPA diets. Thus, rat mammary tumour phosphatidylinositol was also 
unresponsive to dietary manipulation.
The unresponsiveness of phosphatidylinositol to dietary manipulation has been 
shown previously by Galloway et a l, (1985) who demonstrated that after fish oil 
supplementation, eicosapentaenoic acid was incorporated into human platelet 
phosphatidylcholine and phosphatidylethanolamine to a considerable degree but 
showed no incorporation of these polyunsaturated fatty acids into 
phosphatidylinositol. Conversely, Weiner and Sprecher (1984) have shown that 
diet can cause a significant change in rat platelet and liver phosphatidylinositol. 
However, these workers used purified fatty acid ethyl esters as the sole fat source 
which is more likely to lead to incorporation of these fatty acids than a mixed fat 
diet.
The fatty acid profile of phosphatidylinositol has been a subject of limited study 
for several years. Recent investigations in platelets have supported the traditional 
view that this phospholipid contains mainly stearic acid (approximately 40 mol%) 
and arachidonic acid (approximately 40 mol%), (Prescott & Majerus, 1981; 
Broekman et a l, 1981). However, Dougherty et a l, (1987) have demonstrated 
that the precise profile differs according to dietary habits. They showed that 
platelet and erythrocyte phosphatidylinositol from men from Finland, Italy and
-196  -
America, all consuming their traditional diets, have very different fatty acid 
profiles. It therefore could be concluded that supplementing diets with marine 
oils, or doing 'short term' animal feeding studies, is insufficient to elicit changes in 
phosphatidylinositol which certainly is more resistant to dietary manipulation than 
phosphatidylcholine and phosphatidylethanolamine. This resistance to short term 
dietary modification may reflect stricter control of this functionally important 
membrane component.
In addition to demonstrating that phosphatidylinositol is resistant to dietary 
modification, this study has also demonstrated that its fatty acid profile is not 
constant from one tissue to another, and often does not contain as much 
arachidonic acid as has been found in platelet phosphatidylinositol. A  comparison 
of rat erythrocyte phosphatidylinositol fatty acid profile with rat mammary gland 
phosphatidylinositol fatty acid profile showed a number of small, non-significant 
differences. However, the most notable difference between the two tissues was in 
the content of arachidonic acid. Mammary tissue phosphatidylinositol from rats 
fed a com oil diet contained only 7.5 mol% compared with the 22.3 mol% of this 
fatty acid in the erythrocyte phosphatidylinositol fraction. The reason for these 
differences is unknown but may be due to differing fatty acid availabilities in the 
different tissues, or it may be a reflection of a specific function. The mammary 
gland phosphatidylinositol contained more palmitic acid than did the erythrocytes 
(not statistically significant) and palmitic acid is thought to be the main fatty acid 
present when the phosphatidylinositol molecule is synthesized de novo in the 
endoplasmic reticulum. The palmitic acid is thought to be replaced by 
déacylation and reacylation reactions taking place when the phospholipid 
molecule is in situ in the membrane, and therefore the higher palmitic content and 
lower arachidonic acid content may reflect more newly synthesized 
phosphatidylinositol, possibly following hormone stimulated breakdown of
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polyphosphoinositides in the mammary gland membrane, although this suggestion 
must at present be considered speculative.
In general the relative proportions of membrane phospholipids were not altered by 
diet. In the study of a high fat versus a low fat diet (Chapter 5), there was a small 
but significant increase in the proportion of phosphatidylinositol compared with 
the other phospholipids. Supplementing the diet with marine oil (Chapter 6) did 
not elicit any significant change in the amount of phosphatidylinositol in either 
red blood cell or platelet membranes relative to the other phospholipids. Nor did 
feeding groups of rats a com oil, olive oil or MaxEPA diet result in significant 
differences in the relative proportion of phosphatidylinositol in either mammary 
tissue or erythrocytes.
As cited earlier, there have been several studies which have shown that 
phospholipid content is resistant to dietary fatty acid changes, (Awad & Spector, 
1976; Burns & Spector, 1987; Farquar & Ahrens, 1963). Although fatty acid 
composition of tumour phospholipids can be altered, it has been demonstrated that 
there is no alteration of the relative proportions of the phospholipids, or the total 
content of phospholipids in the membrane, and therefore, what occurs with 
dietary change, is a substitution of fatty acyl groups within the same phospholipid 
framework of the membrane.
Although phosphatidylinositol was not responsive to dietary manipulation, the 
fatty acid profile of this phospholipid was shown to differ between normal 
mammary tissue and mammary tumours in the rat. In all three dietary groups, rat 
tumour phosphatidylinositol contained a greater amount of stearic acid than did 
the control normal mammary tissue. This difference appeared to be moderated by 
diet such that the difference between the tumour and normal tissue was least in the 
MaxEPA group (< 3 mol%) and greatest in the olive oil group (12 mol%; 
p<0.05). Although not statistically significant, in the com oil group there was an
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average of greater than 6 mol% more stearic acid in the tumour tissue compared 
with the normal tissue.
The functional significance of an increase of stearic acid in the 
phosphatidylinositol molecule is unknown. However, it is important to note that 
phosphatidylinositol contains a preponderance of stearic acid in the sn-1 position 
of the phospholipid (Michell, 1975). It may be that the stearic acid in this 
position of the phospholipid molecule is a pre-requisite for phosphorylation or 
receptor mediated hydrolysis. Alternatively it may have a spatial influence on the 
molecule which affects receptor binding, stearic acid having no double bonds, is 
more fluid and able to conform to more positions that unsaturated fatty acids 
which have a 'kink' at the site of each double bond. Thus it could be speculated 
that the lower amounts of stearic acid detected in the tumour tissue from the 
MaxEPA fed group of animals may influence tumour growth via decreased 
binding of the kinase enzyme to the molecule during phosphorylation, or 
decreased binding of phosphatidylinositol to the G protein, or some other 
unknown cellular reaction. On the other hand, the stearic acid in tumour 
phosphatidylinositol may play a greater role after receptor mediated hydrolysis. 
The resulting 1,2-diacylglycerol is known to be an activator of protein kinase C, 
and it could be hypothesized that stearic acid in the sn-1 position of this molecule 
may confer greater specificity to diacylglycerol as an activator of protein kinase 
C. However, this remains speculative at the present time.
In the light of this data it is interesting to note that in human breast samples 
(Chapter 7), malignant tissue phosphatidylinositol contained significantly more 
stearic acid than benign tissue or normal breast tissue. The benign tissue 
contained more than the normal breast tissue although this difference was not 
statistically significant. Thus in both rat mammary tumours and human malignant 
breast tumours, phosphatidylinositol contains significantly more stearic acid than 
control tissue phosphatidylinositol.
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It would appear from the study of phospholipid proportions in the rat tumours and 
in the human tumour tissue that there is no alteration in the relative content of 
phosphatidylinositol in tumour tissue compared with control mammary tissue. 
This would indicate that either there is no increase in the availability of 
phosphatidylinositol for receptor stimulated hydrolysis in the rat mammary 
tumour cell membrane, or that there is a very strict control of membrane 
phospholipid composition with a fast and efficient mechanism for replacing 
phosphatidylinositol as it is hydrolysed.
The present work clearly confirmed that marine oils have an inhibitory effect on 
tumour growth in ENU treated rats. The mechanism for this action remains 
unclear at present, but it would appear not to be mediated via changes in the fatty 
acyl moiety of phosphatidylinositol, since as already discussed, few alterations in 
the fatty acid profile of this phospholipid were evident upon feeding different 
diets. One mechanism proposed for the effect of marine oils on tumourigenesis is 
via the prostaglandins. Prostaglandins have been implicated as having a role in 
the dietary fat promotion of breast cancer as increased amounts of prostaglandins 
have been detected in malignant tumours compared with benign tumours (Bennett 
et a l, 1977; Salmon & Flower, 1979), and investigations in rodents have shown 
that inhibiting prostaglandin biosynthesis results in smaller tumours in these 
animals than in animals not given prostaglandin inhibitors (Carter et a l,  1983). It 
has been suggested that dietary fat influences prostaglandin production by altering 
the precursor fatty acid availability. As the different series prostaglandins have 
different and often opposite functions, major changes in diet, particularly in 
relative amounts of w6 and w3 fatty acids could alter prostaglandin biosynthesis.
Prostaglandins are very unstable and are synthesized as needed from non- 
esterified fatty acids, the precursor fatty acids being stored in the phospholipids. 
Prostaglandins may be released during the hydrolysis of phosphatidylinositol. 
However, the usual cellular stores of the precursor phospholipids are thought to be
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phosphatidylcholine and phosphatidylethanolamine which are the major 
membrane phospholipids and would therefore constitute the largest stores. 
Nevertheless, Rittenhouse-Simmons (1979) has shown the generation o f up to 30- 
fold increased levels of diacylglycerol within 5 seconds of platelet exposure to 
thrombin. Within this short period only phosphatidylinositol lost radioactivity in 
cells pre-labelled with arachidonic acid. Loss of radioactivity from
phosphatidylcholine only became apparent after 30 seconds. Presence of both a 
phospholipase C specific for phosphatidylinositol and a diacylglycerol lipase have 
been shown in platelets, and it was the latter enzyme which was thought to be 
responsible for the early arachidonate (20:4w6) release following thrombin 
stimulation of platelets. It was therefore thought that the initial release of 
arachidonate (20:4w6) was from phosphatidylinositol via the phospholipase C 
plus diacylglycerol lipase pathway, and arachidonate (20:4w6) release from other 
phospholipids by the action of phospholipase A2 was a secondary event. Clearly
further work is required to confirm the major pool of arachidonic acid for cell 
stimulated prostanoid synthesis in different cells and tissues.
As already discussed, marine oils do not greatly affect the fatty acid profile of 
phosphatidylinositol. However, phosphatidylcholine and phosphatidyl­
ethanolamine from rat mammary tumours and normal rat mammary tissue were 
more responsive to dietary manipulation. Although most notable differences in 
fatty acid composition in the phosphatidylcholine fraction was in the oleic acid 
content of mammary tissue and tumours, there was clearly more arachidonic acid 
in corn oil fed rats, less in olive oil fed rats and even less in MaxEPA fed rats. As 
expected, eicosapentaenoic acid was greater in the MaxEPA group. The 
arachidonic acid content of mammary tissue phosphatidylethanolamine also 
decreased in the order com oil>olive oil>MaxEPA. Furthermore, the mammary 
tumour arachidonic acid content decreased in the same order but in all three 
dietary groups there was more arachidonic acid in the tumours compared with the
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normal mammary tissue. The difference between tumour and normal mammary 
tissue was approximately 5 mol% for both the com oil and olive oil dietary 
groups, but only approximately 1 mol% for the MaxEPA group, and thus the 
marine oil may protect against incorporation of arachidonic acid into mammary 
tumour phosphatidylethanolamine possibly reducing 2 series prostaglandin 
production.
As expected, there was an increased incorporation of the w3 fatty acids, 
eicosapentaenoic acid and docosahexaenoic acid into normal mammary tissue 
phosphatidylethanolamine in rats fed the marine oil diet. However, the tumour 
tissue from rats in the marine oil dietary group did not show a greater 
incorporation of these fatty acids into phosphatidylethanolamine than the rats 
from the com oil or olive oil dietary groups. Thus the reduction in incorporation 
of arachidonic acid was not due to a direct displacement with w3 fatty acids, but 
rather greater uptake of other fatty acids such as stearic and oleic acids.
The reduced incorporation of arachidonic acid may also have been due to 
decreased synthesis of this fatty acid from linoleic acid by direct inhibition o f the 
delta-6 desaturase enzyme by the long chain polyunsaturated fatty acids, 
eicosapentaenoic acid and docosahexaenoic acid. Fatty acids are synthesized in 
the endoplasmic reticulum by desaturase and elongase enzymes. Chain elongase 
enzymes add 2 carbon units at a time, and because they are not rate limiting, they 
have not been well studied. Desaturase enzymes have received more attention, 
although these enzymes have not yet been identified and investigated in mammary 
tissue.
It is known that desaturases are membrane bound and the activities of liver delta-6 
and delta-5 desaturases are under endocrine control with insulin increasing the 
activity of both enzymes, and glucocorticoids and adrenaline decreasing the 
activity. In addition glucagon decreases delta-6 activity and 17-5-oestradiol has
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been found to decrease delta-5 activity. Diet has also been shown to affect the 
desaturase enzymes as delta-9, delta-6 and delta-5 desaturase activities were found 
to be elevated in animals fed a com oil diet and lowered in those fed a coconut oil 
diet compared to a control diet (Pugh & Kates, 1984). Preference of the fatty acid 
desaturase enzymes for the fatty acid series is in the order w3>w6>w9>wl. 
Furthermore, the products of the delta-5 desaturase, 20:5w3, 20:4w6, 20:3w9 and 
18:3w7 have been shown to exert a negative feedback on delta-6 desaturase 
activity. Thus it could be envisaged that increasing the 20:5w3 component o f the 
diet would decrease delta-6 desaturase activity, thus reducing the conversion of 
18:2w6 to 20:4w6. However, in the present study the lower amounts o f 20:4w6 in 
rat phosphatidylcholine and phosphatidylethanolamine following a marine oil diet 
compared with a com oil or olive oil diet, are unlikely to be due to a decreased 
delta-6 desaturase activity as there was no concomitant increase in 18:2w6 
content.
Desaturase enzymes in human tissues have not been well studied, and to date 
there has been no investigation of desaturase enzymes in human breast tissue. In 
the study of human malignant and benign breast tumours (Chapter 7), elevated 
levels of 18:2w6 together with reduced levels of its chain elongation and 
desaturation products 20:3w6, 20:4w6 and 22:4w6 compared with normal breast 
tissue were demonstrated, particularly in the phosphatidylcholine fraction. These 
findings suggest that there may be reduced activity of the delta-6 desaturase 
enzyme in patients with breast disease. However, the malignant and benign 
tumours also contained larger amounts of the long chain w3 fatty acids than 
normal tissue and thus there appeared to be increased activity of delta-6 and delta- 
4 desaturase enzymes against w3 substrates with reduced activity against w9 and 
w6 substrates. It is suggested that the reduced delta-6 desaturase activity against 
the w6 fatty acids may be an abnormal mechanism in rapidly dividing cells, which 
acts to maintain low levels of potentially oxidisable polyunsaturated fatty acids.
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with the increase in desaturation of w3 fatty acids being an adaptational response 
to the depletion of w6 polyunsaturated fatty acids in order to maintain membrane 
fluidity.
Another marked finding in the study of normal and diseased human breast tissue 
was in the relative proportions of the membrane phospholipids. It has been 
demonstrated that in general the relative proportions of membrane phospholipids 
remains fairly constant and for example, is not affected by diet, thus showing a 
high degree of homeostasis. However, it would appear that this normal balance of 
membrane phospholipids is affected by disease. In particular, malignant and 
benign tumours contained significantly less phosphatidylserine than normal breast 
tissue. The biological significance of this is unclear at present, but it may be 
related to the function of phosphatidylserine as 'co-factor' for many cell processes.
One of the earliest mechanisms suggested for the involvement of dietary fat and 
breast cancer was via an increase in steroid hormones (Beatson, 1896). Removal 
of the ovaries or anti-oestrogen therapies are common treatments for many breast 
cancers. The steroid hormones themselves are synthesized from ingested 
cholesterol and thus it is easy to envisage that ovemutrition may result in 
excessive amounts of circulating oestrogen. An assessment of oestrogen in 
women ingesting their normal diet followed by a low fat diet for 2 months 
(Chapter 5), showed a decrease in serum oestrogen levels from 120 pg/ml to 105 
pg/ml (p<0.05), thus demonstrating that diet can affect circulating oestrogen 
levels. However, only about one third of breast cancers are oestrogen dependent 
and thus there are likely to be other mechanisms involved in the link between 
dietary fat and breast cancer.
In a study of the influence of dietary fat on luteal phase prolactin (Chapter 5), it 
was demonstrated that there is no significant effect of reducing fat consumption 
from a mean of 81g/day (37% energy) to 36g/day (21% energy) for a period of 2
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months. This finding was in agreement with Gray et a l, (1981) who also found 
no significant alteration in plasma prolactin (measured by radioimmunoassay) in 
normal premenopausal women undertaking a 50% reduction in total fat intake for 
a period of 2 months. Some workers have shown changes in luteal phase 
prolactin in women changing from either a high fat to a low fat diet (Hill & 
Wynder, 1976) or from a low fat to a high fat diet (Hill et a l,  1980). 
Nevertheless, the general consensus would appear to be that changes in the 
amount of dietary fat do not result in significant changes in serum prolactin as 
measured by radioimmunoassay. However, a study by Shultz and Rose (1988) 
indicated that when changing from a low fat to a high fat diet (in their study from 
25% of calories to 46% of calories), although there was no difference in the levels 
of prolactin or growth hormone detected by radioimmunoassay, the lactogenic 
hormone bioactivity appeared to be higher (averaging 28%; p<0.07) in response 
to the high rather than the low fat diet.
There are now known to be various forms of prolactin detectable by 
polyacrylamide gel electrophoresis (Mittra, 1980a). These different forms are 
thought to be cleaved forms of the prolactin molecule and have been shown to 
pocess mammary mitogenic activity in rats in vivo (Mittra, 1980b). Some 
fragments are already known to have the same mitogenic activity but less 
immunoactivity as the intact prolactin molecule (Clapp et a l,  1988) and as such 
the functional significance of these fragments may have been underestimated.
Binding of prolactin to membrane receptors and the influence of diet on this 
process has been little investigated. Diet may alter membrane fluidity and 
therefore influence enzyme activity and receptor functioning. Cave and Erickson- 
Lucas (1982) have demonstrated that NMU-induced tumours in animals fed a 
high fat diet exhibited a greater lactogenic hormone receptor binding capacity 
than tumours from animals fed a low fat diet. This greater lactogenic hormone 
receptor binding was thought to be due to prolactin receptor binding. They
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hypothesized that alterations to the membrane fatty acid milieu caused
modification of the membrane prolactin receptor proteins, thus altering their 
binding capacities. Thus high fat diets were proposed to influence mammary 
carcinogenesis by both increasing circulating hormone and increasing the tissue 
responsiveness to hormonal stimulation. If this hypothesis is correct, it could also 
be envisaged that marine oils could exert their effect via changes in the membrane 
fatty acid milieu causing modification of the membrane prolactin receptor 
proteins, thus altering their binding capacities.
CONCLUSIONS
The major conclusions drawn from this work are:
(i) Phosphatidylinositol is the least responsive of the phospholipids
investigated to dietary modification in erythrocytes, platelets and
mammary tissue.
(ii) Tumour phosphatidylinositol contains significantly more stearic acid than 
control mammary tissue in both patients with malignant breast disease, 
and in rats with ENU induced tumours.
(iii) The relative proportion of phospholipids in cell membranes is not affected 
by dietary manipulation.
(iv) Normal human breast tissue contains more phosphatidylserine than either 
benign breast tumours or malignant tumours, although no clear 
explanation for this can be given at the present time.
(v) Marine oils afford significant protection against the development o f 
mammary tumours in ENU treated rats compared with com oil and olive 
oil.
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(vi) Marine oils limit the incorporation of stearic acid into phosphatidylinositol 
in ENU induced tumours in rats.
(vii) Marine oils reduce arachidonic acid incorporation into 
phosphatidylcholine and phosphatidylethanolamine in rat erythrocytes, rat 
mammary tissue and tumours, human erythrocytes and platelets. This may 
have implications for prostaglandin production in tumours.
(viii) A  low fat diet reduces circulating oestrogen concentration.
FUTURE WORK
During the course of this work, no attempt was made to separate the 
phosphatidylinositol fraction derived from cell membranes into its phosphorylated 
derivatives, or to study the turnover of phosphatidylinositol. Although it has been 
shown that the amount of phosphatidylinositol in the membrane relative to total 
phospholipid content does not alter with diet, or indeed the disease state, nothing 
can be deduced from this regarding its rate of phosphorylation and receptor 
induced turnover. Furthermore, the specificity of phosphatidylinositol containing 
large amounts of stearic acid warrants further investigation. The binding 
properties of sn-1 stearoyl phosphatidylinositol to proteins such as the 
phospholipid transfer proteins, the G-protein involved in receptor mediated 
hydrolysis and the specific phospholipase C should be studied, as well as the 
activity of the resulting 1,2-diacylglycerol on activation of protein kinase C.
It would be pertinent to investigate the triggers for phosphatidylinositol hydrolysis 
in the mammary gland. A number of growth factors are known to stimulate cell 
proliferation in mammary tumour cells, but it has not yet been established which, 
if any, are linked to the phosphatidylinositol second messenger system. In
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particular, it would be of great interest to determine the action of prolactin on 
mammary tumour cells and whether this acts via the polyphosphoinositides.
The human breast disease study (Chapter 7) suggests alteration in desaturase 
activity in malignant and benign breast tumours. Therefore, there is a need for 
further studies of desaturase enzyme activities and specificities in human tissues, 
particularly in human breast tissue in which desaturase enzymes have not yet been 
identified.
Finally, it is clear that marine oils exhibit a protective effect against mammary 
tumour development. However, the mechanism for this is not known and clearly 
warrants further investigation. In particular, a study of the effect of a marine oil 
diet on phosphatidylinositol hydrolysis and prostaglandin synthesis would seem 
justified.
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APPENDIX III
CHAPTER SIX 
QUESTIONNAIRE
-249
MARINE OIL STUDY
NAME:
AGE:
WEIGHT WEEKl 
WEEK 2 
WEEK 3 
WEEK 4
Have you taken aspirin or paracetamol in the past two weeks? Yes/No
Do you take any medication on a regular basis? Yes/No
If yes, please give details .............................................................................................. .
Do you smoke? Yes/No
If yes, please specify approximate no./day .............
Do you suffer from any of the following?
Diabetes Mellitus Yes/No
Other endocrine disturbance Yes/No
Hypertension Yes/No
Have you attempted to lose weight by dietary means in the past 
2 months? Yes/No
If yes, please specify weight loss .............
Have you followed a restricted diet of any kind in the past 2 months? Yes/No
If yes, please specify the nature of the d ie t...................................................................
Do you take any dietary supplements?
e.g. Sunflower oil Yes/No
Evening Primrose oil Yes/No
Marine oil Yes/No
Vitamins Yes/No
Minerals Yes/No
If yes to any of the above please give details ...............................................................
-250-
MARINE OIL STUDY (Continued)
Please give details of any other supplements you use on a regular basis.
Do you take regular exercise? Yes/No
If yes, please specify the following:
Nature of exercise:............................................................................................................
Normal duration of exercise:....................................................................................... .
No. o f times/week:............................................................................................................
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REDUCTION OF FAT INTAKE
High fat foods include:
chocolate
biscuits
crisps
pastries
nuts
meat products (e.g. sausages, beefburgers, salami, luncheon meat) 
mayonnaise
dairy produce (e.g. butter, cream, full fat milk, cheese)
fried and roasted foods
chips
Low fat foods include: 
fruit
vegetables
cereals
ham
poulty (without skin) 
fish
low fat cheeses
lOg of fat is equivalent to approximately:
1 X 28g bag of crisps
1 thick pork sausage
1 small beefburger
enough butter for slices of bread
3/4 pint full fat milk
30g Cheddar cheese
3 or 4 biscuits
30g milk chocolate
Try replacing:
full fat milk with skimmed milk
full fat cheese with low fat cheese
butter or margarine with half fat spreads (Gold or Outline)
Cut down on:
fried foods 
roasted foods
chocolate, biscuits, pastries, nuts & crisps
(cakes and scones are lower in fat if you need 
to replace them).
-252-
APPENDIX IV
CHAPTER SIX 
TABLES OF RESULTS
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TABLE 41 : TRIGLYCERIDE AND CHOLESTEROL VALUES BEFORE AND AFTER 
MARINE OIL SUPPLEMENTATION
V olunteer Triglyceride Total Cholesterol
Initials Baseline W eek 4 Baseline W eek 4
MMu 6.07 2.05 5.11 7.756
SD 1.07 0.89 7.014 6.272
MB 1.55 1.61 7.504 8.246
JW 1.67 0.87 7.784 7.98
HD 0.60 0.60 5.586 6.79
JA 1.19 0.76 5.754 4.886
JM 2.62 1.43 4.228 5.348
LD 3.10 1.25 5.054 7.391
MM 1.49 1.37 5.334 4 .284
CB 1.37 1.19 4.83 6.314
AS 1.97 1.61 7.658 9 .044
KM 1.41 0.89 7.882 6.146
SP 1.49 0.83 4.816 4.088
MW 1.37 0.83 4 .76 4 .326
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TABLE 48: THE RELATIVE PROPORTIONS OF ERYTHROCTE MEMBRANE
PHOSPHOLIPIDS BEFORE AND AT WEEKS 2 & 4 DURING MARINE 
OIL SUPPLEMENTATION.
Results expressed as mol % (mean + standard deviation).
Phospholipid Baseline
n=14
W eek 2
n=14
W eek 4
n=14
Sphingomyelin 25.92 ±  2.51 27.25 ±  2.49 * 26.82 ±  3.61
Phosphatidylcholine 27.26 ±  4.33 29.56 ±  4.19 27.30 ±  3.56
Phosphatidylserine 11.54 ±  3.64 10.07 ±  1.79 10.24 + 2.63
Phosphatidylinositol 9.27 ±  2.71 8.90 + 3.27 9.05 ±  3.34
Phosphatidylethanolamine 25.91 ±  3.46 24.29 ±  2.05 26.69 ±  4.10
p<0.02 compared with baseline.
TABLE 49: THE RELATIVE PROPORTIONS OF PLATELET MEMBRANE
PHOSPHOLIPIDS BEFORE AND AT WEEKS 1 & 3 DURING MARINE 
OIL SUPPLEMENTATION.
Results expressed as mol % (mean + standard deviation).
Phospholipid Baseline
n=14
W e e k l
n=14
W eek 3
n=14
Sphingomyelin 16.23 ±  2.46 17.14 ±  3.57 16.70 ±  2.44
Phosphatidylcholine 23.13 ±  5.52 25.08 ±  4.93 26.58 ±  7.74 #
Phosphatidylserine 20.60 ±  6.86 19.40 + 7.23 18.81 ±  5.16
Phosphatidylinositol 16.32 ±  6.94 16.68 + 5.94 14.18 ±  3.73
Phosphatidylethanolamine 23.73 ±  6.65 21.70 ±  4.24 23.73 + 4.19
# p<0.04 compared with baseline.
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TABLE 50: THE FATTY ACID PROFILE OF PHOSPHATIDYLINOSITOL IN 
MALIGNANT, BENIGN AND NORMAL BREAST TISSUE.
Results expressed in mol% (mean + standard deviation)
Fatty acid Malignant tissue Benign tissue Control tissue
n=12 n=10 n=5
16:0 20.50 ±  8.88 16.50 ±12.27 31.99 ±  2.14 b,c
16:lw9 3.40 ±  3.52 3.48 ±  2.15 4.83 ±  1.66
18:0 35.39 ±  8.54 23.64 ±13.88 a 20.24 ±  4.17 b
18:lw9 15.68 ±  4.86 14.02 ±  6.79 9.83 ±  2.12
18:2w6 3.50 ±  0.94 3.51 ±  2.69 2.02 ±  0.35
18:3w3 0.48 ±  0.35 1.89 ±  3.05 3.63 ±  1.66 b
20:3w6 2.57 ±  2.45 2.98 ±  3.67 5.58 ±  1.75
20:4>v6 5.05 ±  4.59 6.44 ±  6.58 6.51 ±  0.75
20:5tv3 0.21 ±  0.26 1.55 ±  2.70 2.10 ±  0.86 b,c
22:4w6 1.32 ±  2.43 0.78 ±  2.14 0.25 ±  0.20
22:5w3 0.99 ±  1.31 3.08 ±  6.01 2.71 ±  1.42
22:6w3 3.84 + 2.69 9.97 ±14.51 2.79 ±  0.48
S :0 2.53 ±  1.02 1.77 ±  0.85 2.14 ±  0.60
P:S 0.33 ±  0.18 1.67 ±  2.04 a 0.49 ±  0.08
a = Malignant and Benign groups significantly different (p< 0.05) 
b = Malignant and Control groups significantly different (p< 0.05) 
c = Benign and Control groups significantly different (p< 0.05)
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TABLE 51: THE FATTY ACID PROFILE OF PHOSPHATIDYLCHOLINE IN 
MALIGNANT, BENIGN AND NORMAL BREAST TISSUE.
Results expressed in mol% (mean + standard deviation)
Fatty acid Malignant tissue Benign tissue Control tissue
n=12 n=10 n=5
16:0 39.28 ±15.34 31.03 ±14.91 43.00 ±  6.04
16:l>v9 1.61 ±  1.22 2.53 ±  3.60 1.27 ±  0.77
18:0 16.55 ±  9.57 13.09 ±  3.68 17.02 ±  2.53
18:l>v9 15.66 ±  7.85 14.42 ±  5.50 7.04 ±  1.46 b,c
18:2w6 5.64 ±  3.75 6.81 ±  4.13 2.63 ±  0.63
18:3w3 0.93 ±  1.65 0.97 ±  1.61 1.29 ±  0.53
20:3iv6 1.41 ±  2.91 0.82 ±  1.73 6.29 ±  2.25 B,C
20:4w6 2.29 ±  2.80 2.77 ±  2.40 6.65 ±  1.87 B,C
20:5w3 1.03 ±  2.23 1.15 ±  2.13 2.27 ±  1.84
22:4w6 1.91 ±  5.25 1.15 ±  2.66 0.36 ±  0.45
22:5w3 1.30 ±  3.60 4.37 ±  7.94 3.59 ±  1.49
22:6w3 2.30 ±  2.56 7.19 ±  6.14 A 3.13 ±  0.56
S :0 1.50 ±  1.25 1.09 ±  0.67 2.48 ±  0.45 c
P:S 0.99 ±  2.68 0.94 ±  1.29 0.45 ±  0.15
a = Malignant and Benign groups significantly different (p< 0.05) 
b = Malignant and Control groups significantly different (p< 0.05) 
c = Benign and Control groups significantly different (p< 0.05)
A = Malignant and Benign groups signficantly different (p< 0.02) 
B = Malignant and Control groups significantly different (p< 0.02) 
C = Benign and Control groups significantly different (p< 0.02)
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TABLE 52: THE FATTY ACID PROFILE OF PHOSPHATIDYLINOSITOL IN
ERYTHROCYTES FROM WOMEN MALIGNANT OR BENIGN BREAST 
DISEASE OR HEALTHY CONTROLS.
Results expressed in mol% (mean + standard deviation)
Fatty acid Malignant tissue Benign tissue Control tissue
n=9 n=10 n=15
16:0 16.22 ±  5.45 14.50 ±  7.08 15.21 ±  9.93
16:l>v9 1.27 ±  1.00 1.27 ±  1.15 3.37 ±  1.74 B,C
18:0 37.53 ±  8.83 39.37 ±14.91 44.10 ±11.70
18:lw9 11.82 ±  2.57 12.15 ±  4.00 6.01 ±  4.14 B,C
18:2w6 4.33 ±  2.08 3.97 ±  2.68 1.82 ±  1.39 B,c
18:3w3 0.25 ±  0.13 0.45 ±  0.45 0.74 ±  0.73
20:3w6 0.54 ±  0.43 0.62 ±  0.45 2.43 ±  2.23 B,C
20:4vv6 6.45 ± 2.94 7.14 ±  4.28 5.61 ±  2.88
20:5w3 0.93 ±  1.26 2.15 ±  4.02 0.69 ±  0.56
22:4w6 1.43 ±  1.76 1.93 ±  2.02 0.69 ±  0.56
22:5w3 2.97 ±  4.04 2.98 ±3.39 1.37 ±  1.34
22:6tv3 14.23 ±  8.13 9.13 ±  6.30 a 1.39 ±  1.29 B,C
S :0 3.26 ±  0.86 3.38 ±  1.36 4.14 ±  7.43
P:S 0.63 ±  0.36 0.89 ±  1.39 0.26 ±  0.13
a = Malignant and Benign groups significantly different (p< 0.05) 
b = Malignant and Control groups significantly different (p< 0.05) 
c = Benign and Control groups significantly different (p< 0.05)
A  = Malignant and Benign groups signficantly different (p< 0.02) 
B = Malignant and Control groups significantly different (p< 0.02) 
C = Benign and Control groups significantly different (p< 0.02)
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TABLE 53: THE FATTY ACID PROFILE OF PHOSPHATIDYLCHOLINE IN
ERYTHROCYTES FROM WOMEN WITH MALIGNANT OR BENIGN 
BREAST DISEASE OR HEALTHY CONTROLS.
Results expressed in mol% (mean + standard deviation)
Fatty acid Malignant tissue Benign tissue Control tissue
n=9 n=10 n=14
16:0 46.65 ±  3.78 50.97 ±10.16 53.55 ±  7.36
16:lw9 0.69 ±  0.61 0.76 ±  0.66 1.50 ±  3.83
18:0 13.37 ±  3.79 12.87 ±  2.12 16.55 ±  3.65 b,c
18:lw9 20.57 + 3.02 18.66 ±  3.01 14.23 ±  7.05 B,c
18:2w6 9.99 ±  3.44 8.90 ±  4.12 5.19 ±  3.77 B,c
18:3w3 0.18 + 0.16 0.16 ±  0.12 0.33 ±  0.30
20:3w6 0.64 + 0.49 0.34 ±  0.31 1.13 ±  0.58 b,C
20:4w6 1.36 ±  0.85 0.85 ±  0.74 2.43 ±  1.87 c
20:5w3 1.13 ±  0.77 1.23 ±  1.31 0.90 ±  0.67
22'Aw6 0.15 ±  0.17 0.12 ±  0.29 1.00 ±  0.76 B,C
22:5w3 0.31 ±  0.33 0.34 ±  0.91 0.85 ±  1.30
22:6w3 3.22 ±  4.79 1.71 ±  2.86 0.58 ±  0.55
S :0 0.68 ±  0.31 0.70 ±  0.12 2.06 ±  2.24 b,c
P:S 0.29 ±  0.13 0.23 ±  0.14 0.18 ±  0.08 b
a = Malignant and Benign groups significantly different (p< 0.05) 
b = Malignant and Control groups significantly different (p< 0.05) 
c = Benign and Control groups significantly different (p< 0.05)
A  = Malignant and Benign groups signficantly different (p< 0.02) 
B = Malignant and Control groups significantly different (p< 0.02) 
C = Benign and Control groups significantly different (p< 0.02)
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TABLE 54: THE RELATIVE PROPORTIONS OF MEMBRANE PHOSPHOLIPIDS IN 
MALIGNANT BREAST LUMPS, BENIGN BREAST LUMPS AND 
NORMAL BREAST TISSUE.
Results expressed as mol % (mean + standard deviation).
Phospholipid Malignant Benign Normal
tissue tissue tissue
(n=15) (n=12) (n=5)
sphingomyelin 16.55 + 3.56 18.13 ±  4.45 15.60 ±  2.88
Phosphatidylcholine 26.25 ±  5.12 27.25 ±  6.96 27.00 ±10.42
Phosphatidylserine 16.75 ±  4.22 15.88 ±  6.51 27.60 ±  6.80
Phosphatidylinositol 18.65 ±12.01 17.13 ±  5.67 15.20 ±  3.42
Phosphatidylethanolamine 21.90 ±  7.46 21.50 ±  2.73 15.20 ±  4.76
A = Malignant and Benign groups signficantly different (p< 0.01) 
B = Malignant and Control groups significantly different (p< 0.01) 
C = Benign and Control groups significantly different (p< 0.01)
TABLE 55: THE RELATIVE PROPORTIONS OF ERYTHROCYTE MEMBRANE 
PHOSPHOLIPIDS FROM WOMEN WITH MALIGNANT BREAST 
DISEASE, BENIGN BREAST DISEASE OR HEALTHY CONTROL 
WOMEN.
Results expressed as mol % (mean + standard deviation).
Phospholipid Malignant
(n=12)
Benign
(n=10)
Normal
(n=15)
Sphingomyelin 24.70 ±  2.31 25.00 ±  2.73 28.60 ±  1.80 B,C
Phosphatidylcholine 26.00 ±  4.16 25.88 ±  4.64 22.53 ±  5.34
Phosphatidylserine 10.80 ±  4.47 10.44 ±  2.61 12.00 ±  4.72
Phosphatidylinositol 12.20 ±  4.08 11.19 ±  2.30 12.20 ±  3.08
Phosphatidylethanolamine 26.20 ±  1.99 27.63 ±  2.13 24.53 ±  2.47 C
A = Malignant and Benign groups signficantly different (p< 0.01) 
B = Malignant and Control groups significantly different (p< 0.01) 
C = Benign and Control groups significantly different (p< 0.01)
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TABLE 56: HISTOPATHOLOGICAL AND CLINICAL DIAGNOSIS OF
EXCISED BREAST TISSUE
PATIENT
INITIALS
HISTOLOGY CLINICAL
DIAGNOSIS
TI
LW
ST
MH
IH
LH
VM
LC
JU
PW
MC
PP
MR
EH
GB
GK
DS
IG
JW
JR
NS
PL
ES
MD-M
OB
VG
BS
Fibrocystic change 
Fibrocystic change 
Fibrocystic change 
Fibrocystic change 
Fibroadenoma 
Fibrocystic change 
Lactating adenoma 
Fibroadenoma 
Fibrocystic change 
Fibroadenoma 
Duct ectasia 
Ductal adenoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma 
Invasive lobular carcinoma 
Invasive ductal carcinoma 
Invasive ductal carcinoma
Benign
Benign
Benign
Benign
Benign
Benign
Benign
Benign
Benign
Benign
Benign
Benign
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
Malignant
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